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Abstract 
There is growing evidence that suggests Traumatic brain injury (TBI) may initiate long-term 
neurodegenerative processes. Exposure to a single moderate or severe TBI, or to repetitive 
TBI, reveals a complex of pathologies including abnormalities of tau, amyloid-β and TDP-
43; neuronal loss; neuroinflammation; and white matter degradation. The mechanisms 
driving these late post-TBI neurodegenerative pathologies remain elusive.  
Firstly, a potential association between blood-brain barrier (BBB) disruption and TBI was 
investigated. Results showed that increased and widespread BBB disruption was observed 
in material from patients dying in the acute phase following a single, moderate to severe TBI 
and persisted in a high proportion of patients surviving years following injury. Furthermore, 
there was preferential distribution to the deep layers of the cortex and to the crests of the gyri 
rather than the depths of the sulci. This post-TBI BBB disruption was investigated further 
within a paediatric TBI cohort. BBB disruption was noted in both paediatric and adult TBI 
in a similar pattern and distribution, however, interestingly, in sharp contrast to adult TBI 
cases, BBB disruption in paediatric cases appears preferentially distributed to capillary sized 
vessels. This vulnerability of the small vessels was rarely observed in adult material. 
In addition to the post-TBI vascular change observed, the cellular response was investigated, 
which interestingly, demonstrated regional differences. Specifically, in the grey matter, 
reactive astrogliosis was observed subpially, around cortical vessels, at the grey and white 
matter boundaries and subependymally. This astrogliosis was evident in a proportion of 
acute and continued into the late phase following TBI.  In contrast, microglial activation was 
observed as a delayed response and localised to the white matter tracts. In addition, this 
delayed microglial response expressed an M2-like phenotype. Furthermore, there was an 
increased population of inactivated perivascular microglia beyond the perivascular space in 
the grey matter regions, observed in the acute phase and persisted in a proportion of patients 
surviving years following injury. Collectively these findings are interesting and indicate TBI 
induces both a vascular and cellular responses which may contribute to the long-term post-
TBI neurodegenerative processes. 
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WMI  white matter interface 
 
 
 
17 
 
 Introduction 
Traumatic brain injury (TBI) is a leading cause of mortality and morbidity worldwide. In the 
UK alone, approximately 1.3 million people are living with TBI-related disabilities, with 
160,000 hospital admissions annually (Parsonage, 2016). In the US this number is 
significantly increased with nearly 300,000 patients requiring hospitalisation and a further 5 
million individuals living with chronic disabilities following a TBI (Coronado VG, 2012, 
Faul M, 2010, CDC, 1999). There is growing acknowledgment of the association between a 
history of TBI and late neurodegenerative disorders; however, the pathologies driving these 
late outcomes remain poorly described. Historically, clinical studies in TBI have described 
increased risk of Alzheimer’s disease in a proportion of survivors (Molgaard et al., 1990, 
Mortimer et al., 1985, Mortimer et al., 1991, Graves et al., 1990, O'Meara et al., 1997, Salib 
and Hillier, 1997, Guo et al., 2000, Schofield et al., 1997, Plassman et al., 2000, Fleminger 
et al., 2003), although others have demonstrated conflicting data (Chandra et al., 1987, 
Amaducci et al., 1986, Broe et al., 1990, Ferini-Strambi et al., 1990, van Duijn et al., 1992, 
Katzman et al., 1989, Launer et al., 1999, Williams et al., 1991, Mehta et al., 1999). 
However, common to all studies, thus far, is a striking lack of autopsy confirmation of 
pathology in late TBI series, with resultant absence of adequate clinicopathological 
correlation. 
The first report describing potential late consequences of TBI followed the careful 
observations of Dr Harrison S Martland in 1928, who described a variety of neuropsychiatric 
and motor symptoms in a limited case series of boxers exposed to repetitive traumatic brain 
injury (rTBI); referred to as punch-drunk syndrome (Martland, 1928). Subsequent studies in 
the years following Martland’s original observations provided early accounts of a distinct 
neurodegenerative pathology in former boxers, further supporting the link between rTBI and 
a neurodegenerative disease, termed dementia pugilistica (DP) (J, 1937, Critchley, 1957, 
Mawdsley and Ferguson, 1963, Spillane, 1962). More recently, there has been growing 
recognition that this pathology is not limited to boxers but also observed in brains of 
individuals exposed to rTBI from other sports and circumstances (Omalu et al., 2011a, 
Omalu et al., 2011b, Omalu et al., 2005, Omalu et al., 2006a, Omalu et al., 2010a, Omalu et 
al., 2010b, McKee et al., 2009, McKee et al., 2010, McKee et al., 2013, Goldstein et al., 
2012) and in survivors of a single, moderate to severe TBI (sTBI) (Johnson et al., 2012, 
Smith et al., 2013, Johnson et al., 2013a, Roberts et al., 1991, Roberts et al., 1994). Therefore 
suggesting it is exposure to TBI that is associated with the risk of development of late 
neurodegenerative disease rather participation in a particular sport or activity. Thus, the term 
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chronic traumatic encephalopathy (CTE) replaces DP in current literature, reflecting the 
wider exposures beyond boxing. While 90 years have passed since the first recognition of a 
clinical syndrome in former boxers, there remains remarkably little understanding of the 
complex pathologies of CTE. Limited case series have been described with only autopsy 
assessments to base the criteria of diagnosis on. 
1.1 Traumatic brain injury and dementia  
TBI is widely recognised as the strongest environmental risk factor for dementia (Molgaard 
et al., 1990, Mortimer et al., 1985, Mortimer et al., 1991, Graves et al., 1990, O'Meara et al., 
1997, Salib and Hillier, 1997, Guo et al., 2000, Schofield et al., 1997, Plassman et al., 2000, 
Fleminger et al., 2003), with a direct dose-response relationship proposed between injury 
severity and subsequent risk of dementia (Guo et al., 2000, Plassman et al., 2000). In support 
of this relationship, meta-analyses of case-control studies, head injury which resulted in loss 
of consciousness had approximately a 50% increased risk in developing dementia (Mortimer 
et al., 1991). Further, the Multi-Institutional Research in Alzheimer Genetic Epidemiology 
study (MIRAGE) collected head injury information on a total of 2,233 Alzheimer’s disease 
(AD) patients, and from 14,668 of their first-degree family members, by interviews and 
review of medical records. It was ascertained that a head injury with loss of consciousness 
and, to a lesser extent, head injury without loss of consciousness increased the risk of AD 
(Guo et al., 2000). If there was a loss of consciousness following the TBI, the risk of 
developing AD was double that of a head injury that did not have such an impact. However, 
a common concern with a majority of studies to date is their retrospective nature, with 
inevitable concerns on recall bias. Only one prospective study used level-1 evidence where 
head injured US veterans and non-head injured US veterans were interviewed and clinical 
assessments were carried out 50 years after the injury (Plassman et al., 2000). Those who 
sustained a severe TBI (loss of consciousness or post-traumatic amnesia longer than 24 
hours) were 4 times as likely to have dementia compared with uninjured controls, while 
those who sustained a moderate TBI (loss of consciousness or post-traumatic amnesia 
between 30 minutes and 24 hours) were twice as likely to have dementia. Based on all studies 
to date, there is undoubtedly sufficient evidence to link moderate and severe TBI and an 
increased risk of dementia (Health, 2009, Li et al., 2017, Plassman and Grafman, 2015). 
It has been estimated that between 5% and 15% of current dementia cases are TBI related 
(Shively et al., 2012). While there are currently approximately 850,000 dementia patients in 
the UK alone, this represents between 42,500 and 127,500 dementia patients attributed to 
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TBI. The Dementia UK report estimated that in 2014 dementia care cost £26 billion, 
therefore, the costs of TBI-attributed dementia are upwards of £1.3 billion a year, but as our 
understanding of this link develops these numbers will undoubtedly alter (Prince, 2007). 
To date, cases of TBI-associated dementia have been considered as distinct entities 
dependent on whether exposure to TBI has been through either sTBI or rTBI; the former 
considered AD, the latter CTE. However, the presumption that CTE is restricted to patients 
who sustain rTBI, the majority being sportsmen and women, and development of AD is 
limited to patients who sustain a sTBI is arguably flawed. 
Multiple studies have expanded on Martland’s original observations of chronic 
neuropsychiatric sequelae in former boxers (Martland, 1928, Roberts, 1969, Corsellis et al., 
1973); Roberts et al (Roberts, 1969) reported that out of 224 randomly selected professional 
boxers 17% demonstrated emotional liability, personality change, memory impairment and 
dementia. Corsellis (Corsellis et al., 1973) carried out case reports of 15 ex-boxers and 
noticed neuropsychiatric symptoms, such as speech and motor problems and dementia. More 
recent descriptions of former non-boxer athletes (including from American football, ice 
hockey, and rugby) and military personnel have reported similar neuropsychiatric and 
behavioural problems, while expanding the descriptions to include aggression, poor 
judgment, depression, suicidal ideation, and, in some instances, suicide (McKee et al., 2009, 
McKee et al., 2013, Stewart et al., 2016, McKee et al., 2014). 
Although the dementia that develops following a moderate to severe sTBI is typically 
described as AD in type (Mortimer et al., 1985, Mortimer et al., 1991, Graves et al., 1990, 
O'Meara et al., 1997, Salib and Hillier, 1997, Schofield et al., 1997, Guo et al., 2000, 
Plassman et al., 2000, Fleminger et al., 2003), these studies include no neuropathological 
confirmation that the pathology that follows sTBI conforms to AD. Certainly, there have 
been no suitably designed, robust studies in the current era of understanding of the 
neuropathology of CTE to confirm the dementia occurring in late survivors of a sTBI is AD. 
However, dementia attributed to a sTBI has been reported to demonstrate prominent motor 
and neuropsychiatric symptoms, including depression and suicide (Dams-O'Connor et al., 
2013, Sayed et al., 2013). As such, in cases where it has been critically assessed, the clinical 
syndrome of neurodegeneration following a sTBI appears distinct from AD and echoes that 
of rTBI. Therefore, the current view permeating the literature that a sTBI is specifically 
associated with the development of AD (DeKosky et al., 2013, DeKosky et al., 2010) should 
be regarded as speculative, and without confirmatory neuropathology.  
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1.2 Chronic traumatic encephalopathy  
Following Martland’s original clinical description in 1928, the first neuropathological 
assessment of neurodegeneration in boxers was not performed until 1954 (Brandenburg and 
Hallervorden, 1954), with multiple further case series reported in the following decades 
(Mawdsley and Ferguson, 1963, Payne, 1968, Neubuerger et al., 1959, Constantinidis and 
Tissot, 1967, Ferguson FR, 1965, Grahmann and Ule, 1957). Of these, perhaps the most 
informative was that of Corsellis in 1973 (Corsellis et al., 1973) describing the neurological 
features in the brains of 15 ex-boxers including fenestrated cavum cerebellar scarring, 
enlarged ventricles, thinning of corpus callosum, degeneration of substantia nigra and diffuse 
neurofibrillary tangles. Since these early studies, the picture that has emerged in subsequent 
descriptions is that of a complex of pathologies arising following exposure to TBI, single or 
repetitive, best described as a polypathology.  
1.3 Macroscopic neuropathology  
Often reported in early studies on the brains of boxers was atrophy of the cerebral 
hemispheres (Mawdsley and Ferguson, 1963, McKee et al., 2009, Brandenburg and 
Hallervorden, 1954, Payne, 1968, Neubuerger et al., 1959, Constantinidis and Tissot, 1967, 
Grahmann and Ule, 1957, Corsellis et al., 1973, Roberts et al., 1990a, Jordan et al., 1995, 
Schmidt et al., 2001, Saing et al., 2012, Nowak et al., 2009), demonstrating preferential 
involvement of the temporal (Drachman  and Newell 1999, Areza-Fegyveres et al., 2007) 
and frontal lobes (Mawdsley and Ferguson, 1963, Neubuerger et al., 1959, Ferguson FR, 
1965, Nowak et al., 2009, Areza-Fegyveres et al., 2007) and the cerebellum (Grahmann and 
Ule, 1957, Williams and Tannenberg, 1996). However, more recently, reports on non-boxer 
athletes observe a mild global atrophy and inconsistent reports of a reduction in brain weight 
(Omalu et al., 2011a, Omalu et al., 2006b, Omalu et al., 2006a, Omalu et al., 2010a, Omalu 
et al., 2010b, McKee et al., 2009, McKee et al., 2013). Despite this contrast, there is a pattern 
emerging of macroscopic features in rTBI which includes atrophy of the mammillary bodies, 
a mild degree of ventricular enlargement (perhaps preferentially of the third ventricle), pallor 
of the substantia nigra, and thinning of the corpus callosum (Brandenburg and Hallervorden, 
1954, Payne, 1968, Neubuerger et al., 1959, Constantinidis and Tissot, 1967, Grahmann and 
Ule, 1957, Corsellis et al., 1973, Roberts et al., 1990a, Saing et al., 2012, Nowak et al., 2009, 
Drachman  and Newell 1999). Widespread brain atrophy has been recognised following 
sTBI in both autopsy and imaging studies (Farbota et al., 2012, Ross et al., 2012, Ross, 2011, 
Tomaiuolo et al., 2004, Warner et al., 2010) with the latter suggesting this atrophy continues 
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beyond the acute phase and into longer-term survival. As with rTBI, reports have 
demonstrated a thinning of the corpus callosum in a proportion of sTBI patients with over 
1-year survival (Johnson et al., 2013a). 
Abnormalities of the septum pellucidum are a common feature described in material from 
those exposed to rTBI, in particular cavum septum pellucidum (CSP) or septal fenestration, 
with occasional reports of complete loss of the septum (Mawdsley and Ferguson, 1963, 
Omalu et al., 2011a, Omalu et al., 2006a, Omalu et al., 2005, Omalu et al., 2010b, McKee 
et al., 2009, Brandenburg and Hallervorden, 1954, Payne, 1968, Neubuerger et al., 1959, 
Constantinidis and Tissot, 1967, Ferguson FR, 1965, Grahmann and Ule, 1957, Roberts et 
al., 1990a, Jordan et al., 1995, Schmidt et al., 2001, Saing et al., 2012, Nowak et al., 2009, 
Williams and Tannenberg, 1996, Drachman  and Newell 1999, Allsop et al., 1990, Geddes 
et al., 1999, Hof et al., 1992, Hof et al., 1991). Although CSP has been reported as a normal 
finding in up to one third of participants in population studies (Corsellis et al., 1973, 
Bogdanoff and Natter, 1989, Bodensteiner and Schaefer, 1997, Macpherson and Teasdale, 
1988, JT, 1952) evidence supports CSP is of higher prevalence and to a greater extent in 
those exposed to rTBI (Gardner et al., 2014, Gardner et al., 2016, Corsellis et al., 1973). 
Further, imaging studies confirm CSP in rTBI and provide evidence it is an evolving 
pathology in longitudinal studies (Mawdsley and Ferguson, 1963, Ferguson FR, 1965, 
Casson et al., 1984, Jordan et al., 1992). Thus far, CSP has not been reported as a feature in 
pathology studies of sTBI yet this could be largely a consequence of an absence of studies 
rather than absence of pathology (Smith et al., 2013). 
1.4 Microscopic neuropathology  
While to date over 200 cases have been reported describing the neuropathology of rTBI 
exposure in a range of sports, including boxing (Smith et al., 2013, Brandenburg and 
Hallervorden, 1954, Corsellis et al., 1973), American football, ice hockey, wrestling, soccer, 
rugby union, in former military personnel (Omalu et al., 2011a, Omalu et al., 2006a, Omalu 
et al., 2006b, Omalu et al., 2010a, Omalu et al., 2010b, McKee et al., 2009, McKee et al., 
2010, Goldstein et al., 2012, McKee et al., 2013, Omalu et al., 2011b, Stewart et al., 2016, 
McKee et al., 2014, Shively et al., Lindsley, 2017, Mez et al., 2017) and in cases of domestic 
abuse (Williams and Tannenberg, 1996, Hof et al., 1991, Roberts et al., 1990b), only 
approximately 40 cases have been described reporting the pathology of survival after a sTBI 
(Johnson et al., 2012, Johnson et al., 2013a, Johnson et al., 2011). From these limited case 
series, the pathology of late survival from TBI is recognised as a complex polypathology 
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featuring abnormalities in tau, amyloid β (Aβ), and TDP-43; neuroinflammation; axonal 
degeneration; degradation of white matter; and neuronal loss. 
 Tau  
Axons encounter high strain rates during TBI in which mechanical breaking of the 
microtubules occurs and axoplasmic transport is disrupted (Tang-Schomer et al., 2010, 
Tang-Schomer et al., 2012, Ahmadzadeh et al., 2014). This diffuse axonal injury (DAI) 
(Sirko et al.) arises due to the viscoelastic nature of axons, in turn thought to derive from the 
biophysical properties of the microtubule-associated protein tau (Ahmadzadeh et al., 2014). 
Whilst abnormal accumulation of hyperphosphorylated tau is reported in cases of CTE 
(Smith et al., 2013) and in patients dying 1 year or more after a sTBI (Johnson et al., 2012) 
there has been no evidence of immediate tau pathology in patients dying in the acute phase 
after a sTBI (up to 4 weeks) (Smith et al., 2003a). In late TBI, whether following rTBI or 
sTBI, tau pathology is characterised by the accumulation of abnormal, hyperphosphorylated 
tau in both neurons and glia, around vessels and with preferential involvement of the depths 
of the sulci in the neocortical grey matter (Omalu et al., 2011a, McKee et al., 2009, McKee 
et al., 2010, Goldstein et al., 2012, McKee et al., 2013, Stewart et al., 2016, Geddes et al., 
1999, Johnson et al., 2012) (Figure 1-1). First described in tau pathology of boxers, there is 
an irregular, patchy involvement both within and between the affected cortical areas (McKee 
et al., 2009, McKee et al., 2013, Stewart et al., 2016, Geddes et al., 1996, Geddes et al., 
1999). 
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Figure 1-1 Neocortical tau pathology in CTE Tau immunoreactive profiles are distributed throughout the 
neocortex, though typically show preferential distribution towards the superficial neocortical layers and depths 
of sulci (a: 49M 12 months following single severe TBI), with a distinctive and characteristic perivascular 
accentuation of immunoreactive neurons and glia whether exposed to repetitive mild TBI (b: 56M former rugby 
player) or single moderate to severe TBI (c: 48M 3 years following single severe TBI). Accumulations of 
subpial thorn-shaped astrocytes may also be observed (d: 59M former soccer player). All sections stained for 
phosphorylated tau using antibody CP13 (courtesy Dr P Davies) 
Using antibodies to hyperphosphorylated tau (AT8, CP13, PHF-1) the neuronal tau 
pathologies present as typical neurofibrillary tangles (NFT) and pretangles which, as noted, 
show preferential involvement towards depths of sulci and perivascular accentuation, and 
often demonstrate a distribution to superficial cortical layers (layers II and III) (McKee et 
al., 2013). This contrasts with AD where tau involvement is preferentially in the deeper 
layers of the cortex (Braak and Braak, 1991, Braak et al., 1993). In the hippocampus, CTE 
is noted for the preferential involvement of sector CA2 by NFTs and extracellular tangles 
(Figure 1-2), with NFTs and astroglial tau pathology also a feature in the hypothalamic 
region, in particular the mammillary bodies (McKee et al., 2013). Other regions involved 
may include deep grey nuclei and brainstem in the nucleus basalis of Meynert, substantia 
nigra (Figure 1-2), locus coeruleus, raphe nuclei, and tectum, while the dorsal striatum (the 
caudate and putamen) and cerebellar dentate nuclei are relatively spared. Further, tau-
immunoreactive axonal profiles are often observed in the subcortical and midline white 
matter tracts (Figure 1-2) and tau-immunoreactive thorn-shaped astrocytes are demonstrated 
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in subpial and perivascular locations in the neocortex and subependymally (McKee et al., 
2013). Biochemical characterisation of tau in CTE has only been performed in two former 
boxers (Schmidt et al., 2001) and in both cases the tau deposits were indistinguishable from 
those observed in AD. 
 
Figure 1-2 Tau pathology in CTE In addition to neocortical tau pathology, tau-immunoreactive profiles are 
common in the hippocampus in CTE, with preferential involvement of sector CA2 by NFTs and extracellular 
tangles and astroglial tau pathology (a: 59M former soccer player). Elsewhere, tau pathologies are described 
in the deep grey nuclei and brainstem, where tau-immunoreactive substantia nigra neurons and neurites may 
be present, together with a degree of pigment incontinence (b: same case as in (a)). Scattered tau-
immunoreactive axonal profiles are also common in subcortical and midline white matter (c: same case as (a); 
d: 60M former boxer).  All sections stained for phosphorylated tau using antibody CP13 (courtesy Dr P Davies). 
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While these tau pathologies have been reported in virtually all rTBI cases, there has been an 
unavoidable case-selection bias and a virtual absence of control material from uninjured 
cases in reports of CTE, rendering interpretations of the incidence of this pathology 
meaningless in the context of exposure to rTBI (Mez et al., 2017). In the single study 
examining sTBI, tau pathology was demonstrated in up to 30% of cases which was, in turn, 
in greater density and wider distribution than uninjured, age-matched controls (Johnson et 
al., 2012). However, as a retrospective, archive-based study, no information was provided 
on the clinical status of these post-TBI tau-positive patients. Hence, the clinical significance 
of the pathology identified at autopsy remains uncertain. Some attempts of staging of tau 
pathologies in CTE have been suggested by authors reviewing rTBI cases, from a restricted, 
focal, cortical pathology (stage I) to more extensive, widespread, cortical, hippocampal, and 
brainstem involvement of tau (stage IV) (McKee et al., 2013). However, this proposed 
staging has yet to be validated. 
1.4.1 Amyloid β  
Diffuse axonal injury is an early and consistent event in TBI which results in cytoskeleton 
disruption and interruption of axonal transport (Farbota et al., 2012, Johnson et al., 2013b, 
Adams et al., 1982, Adams et al., 1989a). DAI and transport interruption is demonstrated via 
immunocytochemical staining using β-amyloid precursor protein (APP) which visualises 
abnormal accumulation in injured axons (Johnson et al., 2013b, Gentleman et al., 1993, 
Sherriff et al., 1994). Normally transported by fast axonal transport, following TBI, APP 
may be observed in damaged axons within hours of injury. At the sites of axonal injury, 
colocalisation of APP with enzymes presenilin-1 and β-site-APP-cleaving enzyme, enables 
APP to cleave into Aβ (Smith et al., 2003b, Smith et al., 2003c, Smith et al., 1999, Chen et 
al., 2004, Chen et al., 2009, Johnson et al., 2010). Therefore, DAI creates an environment 
promoting the production of localised, high concentrations of Aβ protein (Johnson et al., 
2010).  
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Figure 1-3 Aβ plaque pathologies following TBI Diffuse Aβ plaques can be identified in autopsy and surgical 
material from approximately 30% of TBI patients in the acute phase post-injury (a: 51M 24hours following 
severe TBI). In the following weeks to months, these diffuse plaques resolve, only to re-emerge in around 30% 
of survivors a year or more from single moderate to severe TBI, as both neuritic and diffuse Aβ plaques (b: 
55F 47 years survival from single severe TBI). Aβ plaques are also present in a majority of cases of CTE 
following exposure to repetitive mild TBI, typically, though not exclusively, diffuse in subtype (c: 60M former 
boxer; d: 59M former soccer player). All sections stained using antibody 6F3D, specific for the N-terminal 
epitope of Aβ (Dako). 
Aβ plaques are a hallmark of AD, but are also identified in autopsy material from up to 30% 
of patients dying acutely following a single moderate to severe TBI, and at higher density 
than observed in equivalent material from uninjured age-matched controls (Figure 1-3) 
(Roberts et al., 1991, Roberts et al., 1994, Johnson et al., 2012). Aβ plaques have also been 
demonstrated in pericontusional, surgically excised tissue from sTBI survivors immediately 
after injury (Ikonomovic et al., 2004). These acute plaques are diffuse in nature and similar 
to those of early-stage AD. However, where plaques in AD are thought to develop slowly 
and occur predominantly in the elderly, TBI-associated plaques are detectable within hours 
of injury and across a range of ages, including in young adults. 
Evidence suggests that, over time, these acute TBI plaques clear and normal amyloid cycling 
is restored (Chen et al., 2009). However, in autopsy material from patients who survived 1 
year or more after a sTBI Aβ plaques were observed in considerably greater density and in 
wider distribution than in material from age-matched, uninjured controls (Johnson et al., 
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2012). In addition, these long-term TBI amyloid plaques are more typically neuritic in type, 
much like the plaques established in AD (Johnson et al., 2012) (Figure 1-3).  
When reviewing the Corsellis Archive material acquired at autopsy from a cohort of 20 
retired amateur and professional boxers, Roberts and colleagues observed often-abundant, 
diffuse Aβ plaques in all but one case; a 22-year-old former professional boxer 3-year career 
and only 3 professional fights. All NFT-positive cases in this cohort contained plaque 
pathology. In current reviews of CTE in former athletes, reports of Aβ plaques are less 
consistent (McKee et al., 2013). However, where documented, this pathology is present in a 
majority of cases, the proportion of cases with plaque pathology increasing with age (Stein 
et al., 2015). In studies of material from patients with exposure to rTBI, these Aβ plaques 
are almost invariably described as diffuse in nature (Figure 1-3), in contrast to the neuritic 
plaque more often observed in long-term survivors of a sTBI. However, although much 
research attention is focused on tau pathology in CTE, comparatively little attention is 
directed toward amyloid pathologies.  
1.4.2 Transactive response DNA-binding protein  
The 43 kDa transactive response DNA-binding protein 43 (TDP-43) is a nuclear protein 
widely expressed throughout the body. TDP-43 can, however, translocate from the nucleus 
into the cytoplasm under certain conditions forming polyubiquitinated and 
hyperphosphorylated inclusion bodies. This abnormal TDP-43 is recognised as a major 
disease-associated protein in a number of neurodegenerative conditions, including 
frontotemporal lobar dementia and amyotrophic lateral sclerosis (Neumann et al., 2006), and 
as a minor component of a variety of other conditions, including AD, Parkinson’s disease, 
and a small proportion of normal-aged individuals (Chen-Plotkin et al., 2010, Geser et al., 
2010, Neumann et al., 2007). Some animal models of TBI have suggested that the 
translocation is caused by upregulation of TDP-43 which is, in turn, caused by axonal injury 
(Sato et al., 2009, Moisse et al., 2009a, Moisse et al., 2009b). This translocation has been 
suggested as part of the acute-phase response as, upon recovery, TDP-43 moves back to the 
nucleus (Sato et al., 2009, Moisse et al., 2009a). Therefore, there is the potential that TBI-
induced axonal injury might influence neuronal TDP-43 processing. 
Following exposure to rTBI in both boxers and non-boxer athletes’, neuronal cytoplasmic 
TDP-43 inclusions and distinctive grain-like profiles in the surrounding neuropil have been 
documented in the hippocampus, temporal neocortex, and amygdala in a majority of CTE 
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cases (McKee et al., 2010, McKee et al., 2013, Johnson et al., 2011, King et al., 2010). This 
abnormal TDP-43 observed coincides with a clinical diagnosis of amyotrophic lateral 
sclerosis in a small proportion of these cases, with the autopsy examination revealing 
features consistent with CTE (McKee et al., 2010). Based on these limited observations a 
diagnosis of CTE has been suggested (McKee et al., 2010) although many more cases are 
required to validate this proposition. 
Where similarities in tau and Aβ pathologies in survivors of rTBI and sTBI are apparent, 
there is a notable difference in TDP-43 pathology. Following late survival of sTBI 
abnormally phosphorylated TDP- 43 cytoplasmic inclusions have not been reported in any 
greater extent than in material from uninjured controls. However, increased cytoplasmic 
immunoreactivity to physiological, non-phosphorylated TDP-43 has been observed in acute 
and late survivors (Johnson et al., 2011). This intriguing apparent difference in pathologies 
between survivors of rTBI and sTBI might suggest a physiological role for TDP-43 in the 
response to injury, which is somehow modified after exposure to repetitive brain injury, and 
thus precipitates cytoplasmic translocation and accumulation of hyperphosphorylated TDP-
43. 
1.4.3 Neuroinflammation  
Neuroinflammation is increasingly regarded as a key feature of the pathology of a range of 
neurodegenerative disorders (Perry et al., 2010, Brettschneider et al., 2012b, Brettschneider 
et al., 2012a), depression (Miller and Raison, 2016) and as an early event in AD pathogenesis 
(Town et al., 2008, Wright et al., 2013, Yamamoto et al., 2007, Yoshiyama et al., 2007); 
studies examining serum or cerebrospinal fluid from patients surviving a sTBI, have also 
shown evidence of elevated proinflammatory cytokine levels that correlated with poor 
neuropsychiatric outcome, including suicidal ideation (Juengst et al., 2014, Lindqvist et al., 
2014, Kumar et al., 2015). 
Immediately following injury, TBI induces a complex neuroinflammatory response in both 
humans and animal models, associated with an acute-phase inflammatory cell reaction 
featuring polymorphonuclear leukocytes, T lymphocytes, macrophages, and natural killer 
cells, together with activation of resident microglia (Johnson et al., 2013a, Loane and 
Byrnes, 2010). It could be expected that this acute-phase inflammation resolves itself under 
normal circumstances; however, in a proportion of survivors there is increasing evidence 
that this post-TBI neuroinflammation persists long-term. In autopsy material from patients 
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surviving a TBI there is evidence of an ongoing neuroinflammatory response years after 
survival following a single injury (Figure 1-4) (Johnson et al., 2013a). Interestingly, where 
these observations demonstrate distinct activated microglia in the corpus callosum, in vivo 
positron emission tomography studies in surviving patients after a sTBI, using the ligand 
[11C]PK-11195, have reported no significant differences in binding in this region, although 
they have reported a difference in binding in the thalamic region compared with control 
patients (Ramlackhansingh et al., 2011a). However, [11C]PK-1195 is a translocator protein 
(TSPO) ligand which is non-specific for microglia and is expressed on other cells such as 
astrocytes and endothelial cells (Chechneva and Deng, 2016b). Therefore, the possibility 
that imaging studies might underestimate or misrepresent neuroinflammation following TBI 
could be considered.  
 
Figure 1-4 Neuroinflammation and white matter degradation in the corpus callosum with survival 
following TBI Approximately 30% of survivors a year or more from single moderate to severe TBI show 
evidence of white matter degradation as rarefaction in staining to Haematoxylin and eosin (d) when compared 
to uninjured control material (a). Accompanying this is evidence of ongoing neuroinflammation in the form of 
numerous amoeboid, activated microglia (e) in contrast to quiescent, ramified microglia in uninjured controls 
(b). Staining from myelin with Luxol fast blue/ Cresyl violet demonstrates an associated loss of myelin with 
evidence of continued myelin degradation (f). (a)(b)(c) sections from the corpus callosum of a 38M non-TBI 
control, cause of death sudden unexpected death in epilepsy. (d)(e)(f) sections from the corpus callosum of a 
56M with a 3-year survival from single severe TBI. (b) and (e) stained for HLA-DP, DQ, DR using antibody 
CR3/43 (Dako) to reveal activated microglia. 
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There has been very little characterisation of the extent and distribution of the 
neuroinflammatory response following rTBI in boxers or non-boxer athletes, although it has 
been mentioned in several publications (Payne, 1968, Corsellis et al., 1973, Saing et al., 
2012, Adams and Bruton, 1989). However, there have been numerous experimental models 
of rTBI which have demonstrated persistent microglial activation with an association with 
degenerative pathology and cognitive deficit (Mouzon et al., 2014, Petraglia et al., 2014a). 
It is still unclear if this neuroinflammatory process that is acquired following TBI is a 
primary response (abnormal inflammation driving late TBI pathology) or a secondary 
response (abnormal inflammation reacting to other ongoing TBI pathologies occurring in 
parallel). Some animal models have suggested that the immediate microglial inflammatory 
response following TBI is both reparative (M2a microglial phenotype) and neurotoxic (M1 
microglial phenotype) which possibly switches to M1 predominant phenotype during the 
late phase (Loane and Byrnes, 2010, Kumar et al., 2013, Loane et al., 2014). The key 
functional effects of the M1 activation state are killing of intracellular pathogens and antigen 
presenting. These produce inflammatory cytokines, reactive oxygen species and reactive 
nitrogen species, which generate a neurotoxic environment (MacMicking et al., 1997); while 
the M2 activation state involves an anti-inflammatory phenotype which promotes tissue 
repair and debris clearance, aiding the healing process (Cherry et al., 2014). Whether the 
microglial responses in human TBI, in particular the phenotypic profiles in early-versus-late 
survivors, mirror observations from animal studies has yet to be confirmed.  
1.4.4 Astrocytic response 
Animal models of TBI have demonstrated that as a consequence of injury astrocytes can 
exhibit membrane instability and cytoskeleton disassembly (Cullen et al., 2011). In response 
to this, a number of events are initiated in astrocytes including rapid influx of extracellular 
calcium, sodium release of matrix metalloproteinase-9, secretion of vasoactive molecules 
and adenosine triphosphate release (Hekmatpanah and Hekmatpanah, Hoffman et al., 2000, 
Ostrow et al., 2011, Ahmed et al., 2000). Astrocytes have been recognised as important early 
responders following TBI, preceding the microglial response (Kim and Dustin, 2006), with 
ATP released from injured astrocytic networks guide the microglial population to site of 
focal injury (Kim and Dustin, 2006, Davalos et al., 2005, Rouach et al., 2002, Stout et al., 
2002, Verderio and Matteoli, 2001). Similar to the heterogeneity in M1 and M2 microglia, 
reactive astrogliosis has been attributed to both neuroprotective and detrimental effects in 
the central nervous system (CNS) (Laird et al., 2008, Sirko et al., 2015, Bardehle et al., 2013, 
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Myer et al., 2006). The characterisation of reactive astrogliosis following a sTBI has yet to 
be defined and developed. One limited post-mortem case series, investigating blast-related 
injuries, recorded prominent astroglial scarring and reactive astrogliosis in grey–white 
matter boundaries and at the subpial glial plate in all chronic blast exposure cases (up to 9 
years survival) and did not find similar such patterns in sTBI; however, numbers were small 
(Shively et al., 2016). 
Following rTBI in transgenic mice, astrocytes display an acute presence of reactive 
astrogliosis (Petraglia et al., 2014a, Ojo et al., 2013). A key focus on astrocytes following 
rTBI, however, remains the tau-immunoreactive astrocytes observed in CTE (McKee et al., 
2009, Stein et al., 2014). This astrocytic p-tau pathology in CTE is proposed to be 
topographically distinct from aging-related tau astrogliopathy (ARTAG) which presents 
itself as four-repeat tau immunoreactive thorn-shaped astrocytes (Lopez-Gonzalez et al., 
2013, Lace et al., 2012) and may go on to form astrocytic tangles. Limited animal work 
suggests a reactive astrocytic response following TBI which may have heterogenic attributes 
and, to date, the late response still requires to be established and expanded.  
1.4.5 Neuronal loss  
In autopsy studies, material from patients who sustained a sTBI demonstrate a degree of 
neuronal loss in the acute-phase (Shaw et al., 2001, Maxwell et al., 2003). Given the multiple 
acute pathologies of TBI, including diffuse axonal injury and the acute-phase 
neuroinflammatory response, this neuronal loss is to be anticipated. However, this neuronal 
loss may continue into the late phase in a proportion of patients, with active degeneration of 
neurons via programmed cell death being observed in material from patients up to 1 year 
following a single, severe TBI (Maxwell et al., 2003, Williams et al., 2001b, Maxwell et al., 
2006). 
With regards to rTBI, neuronal loss in the neocortex, substantia nigra, locus coeruleus, and 
cerebellum has been described in the majority of CTE cases (both boxers and non-boxer 
athletes) (Omalu et al., 2011b, Omalu et al., 2005, Omalu et al., 2006a, Omalu et al., 2010a, 
Omalu et al., 2010b, Brandenburg and Hallervorden, 1954, Neubuerger et al., 1959, 
Constantinidis and Tissot, 1967, Grahmann and Ule, 1957, Schmidt et al., 2001, Nowak et 
al., 2009, Williams and Tannenberg, 1996, Hof et al., 1992, Corsellis et al., 1973, Mann et 
al., 1983). The cell loss has been described as varying from patchy and selective alterations 
through to widespread and diffuse loss. Although there have been reports of neuronal loss 
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from the substantia nigra, synuclein-associated pathologies, including Lewy bodies, have 
not been reported, which, given the evidence of motor symptoms in CTE (Parkinsonian 
symptoms) is unique (Omalu et al., 2006a, Omalu et al., 2005, Brandenburg and 
Hallervorden, 1954, Constantinidis and Tissot, 1967, Corsellis et al., 1973, Drachman  and 
Newell 1999).  This vulnerability of the substantia nigra is unknown in patients surviving a 
sTBI. 
1.4.6 White matter degradation and continued axonal 
degeneration  
In all severities of TBI, DAI is a constant pathology in varying degrees. It is associated with 
interruption of axonal transport via cytoskeletal disruption which creates an environment for 
rapid Aβ genesis in the acute phase post TBI (Johnson et al., 2013c, Adams et al., 1982, 
Adams et al., 1989a, Smith et al., 2003b, Smith et al., 1999, Chen et al., 2004, Johnson et 
al., 2010). In one of the earliest pathologies determined in sTBI, Strich (Strich, 1956) 
demonstrated evidence of ongoing myelin degeneration at autopsy up to 15 months after 
survival from a single, severe TBI using the Marchi technique. Using a swine model of 
axopathy, continual axonal degeneration has been demonstrated months after injury (Chen 
et al., 2004). This observation has also been recognised in patients surviving a single 
moderate-to-severe TBI where there is ongoing axonal pathology in a proportion of 
survivors; decades after injury (Chen et al., 2009, Johnson et al., 2013a). Performing 
immunohistochemistry on brain sections, this continual axonal degeneration is characterised 
as morphologically abnormal APP-immunoreactive swollen axonal profiles throughout the 
white matter regions (Figure 1-5). These swollen bulbs of amyloid precursor protein (APP) 
are found in isolation and in small clusters in the white matter, indicative of disconnected 
axon terminals and providing evidence of ongoing axonal disruption in long-term survival 
in humans. In addition to the axonal degeneration, there is marked thinning of the white 
matter in the corpus callosum and reduced myelin staining which coincided with amoeboid 
microglia that contained myelin breakdown products, in keeping with ongoing myelin 
phagocytosis (Johnson et al., 2013a).  
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Figure 1-5 Axonal pathology in the corpus callosum with varying survival from TBI Diffuse axonal injury 
(DAI) is observed in all severities of TBI with associated axonal transport interruption. DAI is revealed in 
sections stained for APP and is detectable within hours of injury as immunoreactive axonal profiles with 
abnormal morphologies (a) 18M 11hours survival from severe TBI. Beyond this acute phase axonal injury, 
evidence of ongoing axonal transport interruption marked by scattered, morphologically abnormal axons 
staining for APP remains present in survivors a year or more from single moderate to severe TBI (b) 24M 
8years survival from single severe TBI (c) and in material from individuals exposed to repetitive mild TBI,59M 
former soccer player. All sections stained for an antibody to the N-terminal amino acids 66-81 of APP 
(Millipore). 
Where there is a concordance of reports of white matter pathology following a sTBI, there 
is limited evidence of this pathology following rTBI. Later publications in rTBI have 
described abnormal axonal profiles which accumulates transport proteins such as 
phosphorylated tau (Goldstein et al., 2012, McKee et al., 2013) where earlier publications 
did not seek evidence of such pathology. Some reports have described mixed observations; 
from foci of degeneration (Omalu et al., 2011b, Payne, 1968, Saing et al., 2012, Corsellis et 
al., 1973) with reduced myelin staining (McKee et al., 2009, Payne, 1968, Neubuerger et al., 
1959, Corsellis et al., 1973) to no evidence of demyelination at all (Constantinidis and Tissot, 
1967). Thus said, the formal characterisation of this axonal pathology following rTBI still 
remains to be completed. 
1.4.7 Blood-brain barrier 
The breakdown in blood-brain barrier (BBB) integrity is becoming increasingly recognised 
in a range of disorders such as ischemia (Sandoval and Witt, 2008), multiple sclerosis (Kirk 
et al., 2003) and neurodegeneration (Zlokovic, 2011, Bell and Zlokovic, 2009a). Both 
imaging (Starr et al., 2009) and animal models (Zlokovic, 2011, Ujiie et al., 2003) of AD 
have proposed that disruption of the BBB occurs early in the disease process and it may 
contribute to its pathogenesis due to impaired amyloid-β clearance or associated 
neuroinflammation (Zlokovic, 2011, Grammas, 2011, Shibata et al., 2000b, Zlokovic et al., 
2010, Deane et al., 2004a, Jaeger et al., 2009). Additionally, neuropathology studies have 
described multifaceted vascular changes connected to BBB disruption in AD patients (Zipser 
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et al., 2007a, Brown and Thore, 2011a, Buee et al., 1994) with a correlation between 
evidence of BBB leakage and AD-type pathologies in “normal” aging (Viggars et al., 2011). 
BBB disruption following sTBI has been described in the acute phase in several animal TBI 
models; however, the data is inconsistent on the time course of this disruption. While some 
studies have reported that BBB disruption occurs early, within hours of injury, and quickly 
resolves (Barzo et al., 1996, Habgood et al., 2007, Baldwin et al., 1996, Shapira et al., 1993, 
Rinder and Olsson, 1968, Shreiber et al., 1999, Smith et al., 1995, Cortez et al., 1989, 
Ommaya et al., 1964, Hekmatpanah and Hekmatpanah, 1985, Hicks et al., 1993, Povlishock 
et al., 1978), others have described a more dynamic, biphasic course following TBI with an 
early-phase BBB disruption occurring 3 to 6 hours after injury followed by a further BBB 
injury at 1 to 3 days post-injury (Baldwin et al., 1996, Baskaya et al., 1997). BBB disruption 
has also been observed in mice 3 months post-TBI with focal immunoglobulin G (IgG) 
deposition around callosal blood vessels ipsilateral to controlled cortical impact site 
(Glushakova et al., 2014). In support of these observations in animal TBI models, evidence 
of acute BBB disruption has been described following severe TBI in humans through reports 
of elevated serum albumin in cerebrospinal fluid and elevated S100β in serum (Saw et al., 
2014, Stahel et al., 2001, Ho et al., 2014a, Blyth et al., 2009, Di Battista et al., 2015, Csuka 
et al., 1999, Kossmann et al., 1995). This acute BBB disruption following sTBI may predict 
a poor long-term outcome in a population of patients (Ho et al., 2014a). Neuroimaging 
studies have also demonstrated evidence of BBB disruption after TBI in humans, with this 
disruption persisting at sites of focal contusions for up to 11 years post injury and with 
greater frequency in TBI patients with post-traumatic epilepsy (Tomkins et al., 2011). 
Following rTBI, there is imaging evidence of BBB disruption in American football 
participants, independent of clinical evidence of TBI, possibly as a result of exposure to 
“subconcussive” head impacts (Weissberg et al., 2014). Other studies using blood 
biomarkers have also demonstrated elevated serum S100β in American football players 
suggesting transient BBB damage in players with the greatest number of sub-concussive hits 
(Marchi et al., 2013). However, some animal models of rTBI failed to demonstrated BBB 
disruption (Kane et al., 2012) as did studies on boxers and military personnel (chronic blast 
exposure) suggesting the BBB remains undamaged (Blennow et al., 2011, Zetterberg et al., 
2006, Zetterberg et al., 2013b). Longitudinal studies of biomarker levels in patients with 
mild TBI are scarce. In the absence of such studies, it is difficult to determine BBB disruption 
following mild TBI and, therefore, clear biomarkers that could diagnose mild TBI and 
predict clinical outcomes 
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1.5 Genetics 
1.5.1 APOE and traumatic brain injury  
Several studies have examined the relationship between the apolipoprotein ε4 (APOE ε4) 
allele and dementia after TBI. APOE regulates lipid homeostasis by mediating lipid transport 
from one tissue or cell to another (Mahley and Rall, 2000). Specifically in the CNS, ApoE 
is produced by astrocytes and transports cholesterol to neurons via lipoprotein (LDLR) 
receptors (Bu, 2009). The ε4 allele of the APOE gene is associated with hyperlipidaemia and 
hypercholesterolaemia, which lead to atherosclerosis, coronary heart disease and stroke 
(Mahley and Rall, 2000, Lahoz et al., 2001). 
It has been well documented that possession of the ε4 allele of the APOE gene is also 
associated with an increased risk of AD (Corder et al., 1993, Saunders et al., 1993); 
specifically this allele is related to an increased incidence of Aβ pathologies in AD and to 
age-related Aβ deposition in healthy individuals (Jack et al., 2015). Regarding TBI, there is 
increasing evidence of an association between the ε4 allele (ApoE4) and prognosis following 
a sTBI, with worse immediate and 6-month outcomes in carriers of the ε4 allele than in non-
carriers (Teasdale et al., 1997, Sorbi S, 1995, Friedman et al., 1999, Liberman et al., 2002, 
Sundstrom A, 2004, Lichtman et al., 2000, Liaquat et al., 2002, Smith et al., 2006, Diaz-
Arrastia et al., 2003, Teasdale et al., 2005). Long-term survivors of sTBI who are carriers of 
ApoE4 also have a higher risk of dementia following injury than non-carriers (O'Meara et 
al., 1997, Guo et al., 2000, Plassman et al., 2000, Mayeux et al., 1995, Katzman et al., 1989, 
Mauri et al., 2006). Regarding influence on pathology after injury, following sTBI, 
individuals who have the ε4 allele demonstrate more severe contusional injury and more 
notable diffuse hypoxic brain injury than sTBI patients who do not carry the ε4 allele (Smith 
et al., 2006). There is also evidence of increased amyloid plaque pathology in patients dying 
during the acute-phase after a sTBI compared with those who do not carry the ε4 allele 
(Nicoll et al., 1995). However, the long-term implications of APOE genotype on late 
pathology after exposure to TBI are yet to be described. 
There is much less documented evidence of an association between the ε4 allele and 
cognitive impairment in rTBI (Kristman et al., 2008, Tierney et al., 2010). In the longer-term 
outcomes after rTBI some studies have described an association between the ε4 allele and 
increased cognitive impairment in boxers (high exposure only, those with more than 12 
professional bouts) (Jordan et al., 1997) and in older professional American footballers 
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(Kutner et al., 2000); however, as discussed previously, the numbers of participants in these 
studies was small. Studies of the association between the APOE genotype and late pathology 
after exposure to rTBI have been informative. Although original reports described a lack of 
an association between APOE genotype and CTE pathology as defined by characteristic tau 
deposition (Omalu et al., 2011a, McKee et al., 2013), when an appraisal of 
neuropathologically confirmed CTE cases was carried out, specifically those with Aβ 
pathologies, a clear association was discovered between the ε4 allele, Aβ pathologies and an 
acceleration of CTE disease progression (Stein et al., 2015). 
Interestingly, where the majority of the literature on CTE has focused on pathognomonic 
lesion being tau, the limited clinical reports of outcomes after rTBI and of dementia 
following a sTBI indicate an association between the possession of the APOE ε4 allele and 
a worse prognosis. In addition, the ε4 allele has been described as being associated mainly 
with Aβ pathologies rather than with tau pathologies. This information suggests that 
clinically relevant CTE might extend beyond the description of a tauopathy, with other 
pathologies such as Aβ deposition being as (if not more) important in the disease 
progression. 
1.5.2 Neprilysin and traumatic brain injury  
Neprilysin is the main Aβ-degrading enzyme, with microsatellite GT repeat polymorphism 
in the promoter region of the neprilysin gene (NEP) linked to amyloid pathologies, including 
AD and cerebral amyloid angiopathy (CAA) (Iwata et al., 2000, Turner et al., 2001, 
Yasojima et al., 2001). Following a sTBI, this polymorphism has been associated with Aβ 
plaque pathology (Johnson et al., 2009) where individuals carrying a longer repeat (greater 
than 41 GT repeats) were at higher risk of Aβ pathology than those carrying the shorter 
repeats. This suggests NEP has a key role in the breakdown of Aβ and plaque formation. 
Although an increase in intra-axonal neprilysin immunoreactivity and an association with 
Aβ accumulation has been described in patients surviving up to 3 years following a sTBI 
(Chen et al., 2009), the longer-term relationship between NEP and neurodegenerative 
pathologies are yet to be described.  In terms of the role of NEP in the predictor of outcome 
in rTBI and relationship of neuropathologies, this is yet to be examined. 
The pathology of late survival from TBI is recognised as a complex polypathology featuring 
abnormalities in tau, amyloid β (Aβ), and TDP-43; neuroinflammation; axonal degeneration; 
degradation of white matter; and neuronal loss; however, the literature is limited in parts. 
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Thus far, it is acknowledged that tauopathy is a key feature of CTE following rTBI and is 
observed in late survivors of sTBI. Amyloid-β has been revealed in tissue acutely following 
a sTBI and can be found in higher density and in younger cases in the late response following 
a sTBI, yet evidence following rTBI is limited. In addition, TDP-43 has been demonstrated 
translocated into the cytoplasm following rTBI, however, to date, there appears to be an 
absence of evidence following sTBI and axonal degeneration has been observed in both sTBI 
and rTBI (again there is limited evidence in rTBI).  
1.5.3 MAPT 
The gene MAPT (microtubule-associated protein Tau) encodes for the protein tau. MAPT 
resides within a 900kb inversion polymorphism that results in two haplotypes, H1 and H2 
(Stefansson et al., 2005). Mutations in this gene have demonstrated that tau dysfunction 
alone was sufficient to initiate neurodegeneration (Gasparini et al., 2007), specifically 
tauopathies. Rare missense and exon 10 splicing mutations which result in increased levels 
of tau isoforms (4-repeat) lead to familial frontotemporal dementia with parkinsonism 
(Hutton et al., 1998, Spillantini and Goedert, 1998), whereas H1 haplotype is associated with 
increased risk of progressive supranuclear palsy (PSP) (Pittman et al., 2004). The association 
between these haplotypes and TBI is unknown although one study noted an increase in H1 
haplotype in CTE however this was not significant (Bieniek et al., 2015).  
Where most pathologies have a certain degree of understanding, the complexity of the BBB 
following TBI has yet to be explored. Disruption of the BBB has been demonstrated in a 
limited capacity in animal studies in the acute phase, however the pathology and temporal 
course in humans is unknown. Neuroinflammation following TBI has been observed in 
several studies, however this could be expanded into microglial phenotypes and regional 
locations of inflammation. As could the astrocytic response which has been observed is some 
animal studies and one (very limited) case series. Common to all sTBI and rTBI studies to 
date, is a striking lack of autopsy confirmation of pathology in late TBI series, with resultant 
absence of adequate clinicopathological correlation and, therefore, much more work is 
required to confirm such pathologies. 
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1.6 Hypotheses and aims 
Table 1 Hypotheses and aims 
Hypotheses Background summary Aims 
sTBI results in disruption of 
BBB function acutely and in 
long-term survivors. 
BBB disruption following sTBI has 
been described in the acute phase in 
several animal TBI models; 
however, the data is inconsistent on 
the time course of this disruption. 
Some imaging studies have reported 
BBB disruption up to 11 years post-
injury. 
To characterise the pattern, 
distribution and temporal evolution 
of BBB disruption at varying 
survivals from sTBI. 
sTBI results in a mixed 
astroglial and microglial 
neuroinflammatory response 
that is geographically and 
temporally distinct. 
The characterisation of reactive 
astrogliosis following sTBI has yet 
to be defined and developed; one 
limited post-mortem case series with 
blast-related injuries reported 
reactive astrogliosis in grey–white 
matter junctions and subpial glial 
plate. 
Autopsy studies report activated 
microglia in corpus callosum of 
patients surviving years following a 
sTBI; however, imaging studies 
report binding of PK-1195 in 
thalamic regions. 
To characterise the extent, 
distribution and temporal evolution 
of the astroglial and microglial 
response to sTBI. 
The microglial response to 
sTBI is defined by 
phenotypically distinct 
microglial population. 
Animal models of TBI report an 
immediate microglial inflammatory 
response following TBI of both 
reparative (M2a microglial 
phenotype) and neurotoxic (M1 
microglial phenotype) which 
possibly switches to M1 
predominant phenotype during the 
late phase. The response in humans 
following TBI is unclear. 
To determine the microglial 
phenotypes associated with 
survival from sTBI. 
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2 General Material and Methods 
2.1 Ethical approval for use and source of human tissue 
All human brain tissue used it the following studies were selected from the Glasgow TBI 
Archive of the department of Neuropathology, Glasgow, UK. The Glasgow TBI archive 
contains 1474 TBI cases collected from 1963 to 2006, together with a quantity of uninjured 
controls. Within the TBI archive 1133 cases are males (77%) and 341 cases are females 
(23%). All cases have corresponding post-mortem reports available and, where necessary, 
supplemented by forensic and clinical records. As such, the Archive database includes 
information on demographics, clinical data, and detail on neuropathology findings at the 
original autopsy. All procedures were performed in accordance with approval granted by the 
South Glasgow and Clyde Research Ethics Committee (REC Nos 10/S0704/60) and the 
Greater Glasgow and Clyde Bio-repository Governance Committee (Appendix 1). 
2.2 Studies using post-mortem brain tissue 
All tissue was acquired at routine diagnostic post-mortem and was available for use as 
formalin-fixed, paraffin embedded blocks.  Whole brains were immersed in 10% formol 
saline for a minimum of 3 weeks, then dissected using a standardised block selection 
protocol. Tissue was then processed to paraffin using standardized techniques. All cases 
were anonymised with no patient-identifiers available to the researcher. 
All cases had a confirmed diagnosis of moderate to severe TBI based on clinical and 
pathological assessments. Cases included various survival times and ages. Acute cases 
(survival < 14 days) were included (n = 74) with ages ranging from 4 - 60 years old. 
Intermediate cases were selected (n = 11) with survival intervals ranging from 14 days to 1 
year and long-term TBI cases (n = 32) with ages ranging from 19 – 60 years old and survival 
intervals ranging from 1 year to 47 years. Mean PM delay, sex, cause of injury and cause of 
death can be found in Appendix 2. Age-matched, uninjured controls were included (n = 30), 
with ages ranging from 7 years to 60 years old at time of death and with no known history 
of neurological disease or of TBI. Varying causes of death are reported with SUDEP and 
heart disease predominant. All TBI cases and controls were aged 60 years old or younger at 
time of death to minimise influence of ageing-associated pathologies on observations. 
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2.3 Tissue preparation for immunohistochemistry 
Sections were cut at 8μm using a rotary microtome (Leica Microsystems, Wetzlar, Germany) 
and mounted onto Superfrost Plus microscope slides (Cellpath, Powys, UK). The slides were 
placed into an oven at 37oC for minimum of 72 hours for the tissue to adhere to the slides. 
Sections were then deparaffinised in xylene (3 x 5 minutes) followed by immersion in 100% 
methanol (3 x 5 minutes), 95% methanol (2 x 5 minutes) then rehydrate to distilled water 
(dH20). Sections were then immersed in 3% hydrogen peroxide solution (H202) for 15 
minutes to reduce endogenous peroxidase activity. After washing in water, antigen retrieval 
was performed as required for each specific antibody. Heat/pressure antigen retrieval was 
performed by immersing slides in preheated Tris EDTA buffer (pH8.0) or Citrate buffer 
(pH6.0) and placing them in a microwave pressure cooker for 8 minutes on high power. The 
pin on the pressure cooker should have popped after 3 minutes to guarantee the sections are 
immersed in boiling solution for exactly 5 minutes. To ensure consistent heat dispersion, the 
same number of slides were places in the pressure cooker each run. 
The lid of the pressure cooker was then removed, carefully, and sections left for 10 minutes 
to cool on the bench, followed by slow introduction to cold water to bring up to temperature. 
Once cooled, sections were then blocked for 30 minutes using 50μl horse serum blocking 
agent (Vector Labs, Burlingame, CA, USA) per 5 ml Optimax buffer (Biogenex, San 
Ramon, CA, USA). The primary antibody was diluted in optimax buffer (for specific 
antibody dilutions see appendix 3) and applied to the sections for 20 hours at 4oC. Once 
incubated with the primary antibody, the sections went through 3 separate washes in 
PBS/Tween for 10 minutes each on a belly dancer (Stovall, Life Science Inc, Greensboro, 
US). Following these washes, a biotinylated secondary antibody (10μl horse serum and 10μl 
secondary antibody per 5ml Optimax buffer) was applied for 30 minutes RT (Universal Elite 
Kit, Vector Labs, Burlingame, CA, USA), followed again by 3, 10 minute washes in 
PBS/Tween. The avidin/biotin horse-radish peroxidase (HRP) complex (10μl Avidin DH 
solution and 10μl biotinylated enzyme per 5ml Optimax buffer) was then applied for 30 
minutes RT followed by another washing step in PBS/Tween (3 x 10 minutes). Visualisation 
was achieved using the DAB peroxidase substrate kit (Vector Labs, Burlingame, CA, USA) 
which was applied as per manufacturer’s instructions. The sections were then rinsed in dH20 
and counterstained by immersion in Mayer’s haematoxylin for 1 minute. Slides were rinsed 
again in dH20 and then immersed in Scott’s Tap Water Substitute for 1 minute to ‘blue’ the 
sections. The slides were then dehydrated through 95% and 100% methanol (3 x 5 minutes 
each), immersed in xylene to clear sections (3 x 5 minutes) and then coverslipped. 
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Negative controls were used in each experiment to demonstrate the absence of non-specific 
binding. The primary antibody was omitted from these sections, optimax buffer was used 
only. Positive sections were used in each experiment to demonstrate correct staining of the 
specific antibody. 
All sections were viewed using a Leica DMRB light microscope (Leica Microsystems). In 
addition, sections were scanned and analysed using a 20x optic on a Hamamatsu 
Nanozoomer 2.0-HT slide scanner which has a 0.75NA and scans images at a digital 
resolution of 0.46µm per pixel. Furthermore, where appropriate sections were scanned using 
a 40x optic which scans images at a digital resolution of 0.23µm per pixel. The images 
viewed via the SlidePath Digital Image Hub application (Leica Microsystems). Observations 
were made blind to all clinical and demographic data of all cases. 
 
2.4 Statistical analysis 
Statistical analyses were performed using SPSS (version 22, IBM.com). The exact details of 
particular tests used are given in each chapter. Semi quantitative data of BBB disruption 
(Chapter 3 and 4) and microglia activation (Chapters 6 and 7) were analysed using the χ2 
test to assess differences in scoring between and within cohorts. Cramer’s V was calculated 
to determine the effect size. A Cramer’s V value of 0.1 suggested a low practical 
significance, a value of 0.3 suggested a moderate practical significance and a value of 0.5 
suggested a high practical significance. Where quantitative data were collected (Chapters 5, 
6 and 7) values were, where possible, expressed as mean ± standard error of the mean. The 
Student’s t-test was used to compare data sets between and within cohorts. Cohen’s d was 
calculated to determine the effect size and to indicate the standardised difference between 
two means. A Cohen’s d value of 0.2 suggested a low practical significance, a value of 0.5 
suggested a moderate practical significance and a value of 0.8 suggested a high practical 
significance. All effects were considered statistically significant when p ≤ 0.05. 
.
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3 Blood-brain barrier disruption is an early event 
that may persist for many years after traumatic 
brain injury 
3.1 Introduction 
Traumatic brain injury (TBI) is acknowledged as the strongest environmental risk factor for 
the development of neurodegenerative disease, historically reported as Alzheimer’s disease 
(AD) (Molgaard et al., 1990, Mortimer et al., 1985, Mortimer et al., 1991, Graves et al., 
1990, O'Meara et al., 1997, Salib and Hillier, 1997, Guo et al., 2000, Schofield et al., 1997, 
Plassman et al., 2000, Fleminger et al., 2003, Lye and Shores, 2000, Johnson et al., 2010, 
Plassman and Grafman, 2015), although more recently regarded as chronic traumatic 
encephalopathy (CTE) (Corsellis et al., 1973, Smith et al., 2013, McKee et al., 2013, McKee 
and Daneshvar, 2015, Hay et al., 2016). In the UK alone, there are approximately 160,000 
hospital admissions annually, this number is significantly higher in the US with 300,000 TBI 
patients requiring hospitalisation (Coronado VG, 2012, Faul M, 2010, CDC, 1999). 
Potentially, this TBI population could significantly impact the financial burden allocated to 
dementia care globally. Exposure to a single moderate or severe, or to repetitive TBI, reveals 
a complex of pathologies including abnormalities of tau, amyloid-β and TDP-43; neuronal 
loss; neuroinflammation; and white matter degradation (Johnson et al., 2010, Smith et al., 
2013, McKee et al., 2013, McKee and Daneshvar, 2015, Johnson et al., 2012, Johnson et al., 
2013a, Ramlackhansingh et al., 2011a, Johnson et al., 2013d). The mechanisms driving these 
late post-TBI neurodegenerative pathologies remain elusive.  
3.1.1 Blood-brain barrier disruption in disease 
Disruption of the blood-brain barrier (BBB) is increasingly recognised in a variety of 
disorders such as ischemia (Sandoval and Witt, 2008), multiple sclerosis (Kirk et al., 2003) 
and neurodegeneration (Zlokovic, 2011, Bell and Zlokovic, 2009b). Various studies suggest 
that disruption of the BBB integrity is an early event in the progression of AD and may 
contribute to its pathogenesis, perhaps as a result of impaired amyloid-β clearance or 
associated neuroinflammation (Zlokovic, 2011, Grammas, 2011, Shibata et al., 2000b, 
Zlokovic et al., 2010, Deane et al., 2004a, Jaeger et al., 2009). Specifically, a case-control 
magnetic resonance imaging (MRI) study investigated BBB permeability in both AD 
patients and healthy, older controls. A noted increase in BBB permeability was present at an 
early stage in AD although the extent of the leakage was similar to the controls of a similar 
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age (mean age of AD patients was 73.7 years and mean age of controls 72.7 years). In a 
systematic review of the literature, increasing age in healthy subjects was a risk factor of 
BBB disruption, which increased further in vascular dementia and AD (Farrall and Wardlaw, 
2009). Animal models of AD have also suggested that BBB permeability is an early event 
in AD (Ujiie et al., 2003). Using an AD model Tg2576 mice, Ujiie et al assessed the uptake 
of Evans blue dye and albumin into the brain of transgenic mice. Increased BBB 
permeability was found in the cortex of 10-month-old Tg2576 mice, preceding AD 
presentation. Furthermore, younger (4-month-old) Tg2576 mice exhibited BBB disruption 
compared to their non-transgenic counterparts (Ujiie et al., 2003). 
Neuropathology studies also suggest complex vascular changes associated with increased 
BBB permeability in AD patients (Zipser et al., 2007b, Brown et al., 2001, Buee et al., 1994), 
where an association between histologic evidence of BBB leakage and AD-type pathologies 
in “normal” aging has also been demonstrated (Viggars et al., 2011). Utilising the brain 
donations from the Medical Research Council Cognitive Function and Ageing Study (MRC 
CFAS), Viggars et al investigated BBB disruption in the temporal cortex of 92 participants 
in the study. By staining sections with BBB permeability markers albumin and fibrinogen, 
along with tight-junction protein markers claudin-5, ZO-1 and occludin they demonstrated 
that BBB disruption increased with the progression of AD-type pathology, such as 
neurofibrillary tangles, and this increase in disruption was accompanied with an increase in 
vascular density (Viggars et al., 2011). 
3.1.2 Blood-brain barrier disruption after TBI 
Blood-brain barrier disruption has been demonstrated in the acute phase following TBI using 
several animal models, but the temporal course of this disruption is unclear. Some studies 
suggest a short-lived opening of the BBB following injury which is resolved within hours 
(Barzo et al., 1996, Habgood et al., 2007, Baldwin et al., 1996, Shapira et al., 1993, Rinder 
and Olsson, 1968, Shreiber et al., 1999, Smith et al., 1995, Cortez et al., 1989, Ommaya et 
al., 1964, Hekmatpanah and Hekmatpanah, 1985, Hicks et al., 1993, Povlishock et al., 1978). 
However, other models of TBI suggest a more dynamic biphasic course of BBB disruption 
where an early-phase BBB opening occurs at 3–6 hours post-injury followed by a later BBB 
opening at 1–3 days post-injury (Baldwin et al., 1996, Baskaya et al., 1997). Of note, several 
of the studies that suggest a short-lived opening of the BBB also suggest some continual 
leakage for up to 4 days post-injury (Shapira et al., 1993, Habgood et al., 2007), while others 
only monitored the rodents for a short time-period following the injury (Barzo et al., 1996, 
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Shreiber et al., 1999). Deposits of focal immunoglobulin-G (IgG) around callosal blood 
vessels ipsilateral to controlled cortical impact in mice have been demonstrated 3 months 
following injury, which supports this later BBB disruption (Glushakova et al., 2014). 
Where evidence of acute-phase BBB disruption following injury has been demonstrated in 
various animal models of TBI, several clinical studies report elevated levels of serum 
albumin and S100β in the cerebrospinal fluid (CSF) following a severe TBI (Saw et al., 
2014, Stahel et al., 2001, Ho et al., 2014a, Blyth et al., 2009). Ho et al performed a 
retrospective cohort study on 97 TBI patients in which they observed BBB disruption in 43 
of the 97 patients. Furthermore, this disruption is associated with more severe TBI and may 
predict an unfavourable long-term outcome (Ho et al., 2014a). In addition, neuroimaging 
studies have reported evidence of prolonged BBB disruption in patients following TBI, even 
mild to moderate injury in some cases, which can present in greater frequency in patients 
with post-traumatic epilepsy (PTE) (Tomkins et al., 2011). Using MRI, Tomkins et al 
investigated BBB breakdown in 37 TBI patients, 19 of which suffered from PTE. Disruption 
was observed in 53% of TBI patients, lasting up to 11 years post-injury, with PTE patients 
more likely to have BBB disruption than non-epileptic patients (82.4% versus 25%) 
(Tomkins et al., 2011). Furthermore, BBB disruption has been observed following mild TBI 
in American football participants using imaging techniques, independent of clinical evidence 
of TBI (Weissberg et al., 2014). Weissberg et al recruited 16 football players and 13 track 
and field athletes where, following at least 2 months of training and competing, they 
underwent MRI to assess BBB integrity. The results revealed that BBB disruption was 
evident in 40% of the football players and 8.3% of the control athletes. Furthermore, elevated 
S100β serum levels have been reported in football players, in the absence of recorded 
concussions, indicating that this BBB disruption may be a result of ‘subconcussive’ events 
(Marchi et al., 2013). 
There is, therefore, evidence from both animal models and limited clinical studies of BBB 
disruption following a TBI; however, the extent and temporal course of this BBB 
dysfunction in humans has not been researched fully. Specifically, evidence of late phase 
BBB disruption has not been explored. In this study, material from the Glasgow TBI Archive 
will be used to characterise the extent, distribution and temporal dynamics of BBB disruption 
following a moderate or severe single TBI in comparison with age-matched controls. 
Hypothesis:  BBB disruption is present following TBI observed by increased deposits of 
fibrinogen and IgG throughout the brain compared to uninjured controls. 
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3.2 Specific methods 
3.2.1 Case selection and brain tissue preparation 
Ethical approval for this study was granted by the Greater Glasgow and Clyde Bio-repository 
Governance Committee. From the Glasgow TBI Archive, cases aged 60 years or younger at 
the time of death with a history of a single moderate or severe TBI were selected. They 
represented a range of survival times from injury to include acute cases with survival times 
of 10 hours to less than 14 days (n = 27); intermediate cases with survival times of 14 days 
to less than 1 year (n = 11); and long-term cases with survival times from 1 year to 47 years 
(n = 32). Detailed reports from the original diagnostic autopsy were available for all cases; 
where necessary these were supplemented by forensic and clinical records, and a history of 
moderate or severe TBI at presentation was confirmed, as defined by Glasgow Coma Scale. 
Age-matched uninjured controls aged 60 years or younger at the time of death and with no 
known history of neurologic disease or history of TBI (n = 21) were selected for comparison. 
Post-mortem delays were comparable across the cohorts (p > 0.05 in all comparisons across 
cohorts; Student’s t-test). Demographics, clinical data, and detail on neuropathology 
findings at the original autopsy for each cohort are presented in Table 2. 
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Table 2 Demographic and clinical information of all groups 
 TBI: Acute 
survival  
(n = 27) 
TBI: 
Intermediate 
survival (n = 11) 
TBI: Long-term 
survival  
(n = 32) 
Controls  
(n = 21) 
Mean age (range) 44.4 years 
(9-60) 
32 years 
(17-56) 
46.3 years 
(19-60) 
39.9 years  
(14-60) 
 
Males 17 
(63%) 
11 
(100%) 
31 
(96.9%) 
13  
(62%) 
Mean PM delay (range) 56.1 hours  
(3-240) 
 
74.7 hours  
(26-192) 
 
65.5 hours  
(9-184.5) 
 
71.6 hours 
(12-144)  
Mean survival interval (range) 69.3 hours 
(6-216)  
72.8 days 
(14-279)  
7.8 years 
(1-47)  
Not applicable 
Cause of 
TBI 
Fall 15 
(55.5%) 
2 
(18%) 
15 
(46.9%) 
Not applicable 
(No history of 
TBI) 
RTA 7 
(25.9%) 
5 
(45.5%) 
5 
(15.60%) 
Assault 4 
(14.8%) 
3 
(27%) 
8 
(25%) 
Unknown 1 
(3.7%) 
1 
(9.1%) 
4  
(12.5%) 
Cause of 
death 
Head injury 25(92.6%) 4(36.4%) 0 0 
Bronchopneumonia 2(7.4%) 4(36.4%) 7(21.9%) 1(4.8%) 
ARDS 0 2(18.1%) 1(3.125%) 0 
Pulmonary 
thromboembolism 
0 1(9.1%) 0 0 
Heart disease 0 0 6(18.8%) 5(23.8%) 
Alcohol related 0 0 2(6.25%) 0 
Pyelonephritis 0 0 1(3.125%) 0 
Multi-organ failure 0 0 1(3.125%) 0 
GIT haemorrhage 0 0 1(3.125%) 0 
Polytrauma 0 0 1(3.125%) 0 
Drug overdose 0 0 0 3(14.3%) 
SUDEP 0 0 7(21.9%) 8(38.1%) 
Pulmonary oedema 0 0 1(3.125%) 0 
Septicaemia 0 0 0 2(8.3%) 
Inhalation of gastric 
contents 
0 0 0 2(8.3%) 
Unknown 0 0 4(12.5%) 0 
Key: TBI = traumatic brain injury; SUDEP = sudden unexpected death in epilepsy; GIT = 
gastrointestinal tract; ARDS = acute respiratory distress syndrome; RTA = road traffic accident 
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3.2.2 Routine histology 
Haematoxylin and eosin staining was performed on sections from all tissue blocks. Slides 
were deparaffinised in xylene and rehydrated to water followed by immersion for 10 minutes 
in haematoxylin (Mayer; Leica Microsystems, Wetzlar, Germany). After rinsing and 
immersion in Scott's tap water substitute (Leica Microsystems) to “blue” the sections, slides 
were differentiated in 1% acid alcohol and rinsed. The sections were then immersed in 25% 
aqueous eosin Y solution (TCS Biosciences, Buckingham, United Kingdom) for 5 minutes, 
rinsed, dehydrated, cleared, and coverslipped. 
3.2.3 Immunohistochemistry 
After deparaffinisation and rehydration, sections were immersed in 3% aqueous H2O2 for 
15 minutes to quench endogenous peroxidase activity. Antigen retrieval was performed via 
microwave pressure cooker for 8 minutes in preheated 0.1 mol/L Tris EDTA buffer (pH8). 
Subsequent blocking was achieved by applying 50 μL of normal horse serum (Vector Labs, 
Burlingame, CA) per 5 mL of Optimax buffer (BioGenex, San Ramon, CA) for 30 minutes. 
Incubation with the primary antibody was then performed for 20 hours at 4°C. Polyclonal 
rabbit anti-human antibodies for fibrinogen (FBG) and IgG (Dako, Carpinteria, CA) were 
used at dilutions of 1: 17,500 and 1: 10,000, respectively. A biotinylated secondary antibody 
was then applied for 30 minutes, followed by avidin-biotin complex as per the 
manufacturer's instructions (Vectastain Universal Elite kit, Vector Labs). Finally, 
visualisation was achieved using the DAB peroxidase substrate kit (Vector Labs) followed 
by counterstaining with haematoxylin. Known positive tissue sections were run in parallel 
with test sections in all antibody runs, in addition to sections with primary antibody omitted 
as standard controls for antibody specificity. 
3.2.4 Image analysis 
All sections were viewed using a Leica DMRB light microscope (Leica Microsystems). In 
addition, sections were scanned at 20x using a Hamamatsu Nanozoomer 2.0-HT slide 
scanner, with the images viewed via the SlidePath Digital Image Hub application (Leica 
Microsystems). Furthermore, where appropriate sections were scanned using a 40x optic 
which scans images at a digital resolution of 0.23µm per pixel. The images in this chapter 
have been digitally captured at 4x (2.3µm per pixel), 20x (0.46µm per pixel) and 40x 
(0.23µm per pixel). 
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All observations were conducted blind to demographic and clinical data. Anatomically 
distinct regions were defined for assessment to include the neocortical grey matter of the 
cingulate gyrus, cingulate sulcus, superior frontal gyrus, parahippocampal gyrus, collateral 
sulcus, fusiform gyrus, and insular cortex. A sub-analysis of neocortical grey matter was 
performed by dividing the cortex into superficial (layers 1 and 2), mid (layers 3 and 4), and 
deep layers (layers 5 and 6) (Figure 3-1). In addition, the white matter of the midline and 
lateral extent of the corpus callosum and internal capsule, hippocampal sectors CA1 to CA4, 
and the thalamus (subdivided into medial, intermediate, and lateral regions) were assessed. 
Each anatomic region was reviewed, and, in a semi-quantitative assessment, the frequency 
and intensity of immunoreactivity were determined as absent (score 0), sparse (score 1), 
moderate (score 2), or extensive (score 3). Representative examples of 
immunohistochemical findings and the corresponding semi-quantitative scores are shown in 
Figure 3-2. 
 
Figure 3-1 Separation of Cortical lamination  The sub-analysis of neocortical grey matter was performed 
by dividing the cortex into 3 distinct layers based on the cortical distribution of neurons 
3.2.5 Statistical analysis 
All data were analysed using SPSS (version 22; IBM, Inc). The χ2 test was used to assess 
differences in data between and within cohorts, where appropriate. Cramer’s V was used to 
determine the effect size. A Cramer’s V value of 0.1 suggested a low practical significance, 
a value of 0.3 suggested a moderate practical significance and a value of 0.5 suggested a 
   Layers 1 and 2 (Molecular   
    and external granular  
    layer) 
Layers 3 and 4 (External 
pyramidal layer and internal 
granular layer 
Layers 5 and 6 (internal 
pyramidal layer and 
polymorphic layer 
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high practical significance.  All effects were considered statistically significant when p ≤ 
0.05. 
 
Figure 3-2 Representative images of semi-quantitative scoring Representative examples of the patterns of 
fibrinogen (FBG) immunoreactivity. (a) The superior frontal gyrus of a 47-year-old male traumatic brain injury 
(TBI) patient who died 1 year after a fall. No abnormal FBG immunoreactivity is present (score of 0). (b) 
Limited sparse perivascular FBG immunoreactivity (score of 1) in a 60-year-old male TBI patient who died 16 
years after a road traffic accident. (c) More widespread moderate perivascular FBG immunoreactivity (score 
of 2) in the superior frontal gyrus of a 60-year-old male TBI patient who survived 10 hours after a fall. (d) 
Extensive perivascular and adjacent parenchymal FBG immunoreactivity (score of 3) in a 50-year-old male 
TBI patient who survived 1 year after an assault. (e) Extensive perivascular FBG immunoreactivity (score of 
3) in the thalamic region of a 60-year-old male TBI patient who survived 8 days after a fall. (f) Sparse 
perivascular FBG immunoreactivity (score of 1) in the parahippocampal region of a 56-year-old female TBI 
patient who survived 24 hours after a road traffic accident. Scale bar = 1mm (low magnification), scale bar = 
100μm (high magnification). 
  
a b 
c d 
e f 
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3.3 Results 
3.3.1 FBG immunoreactivity in control group 
In uninjured controls, where present, FBG immunoreactivity was observed in a 
predominantly perivascular distribution highlighting small vessels throughout the neuropil. 
In addition, occasional sparse immunoreactive neurons and glia were observed. In an 
overwhelming majority of controls (17 of 21), FBG immunoreactivity was limited (score 0 
or 1) (Figure 3-3a) and localised (Figure 3-4). In the remaining 4 controls, localised foci of 
moderate (score 2) levels of FBG immunoreactivity were observed in single tissue blocks; 
in 2 cases localised to the thalamus, one to the fusiform gyrus and the last to the superior 
frontal gyrus (Figure 3-5). Causes of death in these controls with localised moderate FBG 
immunoreactivity were mixed; there was 1 case each of sudden death in epilepsy, sudden 
death of cardiac origin, sepsis with multi-organ failure, and pneumonia. 
3.3.2 FBG immunoreactivity in acute TBI survival 
In material from patients dying acutely after TBI (10 hours to less than 14 days survival), in 
addition to perivascular FBG immunoreactivity, regions of more confluent diffuse 
immunostaining were also present (Figure 3-3b). In contrast to the typically limited 
abnormal FBG immunoreactivity observed in controls, in this acute TBI survival cohort, 
88% of cases showed at least 1 anatomic region with moderate (score 2) or extensive (score 
3) FBG immunoreactivity (p < 0.001; χ2; Cramer’s V = 0.703). Furthermore, in contrast to 
the localised pathology in controls, FBG immunoreactivity after TBI often appeared 
multifocal, that is, involving 2 or more regions in 11 of 27 (40%) acute survival cases (Figure 
3-4). Of the regions examined, moderate or extensive FBG immunoreactivity was detected 
most frequently in material from the cingulate and superior frontal gyri (16 cases), followed 
by the thalamus (12 cases), medial temporal lobe (11 cases) and insular cortex (6 cases) 
(Figure 3-5). Within the neocortical regions (cingulate, superior frontal, fusiform and 
parahippocampal gyri), there was evidence of preferential anatomic distribution, with 
moderate or extensive FBG immunoreactivity more evident in the crests of gyri than in the 
depths of the adjacent sulci in both cingulate and medial temporal lobe cortical regions 
(Figure 3-6). Furthermore, within the crests of gyri, FBG immunoreactivity was greater in 
the mid and deeper layers than the superficial layers of the cortex. In the superior frontal 
gyrus, 60% of cases showed moderate or extensive FBG immunostaining in the deeper layers 
versus 15% of cases in the superficial layers (p = 0.0079; χ2; Cramer’s V = 0.46) (Figure 
3-6). There was no notable FBG immunoreactivity in the corpus callosum. 
3 51 
 
 
Figure 3-3 Representative images of fibrinogen (FBG) and immunoglobulin G (IgG) immunoreactivity 
after traumatic brain injury (TBI) and controls  (a) Absence of FBG immunoreactivity in the superior 
frontal gyrus (Score of 0) of a 46-year-old man with no history of TBI. (b) Extensive FBG immunoreactivity 
in the superior frontal gyrus (Score of 3), with preferential distribution of staining to the mid and deep cortical 
layers in a 20-year-old male TBI patient who survived 2 days after an assault. (c, d) Extensive FBG (c) and 
IgG (d) immunoreactivity in adjacent sections from the superior frontal gyrus (Score of 3) of a 60-year-old 
male TBI patient who survived 18 years after a fall (e) FBG immunoreactivity and (f) IgG immunoreactivity 
in astrocytes in a 37-year-old male TBI patient who survived 4 years after a fall. Scale bar = 1mm (low 
magnification), scale bar = 100μm (high magnification), scale bar = 10µm (higher magnification in e and f). 
  
a b 
c d 
e f 
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Figure 3-4 Extent of abnormal FBG immunoreactivity after TBI at varying survivals versus controls  
Moderate or extensive FBG immunoreactivity was an uncommon observation in controls, occurring in just 4 
of 21 cases (19%), but it was a frequent observation after TBI at all survival time points assessed, being present 
in 88%, 64%, and 69% of acute, intermediate, and long-term survival cases, respectively. Furthermore, 
abnormal FBG immunostaining in controls was restricted to single anatomic region in contrast to the often 
multifocal pathology in patients after TBI (** p < 0.001; χ2 TBI cohort vs control FBG positivity).  
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Figure 3-5 Regional distribution of FBG immunoreactivity following TBI versus controls  At all survival 
intervals and in each region analysed there was evidence of BBB disruption following TBI, evidenced by 
moderate/extensive FBG immunoreactivity, in a higher proportion of TBI survivors than matched, uninjured 
controls in material from the (a) cingulate/superior frontal gyri, (b) thalamus, (c) hippocampus, and (d) insular 
cortex. (*p<0.05; **p<0.01; ***p<0.005; +p<0.0005; ++p<0.0001; Χ2 TBI cohort v control). 
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3.3.3 FBG immunoreactivity in intermediate TBI survival 
Similar to material from patients dying acutely after TBI, regions of moderate or extensive 
FBG immunoreactivity were present in a greater number of intermediate (>2 weeks to 1 year 
after TBI) survival patients versus controls, with 7 of 11 (64%) (p = 0.004; χ2; Cramer’s V 
= 0.446) demonstrating at least 1 anatomic sub-region with moderate or extensive FBG 
immunoreactivity; 4 of these cases showed multifocality (Figure 3-4). Again, the cingulate 
and superior frontal gyri most frequently showed increased staining (6 cases), followed by 
medial temporal lobe (4 cases), thalamus (2 cases), and insular cortex (2 cases) (Figure 3-5). 
As in the acute survival cases, there was a predilection for gyral crests over sulcal depths in 
the cingulate gyrus and medial temporal lobe. Although the small number of cases precludes 
formal statistical assessment, there was a trend toward preferential staining in mid to deep 
rather than superficial neocortical layers in all cortical regions (Figure 3-6). As with the acute 
TBI survival, there was no notable FBG immunoreactivity in the corpus callosum. 
 
Figure 3-6 Neocortical distribution of FBG immunoreactivity after TBI  (a) There was a clear preferential 
distribution of abnormal FBG immunoreactivity to the crests of gyri when compared to the depths of sulci 
across all survival points, as illustrated here for the superior frontal gyrus versus the adjacent cingulate sulcus 
(*p<0.01; **p<0.001; χ2 sulcus versus gyrus). (b) Further, within the neocortical grey matter region of the 
cingulate gyrus there was preferential distribution of abnormal staining to the mid (layers 3 and 4) and deep 
(layers 5 and 6) cortical layers when compared to superficial layers (layers 1 and 2). (*p<0.01; **p<0.001; χ2 
deep versus superficial cortical layers). 
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3.3.4 FBG immunoreactivity in long-term TBI survival 
A higher proportion of long-term survival cases showed evidence of increased FBG 
immunoreactivity versus matched uninjured controls (Figure 3-3c); at least 1 anatomic 
region showed moderate or extensive FBG immunoreactivity in 22 of 32 (69%) cases (p < 
0.001; χ2; Cramer’s V = 0.486). Multifocality was again common, present in 15 of the long-
term survival cases (47%) (Figure 3-4). This increased staining was most frequent in material 
from the medial temporal lobe (17 cases), followed by cingulate and superior frontal gyri 
and thalamus (14 cases each) and insular cortex (5 cases) (Figure 3-5). As in acute and 
intermediate cases, there was a preferential distribution to the crests of gyri over depths of 
sulci (Figure 3-6). Furthermore, within the crests of gyri, FBG immunoreactivity was greater 
in the mid and deeper layers than the superficial layers of the cortex. Thus, in the superior 
frontal gyrus, 56% showed moderate or extensive FBG immunostaining in the deeper layers 
versus 12% in the superficial layers (p = 0.0023; χ2; Cramer’s V = 0.461) (Figure 3-6). This 
pattern was reflected in all cortical regions assessed. In the medial temporal lobe, 40% 
showed extensive FBG immunostaining in the deep layers compared with 14% in the 
superficial layers (p = 0.0683; χ2; Cramer’s V = 0.278). In contrast to earlier survival time 
points and controls, 53% of cases in this long-term survival cohort showed hippocampal 
FBG immunoreactivity greater than sparse (score 1) in at least 1 hippocampal sector (p = 
0.0001; χ2; Cramer’s V = 0.124). There was no clear preferential distribution to any 
particular sector; however, in keeping with this widespread increased FBG 
immunoreactivity in these long-term survival cases, 44% showed increased thalamic 
staining versus 10% of controls (p = 0.0015; χ2; Cramer’s V = 0.461). Again, there was no 
increase in FBG immunoreactivity detected in material from the corpus callosum. 
3.3.5 IgG immunoreactivity in all groups 
Observations in the anti-IgG-stained material paralleled the observations in material 
immunostained for FBG (Figure 3-3d). Thus, at all post-TBI survival points and in controls, 
the extent and distribution of IgG immunoreactivity were comparable to those of FBG 
immunoreactivity, that is, there was greater perivascular and confluent diffuse staining IgG 
immunoreactivity in a proportion of TBI cases at all survivals versus controls. Specifically, 
IgG immunoreactivity in the control cohort was limited, with only 4 (19%) of 21 cases 
displaying moderate IgG immunoreactivity (score of 2): in 2 cases, this was localised to the 
superior frontal gyrus; 1 case localised to the thalamus; and 1 to the fusiform gyrus. Again, 
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no multifocality was observed. Causes of death in the controls included sudden death in 
epilepsy (n = 2), drug overdose (n = 1), and pneumonia (n = 1).  
The acute TBI survival cohort demonstrated moderate or extensive IgG immunoreactivity in 
at least 1 anatomic sub-region in 63% of cases (p < 0.005; χ2; Cramer’s V = 0.439), with 
multifocality present in 10 of 27 (37%). Of the regions examined, moderate or extensive IgG 
immunoreactivity was detected most frequently in material from the medial temporal lobe 
(10 cases), followed by the cingulate/superior frontal gyri and the thalamus (8 cases), and 
lastly the insular cortex (2 cases). As with FBG immunoreactivity, there was evidence of 
preferential anatomic distribution, with moderate or extensive IgG immunoreactivity more 
evident in the crests of gyri than in the depths of the adjacent sulci and in the mid to cortical 
deep layers when compared with the superficial cortical layers. 
Following intermediate survival from TBI, regions of moderate or widespread IgG 
immunoreactivity were present in a greater number than in controls, with 6 of 11 (55%) 
demonstrating at least 1 anatomic sub-region with moderate/extensive IgG 
immunoreactivity (p = 0.05; χ2; Cramer’s V = 0.183), multifocality was present in 45%. The 
long-term survival TBI cohort demonstrated 71% (23 of 32 cases) of moderate/extensive 
IgG immunoreactivity in at least 1 anatomic sub-region (p = 0.0002; χ2; Cramer’s V = 
0.517). Multifocality again was common, with 14 of 32 (43%) long-term TBI cases showing 
immunoreactivity in 2 or more sub-regions. Increased IgG staining was most frequent in the 
medial temporal lobe (13 cases each), followed by cingulate/superior frontal gyri and 
thalamus (12 cases), and insular cortex (3 cases). The pattern and distribution of IgG 
immunoreactivity also paralleled the results in anti-FBG-immunostained material, with 
preferential distribution to the crests of gyri over the depths of sulci in both cingulate gyri 
and hippocampal gyri, and greater IgG immunoreactivity observed in the mid and deeper 
layers versus the superficial neocortical layers. 
3.3.6 Association of BBB disruption with TBI-associated 
pathologies 
Reviewing haematoxylin and eosin–stained sections from the multiple tissue blocks 
examined for immunohistochemical evidence of BBB disruption confirmed the anticipated 
BBB disruption in association with acute focal haemorrhagic pathologies, in addition to 
more widespread and diffuse BBB disruption independent of focal pathology. Specifically, 
in material from acute TBI survivors, 21 TBI-associated focal haemorrhagic lesions or 
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contusions were observed across 13 of the 27 cases; virtually all (12 of 13 cases) displayed 
some degree of extravascular FBG immunoreactivity in the surrounding parenchyma. 
However, in the majority of these cases (9 of 13; 69%), BBB disruption was not confined to 
the region of focal pathology, with evidence of widespread diffuse BBB injury present in 
the remaining tissue blocks. Notably, in the 14 acute survival TBI cases without focal 
haemorrhage or contusion, 12 (86%) also displayed extensive FBG immunoreactivity in at 
least 1 region examined. In material from patients surviving beyond the acute phase of 
injury, there was evidence of healed haemorrhages or contusions, with histologic features 
consistent with their having dated from the time of the original TBI in 2 of 11 intermediate 
survival (comprising 6 individual lesions) and 8 of 32 long-term survival cases (12 distinct 
lesions). 
 Although not as extensive as observed in relation to focal haemorrhages or contusions in 
acute survivors, some evidence of BBB disruption was observed in the immediate locality 
of all 6 lesions in material from intermediate survivors. In contrast, evidence of focal BBB 
disruption in association with healed haemorrhages or contusions was less frequently 
observed in material from long-term survivors, with just 6 of 12 lesions associated with 
abnormal FBG or IgG immunoreactivity. Of note, both the intermediate survival cases and 
all 8 of the long-term survival cases with BBB disruption in association with focal 
pathologies also displayed more widespread diffuse BBB disruption remote from focal 
pathology. Six of 9 intermediate and 15 of 24 long-term survival cases showed no evidence 
of focal haemorrhagic or contusion pathology, and the material examined displayed evidence 
of extensive FBG immunoreactivity in at least 1 region. In addition to these focal 
haemorrhagic and contusional pathologies, there was evidence of diffuse hypoxic/ischemic 
injury, microgliosis, and/or astrogliosis in varying stages of evolution identified in a 
proportion of TBI cases across all survivals. No correlation between these TBI-related 
pathologies and evidence of BBB disruption were identified. 
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3.4 Discussion 
This study demonstrates histologic evidence of widespread, diffuse BBB disruption in the 
acute phase, which persists into the late phase of survivors of a single moderate or severe 
TBI when compared with uninjured controls. Increased and widespread immunoreactivity 
for FBG and IgG was observed in material from patients dying in the acute phase following 
a TBI and this increase is demonstrated in a high proportion of patients surviving years 
following injury. Thus, this study raises the possibility that a single moderate or severe TBI 
is responsible for immediate and long-lasting alterations in BBB function after injury, which 
might contribute to post-TBI neurodegeneration.  
Fibrinogen (340kDa) and IgG (150kDa) are plasma proteins which, under normal 
conditions, do not cross the BBB. This study, however, has demonstrated widespread, 
multifocal, perivascular, and parenchymal FBG and IgG deposition in nearly half of acute 
phase patients dying within the first 2 weeks following a single moderate or severe TBI, 
indicating that the BBB has been compromised. Similar post-TBI BBB disruption has been 
demonstrated in a variety of animal models where the presence of disruption is identified 
through extravasated serum proteins or by intravascularly injected labels in the brain 
parenchyma (Barzo et al., 1996, Habgood et al., 2007, Baldwin et al., 1996, Shapira et al., 
1993, Rinder and Olsson, 1968, Shreiber et al., 1999, Smith et al., 1995, Cortez et al., 1989, 
Ommaya et al., 1964, Hicks et al., 1993, Povlishock et al., 1980, Wei et al., 1980). This acute 
phase BBB disruption can be detected in the absence of haemorrhage, which is consistent 
with the observations in this study of human autopsy tissue.  
Possible structural alterations to account for this acute BBB disruption have been explored 
by ultrastructural studies in animal models of TBI which have identified a variety of 
alterations in the vascular endothelia in the acute phase after injury, including the formation 
of vacuoles, craters, and microvilli (Baskaya et al., 1997, Wei et al., 1980, Maxwell et al., 
1988, Vaz et al., 1998). Some of these changes have been demonstrated in human TBI 
(Rodriguez-Baeza et al., 2003, Vaz et al., 1997). These rapid alterations in vascular structure 
have been associated with various mechanisms such as direct perturbation of the vessels by 
mechanical forces, including the immediate disruption of vascular endothelial cells. 
Secondary insults following injury may also indirectly contribute to these changes thus 
damaging the normal endothelial cell integrity and function by increases in arterial pressure 
and intravascular thrombus formation (Hekmatpanah and Hekmatpanah, 1985, Povlishock 
et al., 1980, Wei et al., 1980). Furthermore, active physiological changes such as increased 
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transendothelial vesicular transport via normally intact tight junctions (Povlishock et al., 
1978, Vaz et al., 1998, Vaz et al., 1997, Maxwell et al., 1992) and alterations to other 
components of the BBB, such as early astrocyte disruption and swelling, have been described 
in both animals and humans after TBI (Hekmatpanah and Hekmatpanah, 1985, Maxwell et 
al., 1988).  
Studies suggest that acute BBB disruption may predict a worse long-term outcome after TBI 
clinically (Ho et al., 2014b), although the relative role of these pathologic alterations is 
unknown. However, BBB disruption following TBI may just present itself in severe cases; 
therefore showing poorer outcomes than in those with a better prognosis. Nonetheless, 
specific deleterious mechanisms of BBB disruption after TBI may include influx of fluid 
together with chemical and protein mediators promoting vasogenic oedema, disruption in 
the normal pathways to clear toxic metabolites, and a failure to deliver normal metabolites 
vital for function. In turn, the temporal course and relative contribution of these various 
consequences of BBB disruption may differ with the severity of injury.  
Although some animal studies show evidence of a two-staged BBB opening (Baldwin et al., 
1996, Baskaya et al., 1997), this current study using human autopsy material showed no 
clear evidence of this, in particular, in the acute phase. However, this biphasic approach to 
BBB disruption following injury cannot be excluded due to the diverse and heterogeneous 
nature of post-mortem TBI cases with varying intercurrent illnesses, survival times, and 
causes of injury that conceivably could mask such an observation. Further studies directly 
investigating the temporal course of this BBB disruption following TBI may reveal 
important potential therapeutic targets with defined windows of opportunity. A degree of 
acute BBB disruption was anticipated, based on current literature; however, the proportion 
of long-term survival cases with extensive BBB disruption was surprising and intriguing, 
specifically that extensive, multifocal, extravascular FBG and IgG deposition was observed 
in approximately half of cases surviving a year or longer following TBI. Notably, clearance 
of large soluble proteins from the brain parenchyma, such as IgG or FBG, occurs via 
convective bulk flow of interstitial fluid over hours to days, or more rapidly via reverse 
transcytosis (Zhang and Pardridge, 2001). Thus, the presence of these soluble plasma 
proteins in the brain parenchyma of patients exposed to TBI more than a year before death 
is consistent with ongoing BBB disruption, rather than evidence of protein deposition at the 
time of injury that is not cleared in the intervening period.  
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Observations were made in the study that the pattern and distribution of chronic BBB 
disruption after TBI was more frequently localised to the grey matter of the neocortical 
ribbon and deep grey nuclei, with a preferential distribution in the former to mid and deeper 
cortical layers over superficial layers, and the crests of gyri over depths of sulci.  This pattern 
indicates specific areas of BBB vulnerability within a more global and diffuse process, rather 
than a heterogeneous multifocal pathology. This intriguing observation challenges the 
current descriptions of aspects of the neuropathology of post-TBI neurodegeneration and 
CTE, in which localisation of tau pathologies to the depths of sulci is reported. However, at 
present, the neuropathological criteria for CTE diagnosis remain provisional; therefore, more 
research is required to determine how these pathologies interact. 
With regard to other TBI-associated pathologies, this study did not demonstrate any evidence 
of an association between widespread, diffuse BBB disruption and focal TBI pathologies, 
such as contusions or haemorrhages. Furthermore, there was no correlation between diffuse 
and widespread BBB disruption and diffuse ischemic pathology. The number of cases and 
necessary heterogeneity in pathologies within the examined cohorts were limited. Therefore, 
it was difficult to determine such an association and whether specific diffuse primary or 
secondary pathologies in the acute phase can account for later patterns of BBB disruption.  
This, however, opens opportunities to explore much larger cohorts and animal models. 
There has been increasing evidence reported of the clinical and neuropathologic sequelae of 
TBI and, in particular, the association of TBI survival and the increased risk of 
neurodegenerative disorders, specifically CTE (Corsellis et al., 1973, Smith et al., 2013, 
McKee et al., 2013). Neuropathologic examination of autopsy material from patients with 
survival greater than a year from a single moderate or severe TBI reveals an increased 
frequency of neurodegeneration-associated pathologies when compared with material from 
matched controls, including amyloid-β plaques, neurofibrillary tangles, inflammation, and 
white matter degradation (Johnson et al., 2010, Johnson et al., 2012, Johnson et al., 2013a, 
Johnson et al., 2013c). The role of the BBB in the pathological process of neurodegeneration 
is becoming increasingly interesting with evidence indicating that alterations in the brain’s 
microvasculature contribute to this decline (Zlokovic, 2011). Changes in the microvascular 
such as a decrease in vessel structure and density (Brown and Thore, 2011a), BBB disruption 
and subsequent leakage (Zipser et al., 2007a, Viggars et al., 2011), and secretion of 
potentially neurotoxic factors from the vascular endothelium (Grammas et al., 1999), have 
been reported in AD pathology. 
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Although the extravasation of serum proteins such as FBG have been demonstrated to 
correlate with the presence of AD-type pathology (Viggars et al., 2011), the association 
between the changes observed in the brain’s microvasculature and key neurodegenerative 
pathologies is not known. However, there is increasing clinical and experimental evidence 
that suggests some of these vascular changes occur early in the disease process and may 
contribute to states of hypoperfusion promoting neuronal injury (Zlokovic, 2011, Brown and 
Thore, 2011a, Hirao et al., 2005, Johnson et al., 2005). Future studies to investigate this 
relationship between BBB breakdown and other neurodegenerative pathologies will be 
crucial in understanding the disease progression. 
Fibrinogen alone has been widely attributed to the progression of AD with individuals with 
high serum FBG shown to be at greater risk of the disease (van Oijen et al., 2005, Xu et al., 
2008).  Fibrinogen was also shown to accelerate inflammation and neurovascular damage in 
a mouse model of AD (Paul et al., 2007, Petersen et al., 2018). Perhaps the most widely 
studied aspect of BBB regarding AD is its role in the clearance and sequestration of amyloid-
β to the peripheral circulation (Shibata et al., 2000b, Mawuenyega et al., 2010, Sutcliffe et 
al., 2011, Eisele et al., 2010). Influx of amyloid-β is mediated by receptor for advanced 
glycation end products (RAGE) which is located in the BBB and it has been reported that 
the increase of amyloid-β in the CNS perpetuates increased RAGE expression (Yan et al., 
1996, Yan et al., 2010). Clearance of amyloid-β is also diminished in AD and one of the key 
receptors in this role, the low-density lipoprotein receptor-related protein 1 (LRP1), is also 
located in the BBB. There are indications that reduced LRP1 levels in microvessels (Bell et 
al., 2009, Deane et al., 2004b, Shibata et al., 2000a, Donahue et al., 2006) and blockage by 
the ε4 allele of ApoE (Deane et al., 2008) may contribute to poor clearance and subsequent 
pathological accumulation of amyloid-β. Although the number of cases described in the 
present study precludes analysis of multiple covariants, the interplay and temporal 
relationship between BBB disruption and subsequent progressive neurodegenerative 
pathologies will be an important direction for future investigation. 
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3.4.1 Conclusion 
This study presents the first preliminary data indicating that, after just a single moderate or 
severe TBI, there is neuropathologic evidence of widespread, diffuse, multifocal BBB 
disruption in a proportion of TBI patients, even after many years of survival from injury. 
Given that vascular dysfunction may be an important contributor to neurodegenerative 
disorders, acute and chronic BBB alterations after TBI will be important to examine in this 
context along with associations with known TBI pathologies. 
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4 Blood-brain barrier disruption is a distinct, 
capillary level pathology following paediatric 
traumatic brain injury 
4.1 Introduction 
Traumatic brain injury (TBI) is a leading cause of death and disability amongst children and 
adolescents. In common with all age groups, the majority of TBI in children and adolescents 
is classified as mild (Glasgow Coma Scale 13 or greater), often arising from sports or 
recreational exposure. However, in contrast to adult TBI, injuries in the paediatric age group 
are associated with unique risks of poor, occasionally catastrophic outcome. In particular, 
paediatric TBI patients show increased propensity for diffuse brain swelling (DBS). 
Occurring anywhere from minutes to hours after all severities of injury, even mild TBI, DBS 
is associated with a deteriorating conscious level in the absence of significant intracranial 
haemorrhage. 
4.1.1 Second impact syndrome 
Though a phenomenon first acknowledged in the 1950’s (Pickles, 1950), it was not until 
some decades later that the propensity for DBS in the paediatric population, in particular 
adolescents, came to prominence through short cases series highlighting its occurrence in 
mild TBI (Cantu, 1998, Fekete, 1968, Bruce et al., 1981, Bruce, 1984). Of note, in 1984, an 
index case report describing a patient with fatal DBS arising on a background of a previous 
but recent mild TBI (concussion) introduced the term second impact syndrome (SIS), which 
has since largely supplanted DBS in much of the literature (Saunders and Harbaugh, 1984). 
Despite the catastrophic outcomes associated with DBS/SIS in paediatric TBI, the 
pathophysiology of SIS is relatively unknown; however, alterations in cerebral blood flow 
and damage to the cerebrovasculature are increasingly recognised as contributors. A case 
report studied CT scans of children between the first and second TBI and an additional MRI 
after the second; they confirmed profound rapid blood flow dysautoregulation, vascular 
engorgement and increased intracranial pressure following TBI (Weinstein et al., 2013). 
Along with this absence of autoregulation, which renders the brain incapable of responding 
to increases in blood pressure, there is a rush of catecholamines (stress response to injury) 
which, when occurring simultaneously after injury might produce uncontrolled brain 
swelling (Wetjen et al., 2010). 
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Though only a few cases of SIS have been described, careful autopsy review of cases in the 
Glasgow TBI Archive confirmed a high incidence of DBS in material from paediatric 
patients succumbing in the acute phase following a single moderate or severe TBI when 
compared to adults (Graham et al., 1989). Subsequent review in clinical studies confirms 
incidence of DBS, associated with poorer outcome, is 2 to 5 times greater in the paediatric 
population than in adults (Kazan et al., 1997). Further, in contrast to adult TBI, DBS in the 
paediatric population more often arises in isolation, that is, without evidence of other 
intracranial TBI pathologies. The suggestion from the literature is that an unusually high 
predisposition to disturbed autoregulation or hyperaemia in the immature brain might 
underlie this pathology (Adelson et al., 2011). 
4.1.2 Cerebral blood flow alterations in TBI 
Dysfunction of the cerebral blood flow and autoregulation is a prominent pathology in 
paediatric TBI cases. Some imaging studies report that low cerebral blood flow (CBF) is 
related to poorer outcome and a higher mortality after TBI in children (Pigula et al., 1993, 
Kokoska et al., 1998, Adams et al., 1989b). Another study further confirmed these findings 
and extended them by investigating the relationship with age-associated systolic blood 
pressure (AASBP) and worse neurological outcomes (Vavilala et al., 2003). A higher 
AASBP was associated with a favourable outcome and an AASBP < 90mmHg was 
associated with a poorer neurological outcome. Of note, it is reported that there is a wide 
CBF range varying between 6 months old and 9–10 years old therefore comparisons of data 
between normal and TBI patients could only be valid when small, well-defined age ranges 
are selected (Suzuki et al., 1990, Zwienenberg and Muizelaar, 1999). Studies in alterations 
of cerebral autoregulation following paediatric TBI demonstrate a correlation in impaired 
cerebral autoregulation and severity of brain injury (Muizelaar et al., 1989, Sharples et al., 
1995, Vavilala et al., 2004, Vavilala et al., 2006). One study found that one third of the 
children examined displayed increasing dysautoregulation during the 9 days following the 
TBI (Tontisirin et al., 2007). However, these numbers are small and experiments 
investigating paediatric TBI are poorly replicated in animal models. This does indicate 
evolving and transient changes following TBI in children. 
4.1.3 Diffuse brain swelling 
Low CBF can result in poorer outcome following paediatric TBI and is associated with 
cerebral dysautoregulation and diffuse cerebral brain swelling (Bruce et al., 1981, Muizelaar 
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et al., 1989, Cold and Jensen, 1980). It has been proposed that two types of brain swelling 
exist: vasogenic oedema caused by blood-brain barrier (BBB) disruption resulting in 
extracellular water accumulation; and cytotoxic oedema caused by sustained intracellular 
water collection (Unterberg et al., 2004, Huh and Raghupathi, 2009). Vasogenic oedema was 
originally considered to be the dominant form following TBI yet, in contrast, imaging studies 
suggest the cytotoxic form is prevalent (Unterberg et al., 2004, Marmarou et al., 2006a, 
Marmarou et al., 2006b). Marmarou et al used MRI to study oedema types in 45 brain-
injured patients.  By applying and calculating the apparent diffusion coefficient (ADC) they 
found it was significantly reduced in TBI patients, supporting cytotoxic oedema (Marmarou 
et al., 2006a). 
It has been suggested that the developing brain may have greater susceptibility to TBI than 
an adult brain due to structural differences, such as BBB integrity (Saunders et al., 2012, 
Anderson et al., 2000, Stiles and Jernigan, 2010); however, difficulties in age-adjusting 
animal models results in limited evidence available on the effects of paediatric TBI (Semple 
et al., 2013). The BBB is a key component of cerebral autoregulation and CBF, disruption 
of which may lead to raised intracranial pressure. Previous studies have described evidence 
of widespread BBB disturbance in autopsy-derived material from a high proportion of adults 
dying in the acute phase following a single moderate or severe TBI, manifesting as 
multifocal, abnormal, perivascular fibrinogen (FBG) and immunoglobulin G (IgG) 
immunoreactivity (Hay et al., 2015). Such widespread disruption in vascular integrity might 
serve as a substrate for cerebral oedema and, as such, might contribute to DBS in the 
paediatric TBI population. This study examines autopsy brain sections from paediatric and 
adult acute TBI patients for histological evidence of BBB disruption and, if present, the 
characteristics of involved vessels. 
Hypothesis: BBB disruption is present in paediatric TBI patients as with adult TBI, 
however, an association between DBS and BBB disruption is suggested in the paediatric 
TBI cohort. 
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4.2 Material and methods 
4.2.1 Case selection and brain tissue preparation 
Ethical approval for this study was granted by the Greater Glasgow and Clyde Bio-repository 
Governance Committee. From the unique Glasgow TBI Archive, both adult and paediatric 
TBI cases were selected with a history of a single moderate or severe TBI based on 
information in the detailed autopsy reports and clinical records, as defined by Glasgow Coma 
Scale, and dying in the acute phase post injury (defined as survival less than 14 days from 
injury). For the paediatric TBI, cohort cases were selected as aged 18 or under (mean 13 
years; range 4–18 years; n = 52) at the time of death, with cases aged 19 years or over (mean 
50 years; range 20–60; n = 22) selected as the adult TBI cohort. Control, uninjured paediatric 
patients with no history of TBI or neurological disease were selected for comparison (mean 
14 years; range 7–18; n = 9). Clinical variables, including cause of death, survival time and 
post mortem intervals, were comparable between TBI cohorts. However, the cause of injury 
differed between cohorts. The predominant cause of TBI in the paediatric cohort was road 
traffic accident (RTAs) with 79% of paediatric TBI cases compared with 18% in the adult 
TBI cohort (p = 0.0001; χ2). In the adult TBI cohort the predominant cause of injury was 
falls with 68% of cases compared with 12% in the paediatric TBI cohort (p = 0.0001; χ2). 
Full demographic and clinical data for each cohort are presented in Table 3. 
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Table 3 Demographic and clinical information of all groups 
 Paediatric 
uninjured control 
(n = 9) 
Paediatric TBI 
(n = 52) 
Adult TBI 
(n = 22) 
Mean age (range) 14 years 
(7–18) 
13 years  
(4–18) 
50 years  
 (20–60) 
Males 6 
(67%) 
36 
(69%) 
15 
(68%) 
Mean PM delay (range) 85 hours 
(15–264 hours) 
40 hours 
 (6–120 hours) 
56 hours 
(5–240 hours) 
Mean survival interval (range) n/a 68 hours 
(0–186 hours) 
72 hours 
(6–216 hours) 
Cause of TBI Fall*** n/a 6 (12%) 15 (68%) 
 RTA*** n/a 41 (79%) 4 (18%) 
 Assault n/a 5 (10%) 2 (9%) 
 Unknown n/a 0 1 (5%) 
Cause of 
death 
Head injury 0 50 (96%) 20 (91%) 
 Bronchopneumonia 0 0 2 (9%) 
 Cardiac arrest 0 2 (4%) 0 
 SUDEP 2 (22%) 0 0 
 Drug overdose 2 (22%) 0 0 
 Cardiomyopathy 1 (11) 0 0 
 Aspiration pneumonia 1 (11%) 0 0 
 Inhalation of gastric 
contents 
1 (11%) 0 0 
 Leukaemia 1 (11%) 0 0 
 Unascertained 1 (11%) 0 0 
Key: TBI = traumatic brain injury; SUDEP = sudden unexpected death in epilepsy; GIT = gastrointestinal 
tract; ARDS = acute respiratory distress syndrome; RTA = road traffic accident 
4.2.2 Haematoxylin and eosin staining 
Slides were deparaffinised in xylene and rehydrated to water by graded alcohol.  They were 
then immersed in haematoxylin (Mayer’s, Leica Microsystems, Wetzlar, Germany) for 10 
minutes. After rinsing in water and immersing in Scott’s tap water substitute (Leica 
Microsystems, Wetzlar, Germany) the slides were differentiated in 1% acid alcohol and 
rinsed again. The slides were then immersed in 25% aqueous eosin Y solution (TCS 
biosciences, Buckingham, UK) for 5 minutes, rinsed, dehydrated by graded alcohol, cleared 
in xylene and then coverslipped. 
4.2.3 Immunohistochemistry 
Tissue sections were deparaffinised, rehydrated and immersed in 3% aqueous H202 to quench 
endogenous peroxidase activity, following which heat induced antigen retrieval was 
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performed using a microwave pressure cooker for 8 minutes in preheated 0.1M Tris EDTA 
buffer. Subsequent blocking was achieved by applying 50μL of normal horse serum (Vector 
Labs, Burlingame, CA, USA) per 5 mL of Optimax buffer (BioGenex, San Ramon, CA, 
USA) for 30 minutes. Sections were then incubated for 20 hours at 4°C with polyclonal 
rabbit anti-human antibodies for fibrinogen (FBG; 1:17,500; Dako, Carpinteria, CA, USA) 
or IgG (1: 10,000; Dako, Carpinteria, CA, USA) or monoclonal mouse anti-human antibody 
for CD34 (1:100; Leica Biosystems, Milton Keynes, UK). A biotinylated secondary 
antibody was applied for 30 minutes followed by avidin-biotin complex as per the 
manufacturer’s instructions (Vectastain Universal Elite kit, Vector Labs, Burlingame, CA, 
USA). Visualisation was achieved using the DAB peroxidase substrate kit (Vector 
Laboratories, Burlingame, CA, USA) followed by counterstaining with haematoxylin. All 
sections were viewed using a Leica DMRB light microscope (Leica Microsystems, Wetzlar, 
Germany). All sections were viewed using a Leica DMRB light microscope (Leica 
Microsystems). In addition, sections were scanned at 20x using a Hamamatsu Nanozoomer 
2.0-HT slide scanner, with the images viewed via the SlidePath Digital Image Hub 
application (Leica Microsystems). Furthermore, where appropriate sections were scanned 
using a 40x optic which scans images at a digital resolution of 0.23µm per pixel. The images 
in this chapter have been digitally captured at 4x (2.3µm per pixel), 20x (0.46µm per pixel) 
and 40x (0.23µm per pixel). 
4.2.4 Analysis of immunohistochemical findings 
4.2.4.1 Fibrinogen and Immunoglobulin G quantification  
All observations were conducted blind to demographic and clinical data by two independent 
observers (JH, WS). Extent and distribution of FBG and IgG immunoreactivity were 
assessed using established semi-quantitative techniques (Hay et al., 2015). Briefly, the 
neocortical grey matter of the cingulate gyrus, cingulate sulcus, superior frontal gyrus, 
parahippocampal gyrus, collateral sulcus, fusiform gyrus and insular cortex were divided 
into superficial (layers 1–2), mid (layers 3–4) and deep layers (5–6). In addition, the 
thalamus was divided into medial, intermediate and lateral regions. Each of these cortical 
divisions and thalamic regions were then semi-quantitatively assessed for the frequency and 
intensity of immunoreactivity determined as absent (0), sparse (1), moderate (2) or extensive 
(3). 
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4.2.4.2 Assessment of vessel diameters  
In all cases where FBG immunoreactivity was scored moderate to extensive (score of 2 or 
3) in any layer of the cingulate gyrus, assessment of the diameters of cortical vessels and of 
vessels showing BBB disruption was performed. In scanned images of either FBG or CD34 
stained sections a 3 x 3 mm grid comprising of 10 x 10 300μm smaller squares was placed 
over the cortical region of the cingulate gyrus (Figure 4-1). The grid diameter was selected 
to maximise the number of vessels measured in order to obtain robust results. If any larger, 
the grid would be too big for the gyral area. Within the 3 x 3 mm grid, a sample of vessels 
showing abnormal staining in FBG stained sections and a sample of all immunoreactive 
vessels in CD34 stained sections were measured. Vessels were measured at the smallest 
diameter (Figure 4-2). Vessels that transected all gridlines, internal and external, through all 
100 individual 300μm squares were measured. Those vessels that landed in the middle of 
each square, not transected by a gridline, were not measured. This was to reduce sampling 
bias. 
 
Figure 4-1 Example of grid placement A 3 x 3 mm grid comprising of 10 x 10 300µm smaller squares was 
placed over the cortical region of the cingulate gyrus. 
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Figure 4-2 Example of capillary measurement Example of capillary measurement of those vessels that 
transect the grid using the SlidePath measuring tool. 
4.2.5 Statistical analysis 
All data were analysed using SPSS (version 22; IBM, Inc). The χ2 test was used to assess 
differences in data between and within cohorts, where appropriate. Cramer’s V was used to 
determine the effect size. A Cramer’s V value of 0.1 suggested a low practical significance, 
a value of 0.3 suggested a moderate practical significance and a value of 0.5 suggested a 
high practical significance. All effects were considered statistically significant when p ≤ 
0.05. 
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4.3 Results 
4.3.1 Evidence of BBB disruption in paediatric TBI compared with 
controls 
Where 79% of the paediatric TBI cohort demonstrated moderate or extensive FBG 
immunoreactivity score of 2 or 3, 44% of uninjured paediatric patients also demonstrated 
moderate or extensive FBG immunoreactivity in at least one region. Although not 
significant, an overall lowered FBG immunoreactivity is observed in the control group 
(Figure 4-3). Within those uninjured control cases with diffuse FBG immunoreactivity, the 
reported cause of death was SUDEP, cardiomyopathy, leukaemia and one was 
unascertained. 
 
Figure 4-3 Extent of abnormal FBG immunoreactivity in the Paediatric TBI cohort versus Paediatric 
Uninjured controls  Moderate or extensive FBG immunoreactivity was a frequent observation in both 
Paediatric TBI and in the Paediatric Uninjured controls, where it was present in 79% of the Paediatric TBI and 
in 44% of the Paediatric Uninjured controls (NS). Furthermore, abnormal FBG immunoreactivity was a 
common multifocal pathology in both cohorts (NS). 
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Where FBG immunoreactivity was present, the pattern and distribution of FBG 
immunoreactivity between the paediatric TBI group and the control group was similar. In 
both groups FBG immunoreactivity was largely confined to the grey matter; however, in the 
control group evidence of BBB disruption was higher in the white matter of the corpus 
callosum (NS) (Figure 4-4). Finally, preferential distribution to the crests of gyri and deeper 
cortical layers (layers 3–6) over depths of sulci and superficial cortical layers was common 
to both paediatric TBI and the control group showing moderate or extensive abnormal FBG 
or IgG immunostaining (Figure 4-5). 
 
Figure 4-4 Regional Distribution of FBG immunoreactivity in Paediatric TBI cohort versus Uninjured 
Paediatric controls In all regions analysed in the Paediatric TBI cohort there was evidence of FBG 
immunoreactivity in a higher proportion of Paediatric TBI survivors than uninjured Paediatric cohort, however 
in the white matter of the corpus callosum 22.2% of the Uninjured Paediatric cohort demonstrated moderate or 
extensive fibrinogen compared with only 8% in the paediatric TBI cohort (NS). 
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Figure 4-5 Neocortical distribution of FBG immunoreactivity in Paediatric TBI cohort versus Paediatric 
Uninjured cohort  (a) Similar to the Adult TBI there was a clear preferential distribution of abnormal FBG 
immunoreactivity to the crests of the gyri when compared to the depths of the sulci in the Paediatric TBI cohort 
as illustrated here for the cingulate gyrus versus the adjacent cingulate sulcus (***p<0.0001; χ2 sulcus versus 
gyrus) (b) Further, within the neocortical grey matter region of the cingulate gyrus there was preferential 
distribution of abnormal staining to the mid (layers 3 and 4) and deep (layers 5 and 6) cortical layers when 
compared to superficial layers (layers 1 and 2) in the Paediatric TBI cohort. (***p<0.0001; χ2 deep versus 
superficial cortical layers). 
4.3.2 Evidence of BBB disruption in paediatric TBI compared with 
adult TBI 
Moderate or extensive abnormal perivascular FBG and IgG immunostaining representing 
evidence of BBB disruption was confirmed in a similar proportion of both adult and 
paediatric TBI patients dying in the acute phase (Figure 4-6). Specifically, 86% (19 out of 
22) of adult and 79% (41 out of 52) of paediatric acute TBI cases demonstrated moderate or 
extensive FBG immunoreactivity, whilst 68% (15 out of 22) of adult and 64% (33 out of 52) 
of paediatric acute TBI cases demonstrated moderate or extensive IgG immunoreactivity in 
at least one anatomical region. Further, evidence of multifocal BBB disruption, defined as 
abnormal moderate or extensive FBG immunoreactivity in 2 or more anatomical regions, 
was identified in a similar proportion of cases in both cohorts, being present in 60% of adult 
and 62% of paediatric cases stained for FBG (Figure 4-6) and 50% of adult and 44% of 
paediatric cases stained for IgG. 
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Pattern and distribution of FBG immunoreactivity between the paediatric TBI group and the 
adult TBI group was similar. In both paediatric and adult acute TBI, BBB disruption was 
largely confined to grey matter, with only occasional cases showing evidence of BBB 
disruption in the white matter of the corpus callosum (Figure 4-7). Finally, there was 
preferential distribution to the crests of gyri rather than the depths of the sulci in both groups 
(p = 0.0001; χ2; Cramer’s V = 0.471, paediatric TBI gyrus versus sulcus; p = 0.0324; χ2; 
Cramer’s V = 0.42, adult TBI cingulate gyrus versus cingulate sulcus). Furthermore, 
preferential distribution to the deeper cortical layers rather than the superficial cortical layers 
was common to both paediatric and adult TBI cases (p = 0.0001; χ2; Cramer’s V = 0.461, 
paediatric TBI deep layers versus superficial layers; p = 0.0134; χ2; Cramer’s V = 0.462, 
adult TBI deep layers versus superficial layers) showing moderate or extensive abnormal 
FBG or IgG immunostaining (Figure 4-8).  
 
Figure 4-6 Extent of abnormal FBG immunoreactivity following TBI in Adult versus Paediatric cohorts 
in acute survival  Moderate or extensive FBG immunoreactivity was a frequent observation in both Paediatric 
and Adult TBI groups where it was present in 79% or the Paediatric TBI cohort and in 86% of the Adult TBI 
cohort (NS). Following TBI, the Paediatric cohort expressed multifocal FBG immunoreactivity in 62% of cases 
where the adult TBI cohort expressed multifocality in 64% of cases (NS). 
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Figure 4-7 Regional Distribution of FBG immunoreactivity following TBI in both Adult and Paediatric 
cohorts In all regions analysed there was evidence BBB disruption following TBI, evidenced by 
moderate/extensive FBG immunoreactivity with a similar pattern of FBG immunoreactivity observed in both 
Adult TBI and Paediatric TBI.  
  
Figure 4-8 Neocortical distribution of FBG immunoreactivity after TBI   A similar pattern of BBB 
disruption was observed between the Adult TBI and Paediatric TBI where there was preferential distribution 
of abnormal FBG immunoreactivity to the crests of the gyri when compared to the depths of the sulci in both 
TBI cohorts (*p<0.01’ **<0.001; ***p<0.0001; χ2 sulcus versus gyrus). (b) In addition, within the neocortical 
grey matter region there was preferential distribution of abnormal FBG to the mid layers (layers 3 and 4) and 
deep (layers 5 and 6) cortical layers when compared to superficial layers (layers 1 and 2) in both TBI cohorts 
(*p<0.01’ **<0.001; ***p<0.0001; χ2 deep versus superficial cortical layers). 
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4.3.3 BBB disruption is a capillary-level pathology in paediatric 
acute TBI 
Although incidence and distribution of FBG immunoreactivity in acute TBI was similar in 
adult and paediatric TBI patients, the pattern of vascular involvement appeared qualitatively 
different between the two cohorts. Specifically, in paediatric material abnormal FBG or IgG 
immunoreactivity was marked by numerous punctate, perivascular foci of staining in cortical 
sections (Figure 4-9a-d). In contrast, in adult acute TBI patients immunoreactivity for these 
markers was typified by fewer and larger foci of staining (Figure 4-9e-f), suggesting BBB 
disruption was localised to larger diameter vessels in adults than in paediatric patients. 
Examination of sections from the cingulate gyrus stained for the endothelial protein CD34 
revealed the overwhelming majority of cortical vessels in both adult and paediatric material 
to be less than 10µm in diameter, in keeping with capillary-sized small vessels (Figure 4-10). 
Thus, vessels measured at less than 10µm in diameter comprised 92% and 95% of all cortical 
vessels in adult and paediatric TBI cohorts respectively. In contrast, however, where a 
proportion of capillary-sized vessels was similar in adult and paediatric material, BBB 
disruption was preferentially distributed to capillary-level vessels in paediatric cases when 
compared to adults. In material from the paediatric TBI cohort 82% of vessels showed 
abnormal FBG immunoreactivity less than 10µm in diameter, compared to just 41% of 
vessels in adults (p = 0.0001; χ2; Cramer’s V = 0.394) (Figure 4-11).  
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Figure 4-9 Representative images of FBG immunoreactivity in adult and paediatric TBI  (a) Perivascular 
FBG immunoreactivity in small vessels of the cingulate gyrus in a 13-year-old male TBI patient who died 3 
hours after an RTA (b) Similar pattern of FBG immunoreactivity around small vessels observed in the cingulate 
gyrus of an 18-year-old male TBI patient who died 72 hours after an assault. (c) FBG immunoreactivity around 
small vessels observed in a 20-year-old male who died 24 hours after an assault (d) The same case as (c) but 
using IgG immunoreactivity (e) FBG immunoreactivity apparent surrounding larger vessels in the cingulate 
gyrus of a 60-year-old male TBI patient who survived 8 days after a fall (e) Similar FBG immunoreactivity 
pattern around the larger vessels of the cingulate gyrus of a 51-year-old male who died 96 hours after an assault 
(g) 40x image of FBG immunoreactivity around the capillaries of a 18-year-old male TBI patient who survived 
3 days following an assault and (h) diffuse FBG immunoreactivity surrounding a large vessel in a 37-year old 
TBI patient who survived 4 years following a fall. Scale bars = 1mm, scale bar = 100µm (high magnification) 
and scale bar = 10µm in 40x image (g and h). 
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Figure 4-10 Distribution of vessel size following TBI in all vessels in cingulate gyrus in Adult TBI versus 
Paediatric TBI. Similar patterns of distribution of vessels were observed in both age groups. In the adult TBI 
cohort 92% of vessels were less than 10µm in diameter. In the paediatric TBI cohort this was 95% (NS). In the 
adult TBI cohort vessels 10-20µm in diameter made up 7% and the remainder were distributed between 20-
100µm. In the paediatric cohort vessels 10-20µm in diameter made up 4.5% and the remainder were distributed 
between 20-100µm. 
 
Figure 4-11 Distribution of BBB disrupted vessel size in cingulate gyrus in Adult TBI versus Paediatric 
TBI. Of all disrupted vessels in the adult TBI cohort small vessels (less than 10µm) accounted for 41%; in the 
paediatric cohort, this was 82% (p = 0.0001; χ2). Disrupted vessels 10-20µm accounted for 32% in the adult 
TBI cohort and 8% in the paediatric TBI cohort (p = 0.0001; χ2). Disrupted vessels over 20μm in size accounted 
for 27% in the adult TBI cohort and only 10% in the paediatric TBI cohort (p = 0.0242; χ2).  
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Of the cases in the uninjured paediatric cohort, which demonstrated widespread moderate or 
extensive FBG immunoreactivity, only 2 cases displayed BBB disruption in the cingulate 
gyrus. One case demonstrated a mean vessel diameter for damaged vessels of 43μm and one 
case demonstrated a mean vessel diameter for damaged vessels of 5μm. 
4.3.4 Association of BBB disruption with focal TBI pathologies 
As anticipated, reviewing haematoxylin and eosin-stained sections demonstrated evidence 
of BBB disruption in association with acute focal haemorrhagic pathologies in both adult 
and paediatric material. In addition, more widespread and diffuse BBB disruption 
independent of focal pathologies was also present. In the paediatric TBI cohort, 53 TBI-
associated focal haemorrhagic lesions or contusions were observed across 27 of the 52 cases 
(52%). Virtually all of these cases (25 out of 27) displayed extravascular FBG 
immunoreactivity adjacent to focal pathology. In addition, 18 cases (72%) demonstrated 
evidence of widespread diffuse BBB disruption remote from focal pathology. Furthermore, 
in the 25 remaining cases with no focal haemorrhagic or contusional pathology, 17 (68%) 
displayed extensive FBG immunoreactivity in at least 1 anatomical area. Similarly, whilst 
localised BBB was identified adjacent to the TBI-associated focal haemorrhagic or 
contusional pathologies in 11 of the 12 (92%) cases, where present it was not limited to these 
regions, with 7 of these adult cases also exhibiting widespread diffuse BBB injury. In the 
remaining 10 adult cases without focal haemorrhage or contusion, extensive FBG 
immunoreactivity in at least 1 anatomical region was displayed in all cases. There was 
evidence of diffuse hypoxic/ischemic injury in a similar proportion in both acute paediatric 
TBI (85%) and acute adult TBI (90%) cohorts. No correlation with BBB disruption and this 
TBI-associated pathology was identified. 
4.3.5 Brain swelling and BBB disruption  
Where clinical data was available, 41 of 42 (98%) of the paediatric TBI cases showed 
evidence of brain swelling, in contrast, 12 of 22 (55%) of adult cases showed evidence of 
brain swelling at autopsy (p = 0.0001; χ2; Cramer’s V = 0.542). Further, where brain 
swelling was identified, 63% of paediatric TBI cases was bilateral swelling, compared to 
just 17% of adult TBI cases (p = 0.004; χ2; Cramer’s V = 0.416) (Table 4).  
Of the 42 paediatric TBI cases with clinical data available, 32 cases had BBB disruption 
(76%), of those cases, 31 cases had brain swelling (97%) and only 1 case had no swelling 
(3%) (Figure 4-12). Where both BBB disruption and brain swelling were present, 77% had 
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widespread BBB disruption and 23% had localised BBB disruption (p = 0.0001; χ2; 
Cramer’s V = 0.563). In the paediatric TBI cases with bilateral brain swelling, 14 
demonstrated widespread BBB disruption (70%). In the adult TBI cohort 10 cases had BBB 
disruption (45%), of which 5 cases were reported to have brain swelling (50%) and 5 cases 
had no swelling (50%) (p = 0.0016; χ2; Cramer’s V = 0.248). (Figure 4-12). Where both 
BBB disruption and brain swelling were present, 60% had widespread BBB disruption and 
40% had localised BBB disruption (NS). In the adult TBI cases with bilateral brain swelling 
(2 out of 12), no cases demonstrated widespread BBB disruption. In the uninjured paediatric 
cohort, 44% of cases demonstrated multifocal BBB disruption, 3 out of the 4 cases had no 
abnormalities in the brain at autopsy. Of note, the remainder case was reported to show 
vascular engorgement in the white matter where moderate/extensive FBG immunoreactivity 
was also demonstrated. 
Table 4 Pathologies of all cohorts 
Pathologies Paediatric 
uninjured 
cohort (n = 9) 
Paediatric TBI  
(n = 42) 
Acute adult TBI (n 
= 22) 
p value 
Skull fracture 0 25 (60%) 15 (68%) p = 0.5918 
Contusions 0 38 (90%) 19 (86%) p = 0.6837 
DAI 0 20 (48%) 9 (40%) p = 0.7920 
Brain Swelling 
of which bilateral 
0 41 (98%) 
26 (63%) 
12 (55%) 
2 (17%) 
p = 0.0001 
p = 0.0082 
SDH 0 19 (45%) 15 (68%) p = 0.1145 
EDH 0 8 (19%) 1 (5%) p = 0.192 
SAH 0 16 (38%) 11 (50%) p = 0.649 
 
4 81 
 
 
Figure 4-12 Proportion of cases with FBG immunoreactivity and presence or absence of brain swelling.  
There was a clear relationship between TBI cases with increased abnormal FBG immunoreactivity and TBI 
cases with DBS as reported in clinical data. Where 97% of Paediatric TBI cases demonstrated both abnormal 
FBG immunoreactivity and brain swelling (both unilateral and bilateral) only 50% of Adult TBI cases 
demonstrated this relationship (p = 0.0016; χ2). 
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4.4 Discussion 
This study has demonstrated autopsy evidence of BBB disruption in the majority of 
paediatric patients dying in the acute phase following a single moderate or severe TBI. 
Further, for a considerable number of those patients, BBB disruption is widespread and not 
solely localised to regions of focal TBI pathologies, again paralleling observations in adult 
material. However, in sharp contrast to adult TBI cases, BBB disruption in paediatric cases 
appears preferentially distributed to vessels of 10μm or less in diameter, in keeping with 
capillary sized vessels. This vulnerability of the small vessels was rarely observed in adult 
material. Indeed, in only one case within the adult cohort was this preferential capillary-level 
vascular involvement observed, intriguingly, in a younger adult, aged 20 years.  
Blood-brain barrier disruption was also demonstrated in the uninjured paediatric cohort, but 
to a lesser extent than in the paediatric TBI cohort. The cause of death for those uninjured 
control cases displaying diffuse BBB disruption were reported as epilepsy, leukaemia, 
cardiomyopathy and unascertained. The majority of these disorders are known to affect the 
BBB integrity (Michalak et al., 2017, van Vulpen et al., 2002). White matter BBB disruption, 
specifically in the corpus callosum, was also more prominent in the uninjured paediatric 
controls than the both paediatric and adult TBI cohorts. Interestingly, vascular pathology 
was reported in the white matter in one control case at autopsy, which may be associated 
with BBB disruption. Such complex cohorts generate difficulties in drawing conclusions 
between paediatric TBI and uninjured paediatric controls; however, since BBB disruption 
was demonstrated in both paediatric and adult TBI cohorts, comparisons could be made 
between these groups.  
A particular phenomenon recognised in paediatric TBI populations is a risk of diffuse brain 
swelling (DBS), even after apparently mild injury when it is often referred to as second 
impact syndrome (SIS). With incidence of DBS in clinical series of paediatric severe TBI 
approximately twice that recorded in adults, DBS is also associated with high mortality 
(Kazan et al., 1997). In line with this, whilst autopsy studies in fatal TBI confirm similar 
overall patterns of brain injury in paediatric and adult TBI, a notable observation is of a 
considerably higher incidence of DBS in paediatric cases (Graham et al., 1989, Adams et 
al., 1989b) with one series reporting its presence in 70% of paediatric cases compared to just 
17% of adults (Graham et al., 1989). This current data is broadly in line with this observation, 
demonstrating DBS in 63% of paediatric cases compared to just 17% of adult cases. 
Furthermore, 70% of paediatric TBI cases with DBS also demonstrated BBB disruption.  
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Although cases included in this current study were moderate or severe TBI, DBS after even 
mild TBI is recognised in the paediatric population, often in context of sports participation. 
In 1984, ‘second impact syndrome’ (SIS) was first described by Saunders et al (Saunders 
and Harbaugh, 1984) where it was observed in a 19-year-old college and is suggested to 
occur when an individual suffers a second head injury before the symptoms of the first injury 
have resolved (Saunders and Harbaugh, 1984, Cantu, 1998). A study by Thomas et al. aimed 
to define the clinical profile, epidemiology and frequency of trauma-related deaths in young 
US-athletes (Thomas et al., 2011). Of the 138 football players who died due to head blows, 
12% had previously reported a history of concussion between a few days and 4 weeks prior 
to the blow; these were all 14–18 year olds (Thomas et al., 2011); consistent with SIS. 
However, a systematic review completed in 2016 states there is a lack of established 
diagnostic signs and symptoms and studies to support a standardised definition for SIS 
(Hebert et al., 2016).  
This study demonstrates a clear neuropathological difference between paediatric and adult 
TBI, which could explain the increased risk of cerebral swelling observed in children after 
injury and suggested vascular vulnerability of DBS/SIS. The association of these unique 
pathologies, however, is poorly understood. Suggestions have been made that poor outcome 
following DBS may be due to disrupted autoregulation. Studies by Bruce et al. (Bruce et al., 
1978, Bruce et al., 1981) discuss that DBS is due to an increase in intracerebral blood, either 
as an increase in cerebral blood volume or as a redistribution of intracranial blood from the 
pial to the intraparenchymal vessels. Vasogenic oedema which results in extracellular water 
accumulation, and is induced by BBB disruption, has been suggested to be predominant 
following TBI (Marmarou et al., 2006a, Unterberg et al., 2004, Huh and Raghupathi, 2009). 
In this study almost all paediatric TBI cases with BBB disruption demonstrated brain 
swelling which indicates a capillary vessel vulnerability possibly resulting in a propensity 
for brain swelling. 
In an animal model of hypertensive encephalopathy, BBB disruption precedes a reduction 
in CBF (Tamaki et al., 1984). Rapid, transient changes to the permeability of BBB were also 
observed in a neonatal animal model of cerebral ischemia (Ek et al., 2015) where the areas 
of BBB disruption correlated to the areas of ischemic damage and reduced CBF. A similar 
pattern of ischemic damage was observed between adult TBI (90% of cases) and paediatric 
TBI (85% of cases) although no correlation with BBB disruption in the acute phase was 
identified. This suggest ischemia is a prominent pathology in the acute phase following TBI; 
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however, further studies would warrant an understanding of how this pathology is linked, 
directly or indirectly, to vascular changes. 
In a rat model of intracerebral haemorrhage, Yang et al demonstrated a relationship between 
a decrease in CBF, an increase in BBB permeability and oedema formation (Yang et al., 
1994). After an initial drop in CBF levels post haemorrhage, levels returned to normal before 
dropping again due to oedema development which, subsequently, was caused by BBB 
disruption (Yang et al., 1994). In a similar rat model of subarachnoid haemorrhage (SAH), 
Li et al (Li et al., 2015) demonstrated 2 peaks of BBB dysfunction at 3 hours and 72 hours 
following SAH. In this study, evidence of BBB disruption in association with acute focal 
haemorrhagic pathologies was identified in both adult and paediatric material. In addition, 
more widespread and diffuse BBB disruption independent of focal pathologies was also 
present in both cohorts. 
Many reports state that low CBF and dysfunctional autoregulation lead to a poorer outcome 
after head injury (Adelson et al., 2011, Tontisirin et al., 2007, Pigula et al., 1993, Vavilala 
et al., 2003). Decreased CBF has been documented even in mild TBI amongst young adults 
(Maugans et al., 2012, Wang et al., 2015b). This is contradicted by Sharples (Sharples et al., 
1995), who found normal CBF levels after severe paediatric head injury. Much of the 
evidence following paediatric TBI is surrounding CBF alterations and ICP with regard to 
DBS; however, this is the first autopsy study to address a unique vascular response in 
children following TBI. Where the distribution of vessels is similar between adult and 
paediatric TBI (92% and 95%, respectively) the BBB disruption that occurs after TBI 
favours capillary-sized vessels in paediatric TBI cases (82% of capillaries disrupted 
compared to 41% in adult TBI). This BBB disruption is observed in the majority of 
paediatric TBI cases with bilateral brain swelling, indicating that there may be a relationship 
between capillary-based BBB disruption, brain swelling, and possibly CBF alterations; 
however, further investigations would be required to confirm this. 
4.4.1 Conclusion 
This autopsy study is the first to report significant vascular differences between adult and 
paediatric TBI, demonstrating evidence of BBB disruption is predominantly at the level of 
capillary-sized vessels in paediatric TBI cases. The majority of paediatric TBI cases 
demonstrating bilateral brain swelling also demonstrated BBB disruption. The pathologies 
observed in this current study suggest a potential association between capillary-based BBB 
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disruption and DBS and may play a role in possible CBF changes following TBI. This could 
be important in understanding the pathological processes involved in the poorer outcome 
observed following paediatric TBI, specifically DBS/SIS. However, more work would need 
to be carried out to investigate these interesting and unique pathologies. 
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5 Cortical atrophy and vascular changes following 
TBI  
5.1 Introduction 
Traumatic Brain Injury (TBI) is widely recognised as the strongest environmental risk factor 
for dementia (Molgaard et al., 1990, Mortimer et al., 1985, Mortimer et al., 1991, Graves et 
al., 1990, O'Meara et al., 1997, Salib and Hillier, 1997, Guo et al., 2000, Schofield et al., 
1997, Plassman et al., 2000, Fleminger et al., 2003), with a direct dose-response relationship 
proposed between injury severity and subsequent risk of dementia (Guo et al., 2000, 
Plassman et al., 2000). Key dementia-associated pathologies have been observed following 
TBI, such as, abnormal accumulation of tau, Aβ plaques, neuroinflammation and white 
matter degeneration.  Evidence of vascular alterations in dementia have also been reported 
(Zlokovic, 2011, Sweeney et al., 2018, Buee et al., 1994, Kalaria, 1996, Kalaria and Pax, 
1995, Farkas and Luiten, 2001) however, following TBI the evidence is less clear. Blood-
brain barrier dysfunction has been demonstrated in Alzheimer’s disease (AD) patients 
(Sweeney et al., 2018, Viggars et al., 2011) and this pathology has also been observed in 
TBI cases both in the acute phase and persisting into the later phase (Chapter 3) (Hay et al., 
2015). However, vascular pathologies such as increased collagen deposition and decreased 
vascular density which have been demonstrated in dementia (Kalaria and Pax, 1995, Brown 
and Thore, 2011b) are yet to be investigated and characterised in TBI survivors. 
5.1.1 Cortical atrophy 
Cortical atrophy has been reported in AD patients where it has been suggested that it 
correlates with cognitive decline (Mungas et al., 2002), and might  precede the onset of 
dementia (Im et al., 2008). By means of computational neuroanatomy, Lerch et al. 
demonstrated significant cortical thinning in temporal, orbitofrontal and parietal regions in 
AD; the most pronounced changes occurring in the allocortical region of the medial temporal 
lobes, outlining the parahippocampal gyrus and representing a loss of <1.25 mm of cortical 
thickness (Lerch and Evans, 2005, Lerch et al., 2005). Cortical thinning in different brain 
regions is suggested to correlate with various neurodegenerative disorders; in frontotemporal 
dementia (FTD) cortical thinning occurs in the left cingulate gyrus and the left 
occipitotemporal gyri; yet, in AD it occurs in the inferior parietal, occipitoparietal and the 
pericalcarine regions and is more pronounced in the right hemisphere (Hartikainen et al., 
2012, Blanc et al., 2015, Du et al., 2007, O'Brien et al.). 
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Several studies have investigated cortical atrophy following mTBI, specifically in military 
populations and in athletes (Michael et al., 2015, Hayes et al., 2017, Savjani et al., 2017, 
McKee et al., 2013). In each of these studies, all cases demonstrated a decrease in cortical 
thickness; furthermore, Michael et al. (2015) suggested a correlation between cortical 
atrophy, posttraumatic stress disorder (PTSD), depression and post-concussive symptoms 
(Michael et al., 2015), while Hayes et al.(2017) suggested an association between an 
increased polygenetic risk of AD and cortical atrophy (Hayes et al., 2017). All note varying 
levels of cortical thickness across different regions in the brain with several studies 
collectively suggesting thinning of the frontal and temporal cortex was prominent following 
mTBI (Govindarajan et al., 2016, Michael et al., 2015, Wang et al., 2015a). Mckee et al. 
(2009) noted gross mild cerebral atrophy with dilation of the second and third ventricles in 
athletes that demonstrated stage III CTE with a more severe cerebral atrophy in Stage IV 
CTE (McKee et al., 2013). These studies suggest, similarly to AD, that the cortex undergoes 
atrophy following mTBI. 
Imaging studies have consistently demonstrated cortical atrophy following TBI in humans, 
with one study observing atrophy after mild to moderate TBI and injury with a loss of 
consciousness associated with increased rate of thinning (Bergeson et al., 2004, MacKenzie 
et al., 2002, Ross, 2011). Using a predictive model of normal ageing based on MRI estimates 
of both grey and white matter Cole et al. (2015) reported that TBI brains were ‘older’ than 
their chronological age, suggesting that TBI accelerates the rate of brain atrophy (Cole et al., 
2015). Atrophy following TBI has been reported to be greatest in white matter with higher 
rates of atrophy observed in the cortical sulci compared to the gyri (Cole et al., 2018). White 
matter atrophy has also been demonstrated and confirmed in autopsy studies with a 25% 
reduction in the corpus callosum thickness observed (Johnson et al., 2013a). However, 
cortical atrophy following TBI has not been assessed in autopsy studies using pathological 
techniques. 
5.1.2 Vascular Density 
Increasing evidence suggests changes in the vasculature might be associated with 
progression of dementia. Significant reductions in vessel density of the basal forebrain and 
hippocampal regions, together with  structural alterations, such as kinking and looping of 
vessels have been reported in AD patients, which are absent in non-demented patients 
(Fischer et al., 1990). Furthermore, autopsy studies demonstrate a decrease in microvascular 
density in AD brains (Buee et al., 1994). Although Buee et al. reported changes in both 
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ageing and AD patients, vascular pathology in AD exceeded that of normal ageing (Buee et 
al., 1994). However, conflicting evidence suggests there is an increase in vascular density 
and angiogenesis in AD (Viggars et al., 2011, Desai et al., 2009). Viggars et al., reported 
that the increase in vascular density was associated with the increase of AD-like pathologies, 
such as neurofibrillary tangles (Viggars et al., 2011). 
Regarding vascular changes following TBI, limited animal evidence offers similar 
inconsistencies. Obenaus et al., used a controlled cortical impact (CCI) rodent model of TBI 
and vessel painting perfusion techniques to label the vascular structure in the cortex 
(Obenaus et al., 2017). In the acute phase following TBI, significant global reductions in 
vessel junctions and vessel length were observed. Conversely, a lateral fluid-percussion 
animal model of TBI demonstrated an increase in vessel density in the perilesional cortex 
and thalamus, and no change in vessel density in the hippocampus (Hayward et al., 2010). 
These contradictory results in rodent models of TBI indicate vascular changes may be 
present following injury and warrant further investigation. 
5.1.3 Collagen Deposition 
Changes in the vasculature in the progression of dementia can alter brain perfusion and BBB 
permeability (Kalaria, 1996). Autopsy studies using AD brains demonstrate a thickened 
basement membrane (BM) compared to age-matched non-demented brains (Hardy et al., 
1986, Mancardi et al., 1980, Vinters et al., 1994) associated with increased collagen IV 
deposition (Viggars et al., 2011), which may affect microvascular function (Kalaria and Pax, 
1995). In the study by Viggars et al., this increased collagen deposition was observed to be 
associated with an increase in local neurofibrillary tangle score (Viggars et al., 2011). 
However, to date, there has been no evidence of collagen deposition in humans following 
TBI and reported vascular changes are limited. 
Previously in this thesis evidence of vascular pathology following TBI was described 
(Chapter 3) (Hay et al., 2015). Specifically, following a single, moderate or severe TBI there 
is neuropathological evidence of widespread, diffuse, multifocal BBB disruption in nearly 
half of patients – even after many years of survival from injury. However, the structural basis 
for this acute and persistent BBB disruption following TBI is unknown. This study will 
assess vascular alterations after a single, moderate to severe TBI, in particular, changes in 
vascular density, cortical atrophy and collagen deposition. 
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Hypothesis: Following TBI, vascular density is reduced and there is an increase of collagen 
IV deposition which is associated with BBB disruption. In addition, there will be an observed 
presence of cortical atrophy. 
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5.2 Material and Methods 
5.2.1 Case selection and brain tissue preparation 
From the Glasgow TBI archive cases of a single, moderate to severe TBI were collected, 
with acute survival times ranging from 6 hours to less than 14 days (n = 11); and long-term 
TBI cases ranged from a survival time of 1 year to 47 years (n = 19). Age-matched controls 
were selected as having no history of brain injury or neurological disease (n = 18). All ages 
were matched between cohorts (NS). The demographics and clinical data for all cohorts are 
shown in Table 5. 
At the time of the original diagnostic autopsy, whole brains were immersion fixed in 10% 
formal saline for a minimum of 3 weeks, following which the specimens were examined, 
sampled using standardized techniques and processed to paraffin tissue blocks. For this 
study, blocks from a coronal slice of the cerebral hemispheres at mid-thalamic level were 
selected to include the corpus callosum, with adjacent cingulate, superior frontal gyri and 
sulcus. From these tissue blocks 8μm sections were prepared for immunohistochemistry 
procedures. 
5.2.2 Luxol Fast blue 
Following standard deparaffinisation and rehydration, sections with immersed in Luxol Fast 
blue (LFB) solution (Solvent Blue 38, Sigma) overnight at 27°C. After a rinse in 95% ethanol 
to remove excess stain, sections were washed in deionized water. Differentiation of the 
Luxol stain was carried out by immersion in 0.05% aqueous lithium carbonate for 10 seconds 
followed by multiple immersion in fresh 70% ethanol until grey/white matter boundaries 
could be clearly distinguished.  Following washing in deionized water, sections were stained 
with Cresyl violet solution for 5 minutes at 60°C and washed again in deionised water. 
Sections were then differentiated in 95% ethanol (containing 100ml per 300ml glacial acetic 
acid) and rinsed in 95% ethanol. Sections were then dehydrated and coverslipped. 
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Table 5: Demographic and clinical information of all groups 
  
 TBI: Acute 
Survival (n = 11) 
TBI: Long-Term 
Survival (n = 19) 
Controls  
(n = 18) 
Mean age (Range) (years) 39.3 (16-60) 46 (19-60) 37.7 (20-60) 
Males 8 (73%) 18 (95%) 10 (55.6%) 
Mean PM Delay (Range) 72.6 hours (3-240) 58.4 hours (9-184.5) 72 hours (12-168) 
Mean Survival Interval (Range) 44.4 hours (6-96) 8.1 years (1-47) N/A 
Cause of 
TBI 
Fall 6 (55%) 9 (47.4%) N/A 
RTA 1 (9%) 2 (10.5%) 
Assault 3 (27%) 4 (21%) 
Unknown 1(9%) 4 (21%) 
Cause of 
Death 
Head injury 10 (91%) 0 0 
Bronchopneumonia 1 (9%) 6 (31.5%) 0 
ARDS 0 0 0 
Pulmonary 
thromboembolism 
0 0 0 
Heart disease 0 3 (15.8%) 4 (22.2%) 
Alcohol related 0 2 (10.5%) 0 
Pyelonephritis 0 1 (5%) 0 
Multi-organ failure 0 1 (5%) 0 
GIT haemorrhage 0 0 0 
Polytrauma 0 0 0 
Drug overdose 0 0 2 (11.1%) 
SUDEP 0 3 (15.8%) 8 (44.4%) 
Pulmonary oedema 0 1 (5%) 0 
Septicaemia 0 0 2 (11.1%) 
Inhalation of gastric 
contents 
0 0 2 (11.1%) 
Unknown 0 2 (10.5%) 0 
 Key: TBI = traumatic brain injury; SUDEP = sudden unexpected death in epilepsy; GIT = 
gastrointestinal tract; ARDS= acute respiratory distress syndrome; RTA = road traffic 
accident 
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5.2.3 Immunohistochemistry 
Tissue sections were deparaffinised and rehydrated using xylene and graded alcohols. 
Following this step, sections were immersed in 3% aqueous H202 for a minimum of 15 
minutes to quench endogenous activity. Heat antigen retrieval was performed via microwave 
pressure cooker for 8 minutes in preheated 0.1M Tris EDTA buffer. Blocking was carried 
out by applying 50μL of normal horse serum (Vector Labs, Burlingame, CA, USA) per 5 
mL of Optimax buffer (BioGenex, San Ramon, CA, USA) for 30 minutes. Primary 
antibodies were then applied and sections incubated overnight at 4°C. Polyclonal rabbit anti-
human antibody for CD34 used at a dilution of 1:100 (QBEnd 10, Leica Biosystems, Milton 
Keynes, UK), collagen IV (CIV 22, Dako, Carpinteria, CA, USA) at a dilution of 1:25 and 
fibrinogen at a dilution of 1:17,500 (Dako, Carpinteria, CA). After washing in PBS, a 
biotinylated secondary antibody was applied (100µl in 5ml of horse serum and 100µl of 
secondary per 5ml Optimax buffer) and incubated for 30 minutes. The secondary antibody 
was then washed off with PBS. Visualization was achieved using the DAB peroxidase 
substrate kit (Vector Labs, Burlingame, CA, USA) followed by counterstaining with 
haematoxylin. All sections were viewed using a Leica DMRB light microscope (Leica 
Microsystems). In addition, sections were scanned at 20x using a Hamamatsu Nanozoomer 
2.0-HT slide scanner, with the images viewed via the SlidePath Digital Image Hub 
application (Leica Microsystems). Furthermore, where appropriate sections were scanned 
using a 40x optic which scans images at a digital resolution of 0.23µm per pixel. The images 
in this chapter have been digitally captured at 4x (2.3µm per pixel), 20x (0.46µm per pixel) 
and 40x (0.23µm per pixel). 
5.2.3.1 Cortical thickness 
Once sections were scanned using the Hamamatsu Nanozoomer Slide Scanning Machine 
(Hamamatsu, Hertfordshire, UK), the cortex of the cingulate gyrus and cingulate sulcus were 
measured using the measuring tool in SlidePath Digital Image Hub application (Leica 
Microsystems, Wetzlar, Germany). The narrowest point in the cingulate gyrus and cingulate 
sulcus was chosen to avoid cortical variance within sections. For confirmation of correct 
cortical thickness, sections were also measured under a microscope using the graticule. 
Between the SlidePath tool and graticule the measurements were comparable (NS). 
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5.2.3.2 Vascular density and collagen deposition 
To measure vessel density and collagen deposition and compare with BBB disruption, a 
subset of the cohort was analysed based on the fibrinogen score. Scoring of fibrinogen was 
previously described in Chapter 3. There were 7 acute TBI cases with survival times of 10 
hours to 9 days; which were split based on amount of fibrinogen present in the cingulate 
gyrus region (4 increased and 3 decreased fibrinogen cases). The subset also consisted of 8 
long-term cases with survival times 3 to 18 years; which were split into increased fibrinogen 
deposition (score of 2 or 3; n = 4) and decreased fibrinogen deposition (score of 0 or 1; n = 
4). For comparison, four uninjured, non-demented controls cases were selected. 
ImageJ (ImageJ, USA) software was used to quantify the vascular density and collagen IV 
staining. Using the SlidePath Digital Image Hub application, a 1mm x 1mm square was 
randomly placed over sections of the superficial, mid and deep layers of the cingulate gyrus 
and cingulate sulcus and isolated. A similar region was isolated from the corpus callosum. 
The percentage staining was then calculated using an ImageJ plugin tool. To assess the 
overall density of the cingulate gyrus and cingulate sulcus the mean of all layers was 
calculated. 
5.2.3.3 Fibrinogen analysis 
Extent and distribution of fibrinogen (FBG) and IgG immunoreactivity were assessed using 
established semi-quantitative techniques (Chapter 3). Briefly, the neocortical grey matter of 
the cingulate gyrus, cingulate sulcus, superior frontal gyrus, were divided into superficial 
(layers 1-2), mid (layers 3-4) and deep layers (5-6).  Each of these cortical divisions and 
thalamic regions were then semi-quantitatively assessed for the frequency and intensity of 
immunoreactivity determined as absent (0), sparse (1), moderate (2) or extensive (3). 
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5.2.4 Statistical analysis 
All data were analysed using SPSS (version 22; IBM, Inc). The Student’s t-test was used to 
assess differences in data between and within cohorts, where appropriate. Cohen’s d was 
calculated to determine the effect size and to indicate the standardised difference between 
two means. A Cohen’s d value of 0.2 suggested a low practical significance, a value of 0.5 
suggested a moderate practical significance and a value of 0.8 suggested a high practical 
significance. All effects were considered statistically significant when p ≤ 0.05. Quantitative 
results are expressed as mean ± standard error of the mean.  
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5.3 Results 
5.3.1 Cortical thickness of TBI cases compared with controls 
In the cingulate gyrus there was no difference in cortical thickness between TBI and control 
cohorts. Cortical areas in the LFBs staining were defined as the pale blue region compared 
with the myelin-rich white matter regions defined as dark blue (Figure 5-1). Cingulate gyrus 
measurements were similar between all the groups with comparable gyral thicknesses 
(Figure 5-2). 
The mean cortical thickness of the control group was 2.17 ± 0.075 mm, similar to the acute 
TBI group which had a cortical measurement of 2.30 ± 0.155 mm (p = 0.452; Student’s t-
test; Cohen’s d = 0.3). In the long-term TBI group the mean cortical measurement was 2.39 
± 0.08 mm, again, similar to the uninjured control group (p = 0.0630; Student’s t-test; 
Cohen’s d = 0.7) (Figure 5-2). In the cingulate sulcus the mean cortical thickness of the 
control group in the cingulate sulcus was 1.82 ± 0.067 mm, whereas, the acute TBI group 
had a cortical measurement of 1.92 ± 0.05 mm (p = 0.169; Student’s t-test; Cohen’s d = 
0.51). In the long-term TBI group the mean cortical measurement was 1.80 ± 0.05 mm, 
again, similar to the uninjured control group (p = 0.903; Student’s t-test; Cohen’s d = 0.04) 
(Figure 5-2).  
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Figure 5-1 Representative images of LFB staining for measurement of cortical thickness  (a) Where a 
clear separation of cortical regions and white matter regions as defined by the light blue staining (grey matter), 
in contrast to the darker blue staining of the white matter tracts in the cingulate gyrus of a 37-year-old female 
with no history of TBI (cortical thickness as measurement by SlidePath measuring tool (in red) 2.01mm) (b) 
LFB staining in the cingulate gyrus of a 20-year-old male who died 48 hours after sustaining a TBI by an 
assault (cortical thickness 2.48mm as seen by SlidePath measuring tool in red) (c) LFB staining in the cingulate 
gyrus of a 54-year-old male who died 9 years following a TBI sustained by a fall (cortical thickness 2.25mm 
as seen by SlidePath measuring tool in red 2.25mm) Scale bars =100µm for all images. 
a 
b 
c 
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Figure 5-2 Measurement of cortical thickness in all cohorts in cingulate gyrus and cingulate sulcus (a) 
The mean cortical thickness in the cingulate gyrus of the long-term TBI group was 2.39 mm compared to 
2.17mm in the control group (NS). (b) In the cingulate sulcus, the mean cortical thickness was 1.92 mm in the 
acute TBI group and 1.82 mm in the uninjured control group (NS). 
5.3.2 Vascular density 
There was no difference in percentage area stain of CD34 between the TBI cohorts and the 
control cohort in the cingulate gyrus and the cingulate sulcus, however, a trend toward a 
higher percentage area stain of CD34 was observed in the acute phase. The pattern and 
distribution of vessels was evenly spread throughout the cortical layers in both cingulate 
gyrus and cingulate sulcus and density of vessels in both cortical regions was greater than in 
the corpus callosum. CD34 staining was localised to the blood vessels and predominant in 
the vascular rich cortical regions compared with the white matter regions, as expected 
(Figure 5-3).  
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Figure 5-3 Representative images of CD34 staining in the cortical region of the cingulate gyrus in TBI 
and uninjured controls  (a) where CD34 immunoreactivity highlights the vascular endothelial cells and 
visualises vessel density in the cingulate gyrus of a 55-year-old male with no history of TBI, with corresponding 
40x scanned image (b) (c) CD34 immunoreactivity in the cingulate gyrus of a 51-year-old male who died 96 
hours after sustaining a TBI by an assault with corresponding 40x scanned image (d) (c) CD34 
immunoreactivity in the cingulate gyrus of a 56-year-old male who died 3 years following a TBI sustained by 
an assault with corresponding 40x scanned image (f).  Scale bar = 100µm and scale bar = 10µm (higher 
magnification). In the cingulate gyrus the mean percentage staining of CD34 in the control 
group was 2.73% ± 0.13%. This was similar to all TBI groups with the acute TBI group 
demonstrating a percentage area stain of CD34 of 3.06% ± 0.19% (p = 0.170; Student’s t-
test; Cohen’s d = 0.48). While the long-term TBI group demonstrating a percentage area 
stain of CD34 of 2.62% ± 0.16% (p = 0.502; Student’s t-test; Cohen’s d = 0.26) (Figure 5-4). 
The cingulate sulcus demonstrated a similar pattern of CD34 immunoreactivity as in the 
cingulate gyrus. Percentage staining of CD34 in the control group was 2.36% ± 0.23% with 
both the acute TBI group and Long-term TBI group comparable (Acute TBI vs control: p = 
0.1097; Student t-test; Cohen’s d = 0.78; Long-term TBI vs control:  p = 0.0773; Student’s 
t-test; Cohen’s d = 0.79) (Figure 5-4). In the corpus callosum, in the control group, the mean 
percentage area stain of CD34 was 1.22% ± 0.05% and the acute TBI group had a mean 
percentage area stain of CD34 of 1.45% ± 0.08% (p = 0.092; Student’s t-test; Cohen’s d = 
a b 
c d 
e f 
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0.86). The long-term TBI group the area staining of CD34 was 1.75% ± 0.24% (p =0.056; 
Student’s t-test; Cohen’s d = 1.05) (Figure 5-4).  
  
 
Figure 5-4 Regional distribution of CD34 immunoreactivity following TBI versus controls 
Where the CD34 immunoreactivity was observed to be similar throughout the TBI groups compared with the 
controls in all regions assessed (a) Cingulate gyrus (b) Cingulate Sulcus and (c) Corpus callosum (all NS). 
No association could be demonstrated between CD34 immunoreactivity and fibrinogen 
immunoreactivity. In the cingulate gyrus of the acute TBI cohort the mean percentage 
staining for CD34 was 2.96% ± 0.19% in cases with minimal fibrinogen immunoreactivity; 
this was similar in cases with high fibrinogen immunoreactivity where the percentage area 
stain of CD34 was 3.1% ± 0.29% (p = 0.638; Student’s t-test; Cohen’s d = 0.2) (Figure 5-5). 
A similar pattern was observed in the long-term TBI cohort where cases with minimal 
fibrinogen immunoreactivity had a CD34 percentage staining of 2.5% ± 0.14% this was 
similar in cases with high fibrinogen immunoreactivity where the percentage area stain of 
CD34 was 2.84% ± 0.14% (p = 0.078; Student’s t-test; Cohen’s d = 0.77) (Figure 5-5). The 
cingulate sulcus demonstrated a similar pattern and distribution as the cingulate gyrus, 
however the numbers were challenging as the presence of fibrinogen immunoreactivity was 
minimal in this region. 
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Figure 5-5 Association of CD34 immunoreactivity and abnormal FBG immunoreactivity following TBI 
at varying survivals.  There is no association between CD34 immunoreactivity and presence or absence of 
abnormal FBG immunoreactivity in varying survivals following TBI (NS). 
Of note, the pattern and distribution of fibrinogen immunoreactivity previously described a 
preferential distribution towards the deeper layers of the cortex. However, the CD34 
immunoreactivity did not show such distribution. In the cingulate gyrus of acute TBI cases 
with minimal fibrinogen immunoreactivity the percentage staining of CD34 in the 
superficial, mid and deep layers of the cingulate gyrus was 3.15%, 2.98% and 2.74% 
respectively. Those cases with high fibrinogen immunoreactivity in the acute TBI cohort 
demonstrated similar percentage staining of CD34 of 2.97%, 3.27% and 3.15% for CD34 in 
the superficial, mid and deep layers respectively (Table 6, Figure 5-6). Furthermore, the 
long-term TBI group demonstrated no difference between layers. The mean percentage 
staining of CD34 in cases with minimal fibrinogen immunoreactivity was 2.15%, 2.42% and 
2.32% in the superficial, mid and deep layers respectively. In cases with high fibrinogen 
immunoreactivity the mean percentage area staining of CD24 was 2.62%, 3.19% and 2.72% 
(Table 6, Figure 5-6). A similar pattern was observed in the cingulate sulcus with no 
difference between groups. 
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Table 6 Mean percentage stain of CD34 within cortical layers split by FBG immunoreactivity 
 Acute TBI  Long-term TBI  
Cortical 
Layers 
Low FBG 
immunoreactivity 
High FBG 
immunoreactivity 
p  d Low FBG 
immunoreactivity 
High FBG 
immunoreactivity 
p   d  
Superficial 
(Layers 1- 
2) 
3.15% ± 0.26% 2.97% ± 0.69% 0.82 0.17 2.15% ± 0.12% 2.62% ± 0.18% 0.78 1.64 
Mid layers 
(3-4) 
2.98% ± 0.54% 3.27% ± 0.45% 0.69 0.3 2.42 ± 0.06% 3.19 ± 0.33% 0.10 1.61 
Deep 
Layers (5-
6) 
2.74% ± 0.411 3.15% ± 0.47% 0.54 
 
0.49 2.32 ± 0.13% 2.72 ± 0.14% 0.92 1.57 
 
 
Figure 5-6 Neocortical distribution of CD34 immunoreactivity after TBI in the presence and absence of 
abnormal FBG immunoreactivity Where the pattern and distribution of CD34 immunoreactivity was 
observed to be consistent through the varying survivals of TBI compared with controls with no association 
with abnormal FBG immunoreactivity. 
 
5.3.3 Collagen deposition 
Similar to CD34 distribution, the pattern and distribution of collagen IV was evenly spread 
throughout the cortical layers in both cingulate gyrus and cingulate sulcus and density of 
vessels in both cortical regions was greater than in the corpus callosum. Collagen IV staining 
was localised to the blood vessels and predominant in the vascular rich cortical regions 
compared with the white matter regions, as expected (Figure 5-7). In the cingulate sulcus 
and corpus callosum, there was no difference in the mean percentage area stain of collagen 
IV between the groups. However, in the cingulate gyrus, a reduction in the mean percentage 
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stain of collagen IV was observed in the cingulate gyrus of the TBI groups compared to the 
uninjured controls (Figure 5-8).  
The mean percentage staining of collagen IV in cingulate gyrus of the control group was 
3.39% ± 0.25% which reduced to 1.69% ± 0.31% in the acute TBI group (p = 0.0001; 
Student’s t-test; Cohen’s d = 2) (Figure 5-8). In the long-term TBI group, the percentage 
staining of collagen IV was 2.69% (p = 0.011; Student’s t-test, Cohen’s d = 0.85) (Figure 
5-8). The cingulate sulcus did not demonstrate such a reduction in the percentage staining of 
collagen in the acute TBI cohort. The mean percentage staining of collagen IV in the control 
group was 1.36% ± 0.08% which was similar to the acute TBI group of 1.34% ± 0.12% (p = 
0.297; Student’s t-test; Cohen’s d = 0.04). The long-term TBI group demonstrated a 
percentage area stain of collagen IV of 1.50% ± 0.04% compared with controls (p = 0.246; 
Student’s t-test; Cohen’s d = 0.64) (Figure 5-8). In the corpus callosum, all groups 
demonstrated a similar pattern of percentage area stain of collagen IV (Figure 5-8). 
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Figure 5-7 Representative images of collagen IV immunoreactivity in the cingulate gyrus after TBI and 
in uninjured controls Where collagen IV deposition in blood vessels is evidenced by collagen IV 
immunoreactivity in the neocortical region of the cingulate gyrus.  Collagen IV is highlighted around the blood 
vessels through the cortex and noted in the larger vessels at the subpial plate as expected. (a) Where collagen 
IV immunoreactivity is expressed in blood vessels in the cingulate gyrus of a 46-year-old male with no history 
of TBI and corresponding 40x scanned image (b) (c) in a 54-year-old female who survived 54 hours following 
a TBI sustained by a fall and corresponding 40x scanned image (d) (e) 56-year-old male who survived 3 years 
following a TBI sustained by a fall and corresponding 40x scanned image (f). Scale Bar = 100µm, scale bar = 
10µm (high magnification). 
a b 
c d 
e f 
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Figure 5-8 Regional distribution of collagen IV immunoreactivity in varying survivals after TBI 
compared with controls  (a) where a decrease in collagen IV immunoreactivity was observed in the cingulate 
gyrus in the acute TBI group compared with controls and in the long-term TBI cohort compared with uninjured 
controls (b) No difference in collagen IV immunoreactivity in the cingulate Sulcus after TBI and a similar 
pattern was observed in the (c) Corpus callosum (* p < 0.05; *** p < 0.0001; Student’s t-test; TBI cohort vs 
control mean) 
No association could be demonstrated between collagen IV immunoreactivity and fibrinogen 
immunoreactivity. In the cingulate gyrus of the acute TBI cohort the mean percentage 
staining for collagen IV was 2.05% ± 0.11 in cases with minimal fibrinogen 
immunoreactivity; in cases with high fibrinogen immunoreactivity this was 1.45% ± 0.50 (p 
= 0.416; Student’s t-test; Cohen’s d = 0.55) (Figure 5-9). A similar pattern was observed in 
the long-term TBI cohort where cases with minimal fibrinogen immunoreactivity had a 
collagen IV percentage staining of 2.39% ± 0.27% and in cases with high fibrinogen 
immunoreactivity this was 3.22% ± 0.3% (p = 0.057; Student’s t-test; Cohen’s d = 0.96) 
(Figure 5-9). The cingulate sulcus demonstrated a similar pattern and distribution as the 
cingulate gyrus (Figure 5-9). 
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Figure 5-9 Association with collagen IV immunoreactivity and abnormal FBG immunoreactivity 
following TBI in varying survivals.  Where no association could be made between collagen IV 
immunoreactivity and the presence or absence of abnormal FBG immunoreactivity in varying survivals 
following TBI (NS). 
As described previously, the pattern and distribution of fibrinogen immunoreactivity 
demonstrated a preference of disruption towards the deeper layers of the cortex. In the 
cingulate gyrus of acute TBI cases with minimal fibrinogen immunoreactivity the percentage 
staining of collagen IV in the superficial, mid and deep layers of the cingulate gyrus was 
1.94%, 2.06% and 2.14% respectively. Those cases with high fibrinogen immunoreactivity 
in the acute TBI cohort demonstrated a percentage staining of 0.99%, 1.57% and 1.78% for 
collagen IV in the superficial, mid and deep layers respectively (Table 7, Figure 5-10). 
Similarly, the long-term TBI group showed no difference between layers. The mean 
percentage staining of collagen IV in cases with minimal fibrinogen immunoreactivity 
1.57%, 2.30% and 2.28% in the superficial, mid and deep layers respectively. In cases with 
high fibrinogen immunoreactivity the percentage staining of collagen IV was 2.95%, 3.24% 
and 3.55% in the cortical layers (Table 7, Figure 5-10). A similar pattern was observed in 
the cingulate sulcus with no difference between groups. 
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Table 7 Mean percentage stain of Collagen IV within cortical layers split by FBG immunoreactivity 
 Acute TBI  Long-term TBI  
Cortical 
Layers 
Low FBG 
immunoreactivity 
High FBG 
immunoreactivity 
p  d  Low FBG 
immunoreactivity 
High FBG 
immunoreactivity 
p d  
Superficial 
(Layers 1-
2) 
1.94% ± 0.33% 0.99% ± 0.79% 0.36 0.9 1.57% ± 0.66% 2.95% ± 0.65% 0.20 1.13 
Mid layers 
(3-4) 
2.06 % ± 0.11% 1.57% ± 0.89% 0.63 0.45 2.3% ± 0.81% 3.25% ± 0.41% 0.38 0.85 
Deep 
Layers (5-
6) 
2.14 % ± 0.18% 1.78% ± 1.2% 0.79 0.24 2.28% ± 0.58% 3.55% ±0.49% 0.22 1.5 
 
  
Figure 5-10 Neocortical distribution of collagen immunoreactivity after TBI in the presence and absence 
of abnormal FBG immunoreactivity. Where the pattern and distribution of collagen IV immunoreactivity is 
observed to be similar throughout the neocortical layers for all groups with a noted decreased in collagen IV 
immunoreactivity in the acute TBI with abnormal FBG immunoreactivity in the superficial layer which steadily 
increases through the cortex to the deep layer (NS).   
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5.4 Discussion 
The aim of this study was to identify changes in cortical thickness and vascularity following 
a single, moderate to severe to TBI and their association with evidence of BBB disruption. 
Cortical thickness and vessel density and collagenisation were assessed following TBI. No 
changes were observed in cortical thickness or in vessel density following TBI in the acute 
phase or chronic phase when compared with uninjured controls. However, in this small 
cohort, a change was reported in collagen deposition in the acute phase following TBI. The 
acute phase TBI cases demonstrated a lower percentage area stain of collagen IV in the 
cingulate gyrus compared with controls.  
Cerebral atrophy has been reported in AD patients where it has been demonstrated using 
volumetric MRI techniques (Mungas et al., 2002, Im et al., 2008). In AD, this cortical 
atrophy correlates to cognitive decline (20) and it may also occur prior to onset of dementia 
(21). From previous literature, varying degrees of cortical thinning are observed across a 
number of brain regions in AD such as frontal, temporal and medial occipital lobes (Im et 
al., 2008). Where overall increased rates of whole-brain atrophy following various dementias 
are similar, analysis of regional atrophy demonstrates differences between dementias such 
as AD and FTLD (Chan et al., 2001). 
Following TBI in humans, cortical atrophy has been previously demonstrated using imaging 
techniques. One study demonstrated that atrophy after mild to moderate TBI injury was 
present and it was associated with the severity of injury where a TBI with a loss of 
consciousness resulted in a greater loss of brain volume (MacKenzie et al., 2002, Wang et 
al., 2015a, Bergeson et al., 2004). Diffuse white matter atrophy following TBI has previously 
been reported in both imaging studies (Gale et al., 2005, Levine et al., 2008) and in an 
autopsy study (Johnson et al., 2013a), however, grey matter atrophy has only been described 
in imaging studies. Both regional grey matter atrophy affecting the frontotemporal and 
limbic cortex has been demonstrated following TBI (Gale et al., 2005, Levine et al., 2008) 
as has significant global cortical atrophy following paediatric TBI (Merkley et al., 2008); all 
reported by imaging techniques. Conversely, in this current autopsy study, no noted 
differences between TBI (both in acute phase and chronic phase) and controls were 
observed. The cohort numbers in this present study were small and from only one region of 
interest, the cingulate gyrus; therefore, multiple brain regions may need to be assessed in 
TBI patients identify any regional changes.  
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To date, there is conflicting data in reporting the changes of vascular density in AD patients. 
In some autopsy studies a decrease in vessel density in AD is reported (Fischer et al., 1990, 
Buee et al., 1994); however, others suggest an increase in mean vessel density in AD 
(Viggars et al., 2011). Cerebral atrophy can often be observed in AD brains, therefore this 
may distort the vessel density numbers due to a smaller surface area containing similar 
numbers of vessels; resulting in conflicting data if not analysed to take into account the 
presence of atrophy (Farkas and Luiten, 2001).  Following TBI, reports on changes in vessel 
density are contradictory. A CCI rodent model reported a decrease in the number of vessel 
junctions and vessel length (Obenaus et al., 2017). Hayward et al. demonstrated alterations 
in vessel density using a lateral fluid-percussion TBI model where vessel density was 
assessed by staining of rat endothelial cell antigen-1 (RECA-1) (Hayward et al., 2010, 
Hayward et al., 2011). Regional changes were reported with an increase in vessel density in 
the perilesional cortex, and in the ipsilateral thalamus, however no change was reported in 
the hippocampus (Hayward et al., 2010). In another fluid percussion rodent model, Park et 
al., reported a global reduction in vessel density where it resolved 2 weeks post-injury in the 
less severe TBI cohort (Eugene et al., 2008).  
A computational model of blast injury investigated the impact on the cerebral vasculature in 
humans (Hua et al., 2015). It reported that where the maximum strain on the brain model 
increased, as did the vasculature density (Hua et al., 2015). Using a scanning electron 
microscope, Rodriguez-Baeza et al., investigated the brain of 10 TBI patients and reported 
morphological alterations in the microvessels comprising of longitudinal folds, sunken 
surfaces with craters and a significant flattening with reduction of vessel lumen (Rodriguez-
Baeza et al., 2003). This present work is the first autopsy study to investigate vascular 
density following TBI. Although no noted changes in vascular density were reported 
between uninjured controls and TBI cases, there was a trend towards an increase in vascular 
density in the acute TBI cohort compared with age-matched non-demented controls. Both 
acute and chronic phase TBI cases which demonstrated an increase in BBB disruption where 
shown to have a slight increase in vessel density compared TBI cases without BBB 
disruption. Although this was an interesting observation it was not significant.  
In AD, a thickening of the basement membrane due to increased collagen deposits has been 
previously reported (Hardy et al., 1986, Mancardi et al., 1980, Vinters et al., 1994, Kalaria 
and Pax, 1995, Viggars et al., 2011). Using laser-induced fluorescence spectroscopy on 
isolated vessels of AD patients and controls, Christov et al., demonstrated significantly 
higher reflecting levels of collagen (Christov et al., 2008). By carrying out a western blot 
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analysis they reported elevated levels of type I and type II collagen; however, a reduction in 
collagen VI subtype was noted. Cheng et al, observed an increase in the subtype collagen 
VI and suggested this increase is a neuroprotective response and may protect neurons against 
Aβ toxicity by blocking the interactions of Aβ42 oligomers and neurons(Cheng et al., 2009). 
Following TBI, the evidence of changes in collagen is limited in animal studies. In one study, 
abnormal visualisation of collagen IV following rodent blast TBI, suggesting a selective 
increase of collagen which indicates a reorganisation of the vascular extracellular matrix 
with generation of new vessels (Gama Sosa et al., 2014). In contrast, a fluid percussion 
rodent TBI model demonstrated a reduction in collagen IV 24 hours after injury; however, 
no reduction was observed 12 hrs after injury (54). This current study demonstrates a 
reduction in collagen deposits following a single, moderate to severe TBI, noted in the acute 
TBI phase that persists into the chronic phase. The distribution of this observation was noted 
in the cingulate gyrus and was absent in the cingulate sulcus and corpus callosum. However, 
numbers are small and this observation warrants further investigation. Disruption of the BBB 
has been previously reported to prevail in the deep layers of the cortex and is notably absent 
in the depths of the sulci and white matter regions (Chapter 3) (Hay et al., 2015) – indicating 
that a decrease of collagen IV follows a similar pattern to BBB disruption. Collagen IV is 
essential for basement membrane stability which is the structural basis of the BBB (Poschl 
et al., 2004). Therefore, this observation is intriguing and may indicate vessels undergo a 
change in collagen IV which could lead to vessel vulnerability following TBI; this could 
predispose vessels to further injury and associated BBB disruption.  
Previously, this thesis identified vascular changes following TBI (Chapter 3; 18), where after 
a single, moderate or severe TBI there is evidence of widespread BBB disruption in a 
proportion of cases in the acute and chronic phases. However, the structural basis for this 
acute and persistent BBB disruption following TBI is unknown.  It has been suggested that 
collagen IV is essential for the stability of the basement membrane (Poschl et al., 2004), a 
key component of the BBB.  Following a subarachnoid haemorrhage in rats, Scholler et al., 
reported both collagen IV degradation and BBB disruption, by albumin extravasation, 
following SAH (Scholler et al., 2007). Therefore, a marked decrease in collagen IV as seen 
in this present study may indicate weakening of the BBB early in the pathogenesis of TBI.  
It has been suggested that following TBI the brain undergoes neovascularization, the 
formation of new vessels. Morgan et al., characterised the angiogenic response in an 
acceleration impact model of TBI and reported a substantial increase in angiogenic growth 
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factor VEGF and noted the presence of newly formed vessels up to 48-hours post injury 
(Morgan et al., 2007). Up-regulation of VEGF following TBI has previously been reported 
and implicated as an important mediator for BBB disruption (Nag et al., 2002, Nag et al., 
1997, Chodobski et al., 2003, Thau-Zuchman et al., 2010).  Zhang et al., reported that VEGF 
can markedly enhance angiogenesis in the ischemic brain of rats and that inhibition of VEGF 
may reduce BBB permeability (Zhang et al., 2000). 
5.4.1 Conclusion 
Although this study resulted in only one anomaly where a reduction in collagen IV staining 
was observed in the acute TBI phase persisting into the chronic TBI phase, it suggests that 
more investigations are warranted to understand the vascular changes following TBI. The 
reduction in collagen IV staining followed a similar pattern and distribution to BBB 
disruption with the noted reduction occurring in the deep layers of the gyri. This may suggest 
a decrease in BM stability in the acute phase following TBI and may contribute towards the 
persistent BBB disruption following TBI. No changes were observed in the cortical thickness 
and vessel density; however, numbers were small and focussed on one region; this may 
present an opportunity to increase numbers and regions to confirm these findings.  
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6 The glial response following traumatic brain 
injury 
6.1 Introduction 
Traumatic brain injury (TBI) is the strongest environmental risk factor for dementia 
(Molgaard et al., 1990, Mortimer et al., 1985, Mortimer et al., 1991, Graves et al., 1990, 
O'Meara et al., 1997, Salib and Hillier, 1997, Guo et al., 2000, Schofield et al., 1997, 
Plassman et al., 2000, Fleminger et al., 2003). Complex neurodegenerative pathologies 
associated with dementia have been recognised in TBI, such as abnormal accumulations of 
tau and amyloid β (Aβ), axonal degeneration, neuroinflammation, degradation of white 
matter and neuronal loss. Reactive glial cells are present in many neurodegenerative 
diseases, such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis 
(ALS) and Huntington’s disease (Miller et al., 2004, Nagele et al., 2004, Hirsch et al., 1998, 
Lobsiger and Cleveland, 2007, Hirsch et al., 2003); this reactive cellular response has also 
been identified in TBI tissue in limited studies. In late TBI, a microglial response has been 
observed (Johnson et al., 2013a), while in CTE tau immunoreactive astrocytes have been 
identified (McKee et al., 2009, Stein et al., 2014) and in blast TBI, reactive astrocytes have 
been recognised (Shively et al., 2016). However, the pattern, distribution and temporal 
dynamics of this cellular response to a single TBI is uncertain. 
6.1.1 Astrocytic Response following TBI 
Both activated microglia and reactive astrogliosis are heterogeneous in nature with 
neuroprotective and detrimental effects in the CNS (Laird et al., 2008, Sirko et al., 2015, 
Bardehle et al., 2013, Myer et al., 2006). Following TBI, astrocytes are important early 
responders, which precedes the microglial response (Kim and Dustin, 2006), with adenosine 
triphosphate (ATP) released from injured astrocytic networks guiding the microglial 
population to site of focal injury (Kim and Dustin, 2006, Davalos et al., 2005, Rouach et al., 
2002, Stout et al., 2002, Verderio and Matteoli, 2001). This astrocytic reaction to TBI evokes 
a number of events including rapid influx of extracellular calcium, sodium release of matrix 
metalloproteinase-9, secretion of vasoactive molecules and ATP (Hekmatpanah and 
Hekmatpanah) release (Hoffman et al., 2000, Ostrow et al., 2011, Ahmed et al., 2000). 
Animal models of TBI have demonstrated that astrocytes exhibit membrane instability and 
cytoskeleton disassembly (Cullen et al., 2011). Following mild rTBI in transgenic mice, an 
acute reactive astrogliosis has been reported (Petraglia et al., 2014a, Ojo et al., 2013, 
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Petraglia et al., 2014b) while in clinical studies investigating head injury in boxers, glial 
fibrillary acidic protein (GFAP) (an astrocyte structural protein) is used as a biomarker for 
injury (Neselius et al., 2012, Zetterberg et al., 2006, Zetterberg et al., 2013a). 
A limited post-mortem case series examining blast related injuries reported prominent 
astroglial scarring and reactive astrogliosis in grey–white matter interfaces and subpial glial 
plate in all chronic blast exposure cases (up to 9 years survival)(Shively et al., 2016). 
However, they did not find the same pattern in sTBI, although these numbers were limited. 
In wider studies, astrocytic p-tau pathology in CTE is proposed to be topographically distinct 
from wider tauopathies, including aging-related tau astrogliopathy (ARTAG) (Lopez-
Gonzalez et al., 2013, Lace et al., 2012). Nevertheless, to date, there remains limited work 
exploring the astrocytic response following TBI, especially sTBI. 
6.1.2 Microglial response following TBI 
Immediately following injury, TBI induces a complex neuroinflammatory response in both 
humans and animal models, associated with an acute-phase inflammatory cell reaction 
featuring polymorphonuclear leukocytes, T lymphocytes, macrophages, and natural killer 
cells, together with activation of resident microglia (Johnson et al., 2013a, Loane and 
Byrnes, 2010). Microglia undergo morphological and expressive alterations which 
contribute to the post-TBI inflammatory pathways (Aihara et al., 1995, Gentleman et al., 
2004, Nagamoto-Combs et al., 2007, Wilson et al., 2004, Loane and Byrnes, 2010, Ziebell 
and Morganti-Kossmann, 2010). Morphological changes can range from  ramified, ‘resting’ 
state microglia through to activated, amoeboid microglia (Walker et al., 2014). Chronic 
neuroinflammation has been demonstrated in limited autopsy (Gentleman et al., 2004, 
Johnson et al., 2013a) and imaging studies, which indicate increased and prolonged 
microglia activity with long-term survival up to 18 years post-injury (Gentleman et al., 2004, 
Ramlackhansingh et al., 2011b, Johnson et al., 2013a). Although there is some discordance 
in autopsy and imaging studies, with persistent microglial activation post-TBI is described 
as predominantly a white matter pathology in autopsy studies (Johnson et al., 2013a), while 
imaging studies report a predominantly grey matter pathology, specifically located to the 
thalamic region (Ramlackhansingh et al., 2011b). In this study, material from the Glasgow 
TBI Archive will be used to characterise the pattern and distribution of astrogliosis and 
microgliosis following exposure to single moderate or severe TBI. 
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Hypothesis:  Reactive astrogliosis is present following TBI observed by an increase in 
GFAP staining at the grey–white matter interfaces and subpial glial plate, with a chronic 
microglial response localised to white matter. 
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6.2 Specific Methods and Materials 
6.2.1 Case selection and tissue preparation 
All brain tissue was obtained from the Glasgow TBI Archive of the Department of 
Neuropathology, Queen Elizabeth University Hospital, Glasgow, UK. Tissue samples were 
acquired at routine diagnostic autopsy, with approval for their use in research obtained from 
the Greater Glasgow and Clyde Biorepository Governance Committee. 
Material from patients aged under 60 years at time of death with a history of a single, 
moderate or severe TBI was selected as acute TBI cases (survival < 14 days from TBI; n = 
27) or long-term TBI cases (survival >1 year from TBI; n = 32). Autopsy reports and, where 
necessary, clinical and forensic records were available for all cases to confirm a history of 
moderate or severe TBI on presentation as defined by the Glasgow Coma Scale. Uninjured, 
age-matched controls with no known history of TBI or neurological disease were selected 
for comparison (n = 21). Demographic and clinical data and detail on neuropathology 
findings at the original autopsy for each cohort are presented in Table 8. 
At the time of the original diagnostic autopsy, whole brains were immersion fixed in 10% 
formal saline for a minimum of 3 weeks, following which the specimens were examined, 
sampled using standardized techniques and processed to paraffin tissue blocks. For this 
study, blocks from a coronal slice of the cerebral hemispheres at mid-thalamic level were 
selected to include the thalamus, with adjacent internal capsule, and corpus callosum, with 
adjacent cingulate and superior frontal gyri. From these tissue blocks 8μm sections were 
prepared for immunohistochemistry procedures. 
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Table 8 Demographic and clinical information of all groups 
 TBI: Acute 
Survival (n = 27) 
TBI: Long-Term 
Survival (n = 32) 
Controls  
(n = 21) 
Mean age (Range) 44.4 years 
(9-60) 
46.3 years (19-60) 39.9 years  
(14-60) 
Males 17 
(63%) 
31 
(96.9%) 
13  
(62%) 
Mean PM Delay (Range) 56.1 hours 
(3-240) 
 
65.5 hours 
(9-184.5) 
 
71.6 hours 
(12-144)  
Mean Survival Interval (Range) 69.3 hours 
(6-216) 
7.8 years 
(1-47) 
Not applicable 
Cause of 
TBI 
Fall 15 
(55.5%) 
15 
(46.9%) 
Not applicable (No 
history of TBI) 
RTA 7 
(25.9%) 
5 
(15.60%) 
Assault 4 
(14.8%) 
8 
(25%) 
Unknown 1 
(3.7%) 
4 
(12.5%) 
Cause of 
Death 
Head injury 25(92.6%) 0 0 
Bronchopneumonia 2(7.4%) 7(21.9%) 1(4.8%) 
ARDS 0 1(3.125%) 0 
Pulmonary 
thromboembolism 
0 0 0 
Heart disease 0 6 (18.8%) 4(16.67%) 
Alcohol related 0 2(6.25%) 0 
Pyelonephritis 0 1(3.125%) 0 
Multi-organ failure 0 1(3.125%) 0 
GIT haemorrhage 0 1(3.125%) 0 
Polytrauma 0 1(3.125%) 0 
Drug overdose 0 0 4(16.67%) 
SUDEP 0 7(21.9%) 8(38.1%) 
Pulmonary oedema 0 1(3.125%) 0 
Septicaemia 0 0 2(8.3%) 
Inhalation of gastric 
contents 
0 0 2(8.3%) 
Unknown 0 4(12.5%) 0 
Key: TBI = traumatic brain injury; SUDEP = sudden unexpected death in epilepsy; GIT = gastrointestinal tract; ARDS= 
acute respiratory distress syndrome; RTA = road traffic accident 
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6.2.2 Routine Histology 
Sections from all tissue blocks were stained with haematoxylin and eosin. Following 
standard dewaxing and rehydration to water, the sections were immersed in haematoxylin 
for 10 minutes (Mayer, Leica Microsystems, Wetzlar, Germany). Slides were rinsed in water 
followed by immersion in Scott’s tap water substitute (Leica Microsystems, Wetzlar, 
Germany) and differentiation in 1% acid alcohol. Following rinsing in water the sections 
were immersed in 25% aqueous eosin Y solution (TCS Biosciences, Buckingham, UK) for 
5 minutes and then the sections were rinsed, dehydrated in graded alcohol, cleared and 
coverslipped. 
6.2.3 Immunohistochemistry 
Following deparaffinization and rehydration, endogenous peroxidase was quenched via 
immersion of the sections in 3% aqueous H202 for 15 minutes. Thereafter, heat induced 
antigen retrieval was performed using microwave pressure cooker for 8 minutes in preheated 
0.1M Tris EDTA buffer (pH 8), followed by blocking in 50µl of normal horse serum (Vector 
Labs, Burlingame, CA, USA) per 5 mL of Optimax buffer (BioGenex, San Ramon, CA, 
USA) for 30 minutes. The sections were then incubated in primary antibody at 4oC for 20 
hours prior to washing and application of biotinylated secondary antibody for 30 minutes, 
followed by an avidin-biotin complex as per manufacturer’s instructions (Vector Labs, 
Burlingame, CA, USA). Visualisation of the target antigen was achieved by applying the 
DAB peroxidase substrate kit (Vector Labs, Burlingame, CA, USA), with the sections then 
counterstained with haematoxylin.  
Primary antibodies were selected to reveal: glial fibrillary acidic protein (GFAP) expressed 
by astrocytes (monoclonal anti-GFAP; clone GA5, 1:250; Leica Biosystems, Milton Keynes, 
UK), human HLA-DP,DQ,DR (monoclonal anti-CR3/43; 1:800; Dako, Carpinteria, USA) 
and ionized calcium binding adaptor molecule 1 (Iba-1) expressed in activated microglia 
(rabbit polyclonal anti-Iba-1; 1:5000; Wako, Japan). Control sections (positive and negative) 
for each antibody were run in parallel with the test sections to confirm antibody specificity.  
Sections were viewed using a Leica DMRB light microscope (Leica Microsystems, Wetzlar, 
Germany). In addition, for quantitative studies, sections were scanned at 20x using a 
Hamamatsu Nanozoomer 2.0-HT slide scanner, with the images viewed via the SlidePath 
Digital Image Hub application (Leica Microsystems, Wetzlar, Germany). The images in this 
chapter have been digitally captured at 4x (2.3µm per pixel) and 20x (0.46µm per pixel). 
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6.2.4 Analysis of immunohistochemistry 
All sections were reviewed and analysed blind to demographic and clinical data. Analyses 
were performed in multiple anatomical regions within each block. Specifically, within the 
callosal block analyses were performed in corpus callosum, crest of cingulate gyrus, depth 
of cingulate sulcus and subcortical white matter of the cingulate gyrus. In the thalamic block, 
analyses were performed in the internal capsule and thalamic grey matter. 
6.2.4.1 Astrogliosis 
In sections stained for GFAP, the extent of the interface astrogliosis was measured, using 
the measuring tool of the SlidePath Digital Image Hub application, at the superficial glial 
limitans and the boundary between neocortical grey and immediate subcortical white matter 
(Figure 6-1a). This was carried out at the crest of the cingulate gyrus and adjacent depth of 
the cingulate sulcus. The extent of subependymal interface astrogliosis associated with the 
lateral ventricle was assessed in sections of the thalamus (Figure 6-1b). Multiple 
measurements were performed for each region in each tissue section, with the largest 
measure taken as the datapoint for that section. 
 
Figure 6-1 Representative measurements of GFAP-immunoreactivity  (a) Extent of interface astrogliosis 
was measured at the superficial glial limitans (SGL) (1) and at the boundary between neocortical grey and 
immediate subcortical white matter (WMI) (2) in the cingulate gyrus region. (b) Extent of astrogliosis was 
measured at the subependymal interface associated with the lateral ventricle in the thalamic region (3). Scale 
bar = 1mm. 
Assessment of astroglial extent for each anatomical region was calculated as percentage area 
of immunostain. Using SlidePath Digital Image Hub software, a 1mm x 1mm square was 
randomly placed over multiple regions of interest (ROIs) in both grey matter and white 
matter of the GFAP stained sections. Images of these ROIs were then captured and exported 
to ImageJ (NIH, Bethesda, MD) where the background was subtracted, and the Colour 
Deconvolution plugin applied using the installed haematoxylin/ DAB vector (H DAB) to 
produce separate colour channels for the counterstain (haematoxylin) and specific 
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immunostaining (DAB). The DAB-specific image was then thresholded and the percentage 
of positive staining in the ROI calculated using standard algorithms in ImageJ (Figure 6-2). 
 
Figure 6-2 Example of Thresholding GFAP using image j (a) original image of GFAP staining in cortex 
(1mm x 1mm square) (b) raw thresholded image of (a) before adjustment and (c) raw thresholded image of 
(a) after manual adjustment  
6.2.4.2 Microgliosis 
Assessments of microglial extent and activation state were performed in sections stained for 
Iba-1 and CR3/43. Multiple anatomical regions of white matter (corpus callosum, internal 
capsule and the subcortical region of the cingulate gyrus) and grey matter (cingulate gyrus, 
cingulate sulcus, superior frontal gyrus and thalamic regions were assessed. For each region, 
extent of microglial staining was calculated as percentage area of immunostain using the 
same methodology employed to calculate extent of GFAP immunostaining. 
In addition to a quantitative assessment microglial staining, standardized semi-quantitative 
scores of microglial morphologies were recorded for each region to assess microglial 
activation state as described previously (Johnson et al., 2013b). Specifically, regions were 
assessed and reported as either displaying a predominance of cells with amoeboid 
morphology (A), ramified morphology (R) or mixed amoeboid/ramified morphology (M) 
(Figure 6-3). 
  
a b c 
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Figure 6-3 Examples of microglia morphology Where (a and d) indicate sparse microglia with fine cell 
processes (ramified) and (b and e) clusters of activated microglia with shortened processes and (c and f) 
extensive and densely packed amoeboid microglia displaying minimal or no processes and enlarged cell 
bodiesFigure 6-3 Scale bar = 100µm (top row) and scale bar = 10µm (bottom row). 
6.2.5 Statistical analysis 
All data were analysed using SPSS (version 22; IBM, Inc). The χ2 test and Student’s t-test 
were used to assess differences in data between and within cohorts, where appropriate.  
Cohen’s d and Cramer’s V were used to determine the effect size and to indicate the 
standardised difference between two means. A Cramer’s V value of 0.1 suggested a low 
practical significance, a value of 0.3 suggested a moderate practical significance and a value 
of 0.5 suggested a high practical significance. While a Cohen’s d value of 0.2 suggested a 
low practical significance, a value of 0.5 suggested a moderate practical significance and a 
value of 0.8 suggested a high practical significance. All effects were considered statistically 
significant when p ≤ 0.05. Measurements results are displayed as means with ± standard 
error of the mean.  
a b c 
d e f 
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6.3 Results 
6.3.1 TBI precipitates an acute, persisting and stereotypical 
interface astrogliosis 
Staining for GFAP in control, uninjured material showed typical pattern staining. 
Specifically, in the neocortex GFAP-immunoreactive astrocytic profiles with fine and 
widely ramifying cellular processes were distributed in low density throughout the cortex, 
with notable concentrations in stereotypical distributions as a thin superficial glial limitans 
immediately beneath the pia. In addition, astrocytes were localised around occasional 
penetrating cortical vessels and as a narrow and interrupted border at the interface between 
neocortical grey matter and underlying subcortical white matter (Figure 6-4a). Within the 
thalamus, GFAP-immunoreactive astrocytes were again encountered in low density, 
typically represented by small immunoreactive profiles with fine, ramifying cytoplasmic 
processes (Figure 6-4b). As in neocortical material, focal concentrations of GFAP-
immunoreactive profiles were noted at interface zones around intrathalamic vessels and 
subependymally. Similarly, sparse astrocytic profiles with fine, widely ramifying cellular 
processes were typical of the multiple white matter regions assessed. 
In contrast to the localised and limited GFAP-immunoreactivity observed in uninjured 
controls, material from patients dying acutely (survival <14 days) after single, moderate or 
severe TBI exposure showed increased GFAP-immunoreactivity in a striking and 
stereotypical pattern and distribution, with immunoreactive astrocytes showing 
morphological features of astroglial activation within hours of injury (Figure 6-4c and d). 
Specifically, there was increased percentage area of staining for GFAP in the neocortex of 
the crests of the cingulate and superficial frontal gyri and in the thalamus when compared to 
uninjured controls. In contrast, there was no demonstrable change in area of GFAP-
immunoreactivity in the neocortex of the depths of the cingulate sulcus or in any white matter 
region examined (Table 9). Thus, in the deeper cortical layers of the cingulate gyrus, there 
was a trend of increasing area of GFAP-immunoreactivity in acute TBI cases compared to 
controls (41% ± 5.2% vs 30% ± 3.8 % respectively; p = 0.094; Student’s t-test; Cohen’s d = 
0.61). While in the equivalent region at the depths of the cingulate sulcus there was no 
notable increase in immunoreactivity (19% ± 3.6 % vs 26 ± 3.2 % respectively; p = 0.150; 
Student’s t-test; Cohen’s d = 0.49).  
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Figure 6-4 Representative images of GFAP-immunoreactivity after TBI and in uninjured controls  
Punctuated GFAP immunoreactivity observed around blood vessels, along SGL and sparsely populated in the 
grey matter regions in the cingulate gyrus, as expected (a) in a 33-year-old woman with no history of TBI.  In 
addition, in the thalamic regions GFAP immunoreactivity was limited with a scattering of astrocytes observed 
throughout in a (b) 34-year-old woman with no history of TBI. However, following TBI, extensive and densely 
populated astrocytes are demonstrated around blood vessels and at the SGL with an increase of GFAP 
immunoreactivity observed in the grey matter regions of the cingulate gyrus of a (c) 16-year-old male TBI 
patient who survived 84 hours after an assault. Furthermore, increased activity of astrocytes are observed in 
the thalamic nuclei (TN) with limited activity observed in the internal capsule (IC) of a (d) 57-year-old male 
TBI patient who survived 15 hours after a fall. Extensive GFAP immunoreactivity extending from the WMI 
into the cortex (as defined by the arrows) and thickening of the SGL (as defined by the arrows), in addition to 
the densely packed perivascular astrocytes are observed in the cingulate gyrus of a (e) 51-year-old TBI patient 
who survived 3 years from an assault. Again, densely populated astrocytes are evidenced by an increase of 
GFAP immunoreactivity in the thalamic nuclei, in contrast to the pale, sparsely populated region of the IC 
(bottom of the picture) in a (f) 48-year-old male TBI patient who survived 3 years after a fall. (g) GFAP 
immunoreactivity around blood vessels in the cingulate gyrus of a 33-year-old female with no history of TBI 
(h) extensive and densely populated astrocytes in the cingulate gyrus of a 60-year-old male TBI patient who 
died 8 days following a fall of TBI (i) again, increased activity of GFAP immunoreactivity in the cingulate 
gyrus of a 51-year-old male TBI patient who survived 3 years following an assault. Scale bar = 1mm (low 
magnification), scale bar = 100μm (high magnification), scale bar = 10µm (g, h and i).  
WMI 
SGL 
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Table 9 Percentage area staining of GFAP immunoreactivity in the cingulate sulcus and white matter 
regions. 
 
Cingulate 
Sulcus 
p  d  
Subcortical 
p  d  Corpus 
callosum 
p  d  Internal 
Capsule 
p  d  
Control 
25.87% ± 
3.19% 
  
7.93% ± 1.25% 
  6.78% ± 
1.35% 
  8.54% ± 
1.21% 
  
Acute 
TBI  
18.72% ± 
3.64% 
0.15 0.49 
8.88% ± 0.94% 
0.54 0.2 7.05% ± 
0.78% 
0.86 0.06 9.49% ± 
1.08% 
0.
54 
0.18 
Long-
term 
TBI 
24.22% ± 
4.71% 
0.78 0.09 
9.75% ± 1.08% 
0.28 0.35 
8.08% ± 
0.96% 
0.42 0.25 
10.04% 
± 0.73% 
0.
26 
0.32 
 
As in controls, GFAP-immunostain was concentrated at stereotypical structural interface 
regions: - around parenchymal vessels; at the SGL and grey/white boundary of the 
neocortex; and in the subependymal zone of the thalamus. Notably, however, there was 
evidence of expansion of these astroglial interface zones at multiple locations, with 
expansion of the SGL and WMI at the crests of the cingulate and superficial frontal gyri and 
extending along penetrating cortical vessels as a widened perivascular astrocytic cuff (Figure 
6-5). Further, there was expansion of the subependymal astrocytic zone (SEZ) in acute TBI 
cases, which almost doubled from 66.6µm ± 15.5μm in controls to 118.7µm ± 17.03μm in 
acute TBI cases (p = 0.032; Student’s t-test; Cohen’s d = 0.72) (Figure 6-5).  
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Figure 6-5 Regional distribution of GFAP interface measurements following TBI versus controls   In 
both acute and long-term TBI survivals there was evidence of an increased of astrogliosis in the WMI and SGL 
as defined by an increase of GFAP immunoreactivity in a higher proportion of TBI survivors than match, 
uninjured controls in material from the cingulate gyrus (CG), cingulate sulcus, superior frontal gyrus (SFG) 
and the thalamic subependymal zone (SEZ) (* p<0.01; ** p<0.001; *** p <0.0001; Student’s t-test TBI vs 
control GFAP measurement).  
 
This stereotypical grey matter astrogliosis with notable localization to interface zones 
observed in material from acute TBI survivors persisted and evolved in material from 
patients dying a year or more after injury (Figure 6-4e and f). Specifically, as in acute 
survivors there was increased percentage area stain of GFAP-immunoreactivity in the grey 
matter of the crests of the cingulate and superficial frontal gyri and in the thalamus in 
material from patients surviving a year or more from a single, moderate or severe TBI than 
in controls. Again, no notable increase in GFAP-immunoreactivity was demonstrated in the 
neocortex of the depths of the cingulate sulcus or in any white matter region assessed (Table 
9). Thus, in the deeper layers of the cingulate gyrus in patients surviving a year or more from 
TBI percentage area stain of GFAP was 43% ± 3.4 % compared with 30% ± 3.8 % in controls 
(p = 0.012; Student’s t-test; Cohen’s d = 0.85) while in the thalamic region percentage area 
stain of GFAP increased from 9.4% ± 1.5 % in controls to 14.4% ± 1 % in the late TBI 
survivors (p = 0.009; Student’s t-test; Cohen’s d = 0.84). As with acute TBI material, there 
was localization to the interface regions of the SGL, WMI, SEZ and perivascularly (Figure 
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6-4e and f). Thus, the SGL of the cingulate gyrus in late survivors of TBI was 208.5µm ± 
19.5μm compared to just 133.1µm ± 101μm in controls (p = 0.002; Student’s t-test; Cohen’s 
d = 0.94) while the WMI rose from 765.9µm ± 115.99μm in controls to 1208.1µm ± 75.3μm 
in late TBI survivors (p = 0.003; Student’s t-test; Cohen’s d = 1.01) (Figure 6-5). Further, 
there was expansion of the SEZ in late survivors of TBI cases, from 66.6µm ± 15.5μm in 
controls to 161.1µm ± 20.7μm in long-term TBI cases (p = 0.001; Student’s t-test; Cohen’s 
d = 1) (Figure 6-5).  
6.3.2 Association of astrogliosis with TBI-associated pathologies 
Assessment of haematoxylin and eosin stained sections from both cingulate and thalamic 
regions confirmed the expected observations of astrogliosis association with a more 
widespread and diffuse pattern of distribution independent of focal injury. In material from 
acute TBI survivors, TBI-associated focal haemorrhagic lesions or contusions were observed 
across 13 of the 27 cases with nearly all (10 out of 13 cases) displaying extensive astrogliosis 
in the surrounding parenchyma. In 8 of 10 cases (80%), extensive astrogliosis was observed 
out with the region of focal pathology. Furthermore, diffuse hypoxic and ischemic injury 
was observed in 93% (25 of 27) of acute TBI cases where no correlation between these 
pathologies and astrogliosis could be identified. In material from patients surviving 1 year 
or more after injury there was evidence of old haemorrhages and contusions; demonstrating 
histologic features consistent with occurring at time of original TBI; in 8 of 32 cases with 
12 lesions in total. Focal astrogliosis was observed in only 4 of the 12 lesions with all 8 cases 
displaying a more widespread diffuse astrogliosis throughout the regions.  Of those long-
term TBI cases that showed no evidence of focal haemorrhagic or contusional pathology (15 
of 32 cases) there was evidence of diffuse astrogliosis in nearly half of cases (7 of 15 cases). 
Diffuse hypoxic and ischemic injury was observed in 22% (7 of 32 cases) of long-term TBI 
cases where no correlation between these pathologies and astrogliosis could be identified. 
6.3.3 The microglial response is largely localized to white matter 
after TBI 
In keeping with previous observations, in all grey and white matter regions examined 
staining for CR3/43 or Iba-1 in uninjured, control material revealed microglia showing a 
predominantly ramified, quiescent morphology, with just occasional cases demonstrating a 
mixed microglial morphology, and no cases with a predominantly activated, amoeboid 
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phenotype (
 
Figure 6-6a and b). 
Survival of less than 14 days from a single, moderate or severe TBI resulted in no measurable 
increase in area staining for either CR3/43 or Iba-1 in any of the multiple white or grey 
matter regions assessed (Table 10, Table 11). However, in isolated white matter regions, 
namely subcortical white matter and internal capsule, there was evidence of microglial 
activation, with an increase in cases displaying activated microglial morphologies, 
predominantly as mixed microglial morphology, rarely as amoeboid (Figure 6-7). Thus, in 
subcortical white matter where only 2 of 19 controls showed an activated microglial 
morphology in staining for CR3/43 (mixed phenotype), in acute TBI activated microglia 
were present in 20 of 26 cases (18 mixed, 2 amoeboid) (p = 0.0001; χ2; Cramer’s V = 0.656). 
Similarly, while in the internal capsule only 6 of 20 controls showed an activated microglial 
morphology (all mixed), this compared to 15 of 26 acute TBI cases with an activated 
phenotype (13 mixed, 2 amoeboid). In contrast to these findings in the internal capsule and 
subcortical white matter, no morphological evidence of increased microglial activation over 
controls was identified in the white matter of the corpus callosum or in multiple grey matter 
regions assessed. (Figure 6-7). 
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Table 10 Percentage area staining of Iba-1 and CR3/43 in grey matter regions 
Iba-1 
Grey 
Matter 
Cingulate 
Gyrus 
p d 
Sulcus 
p d 
Thalamus 
p d 
Control 
6.93% ± 
0.32% 
  6.31% ± 
0.41% 
  7.08% ± 
0.35% 
  
Acute  
6.22% ± 
0.37% 
0.29 0.47 5.88% ± 
0.38% 
0.444 0.26 6.09% ± 
0.41% 
0.078 0.64 
Long-
term 
6.52% ± 
0.31% 
0.56 0.27 5.53% ± 
0.40% 
0.183 0.45 6.24% ± 
0.57% 
0.221 0.44 
CR3/34 
Grey 
Matter 
Cingulate 
Gyrus 
p d 
Sulcus 
p d 
Thalamus 
p d 
Control 
1.88% ± 
0.54% 
  2.09% ± 
0.47% 
  2.20% ± 
0.48% 
  
Acute  
3.1% ± 
0.56% 
0.14 0.55 2.94% ± 
0.54% 
0.246 0.43 2.00% ± 
0.33% 
0.203 0.12 
Long-
term 
2.41% ± 
0.27% 
0.39 0.3 2.61% ± 
0.28% 
0.348 0.35 1.93% ± 
0.32% 
0.647 0.17 
 
Table 11 Percentage area staining of Iba-1 and CR3/43 in white matter regions 
Iba-1 
White 
Matter 
Internal 
capsule 
p d 
Corpus 
callosum 
P d 
Subcortical 
p d 
Control 
6.26% ± 
0.36% 
  6.88% ± 
0.47% 
  6.92% ± 
0.46% 
  
Acute  
5.55% ± 
0.26% 
0.120 0.54 6.00% ± 
0.42% 
0.169 0.46 5.73% ± 
0.42% 
0.063 0.64 
Long-
term 
6.02% ± 
0.43% 
0.662 0.15 7.54% ± 
0.37% 
0.282 0.32 6.70% ± 
0.30% 
0.689 0.13 
CR3/34 
White 
Matter 
Internal 
capsule 
p d 
Corpus 
callosum 
p d 
Subcortical 
p d 
Control 
6.72% ± 
0.66% 
  3.82% ± 
0.50% 
  4.47% ± 
0.41% 
  
Acute  
5.50% ± 
0.60% 
0.183 0.48 4.95% ± 
0.44% 
0.104 0.59 5.43% ± 
0.47% 
0.134 0.51 
Long-
term 
6.92% ± 
0.63% 
0.824 0.08 5.29% ± 
0.59% 
0.063 0.56 5.73% ± 
0.53% 
0.070 0.58 
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Figure 6-6 Representative images of microglia in controls and following TBI in the corpus callosum and 
thalamic region Where microglia appear ramified with small cell bodies and fine processed and sparsely 
populated, as evidenced by CR3/43 immunoreactivity, in the corpus callosum in a (a) 36-year-old woman with 
no history of TBI. A similar pattern is observed in the thalamic region where microglia are evenly spread 
throughout, identifying with ramified morphology in (b) 34-year-old woman with no history of TBI (c) 
demonstrates higher magnification of ramified microglia in the corpus callosum of a 33-year-old female with 
no history of TBI. However, following TBI a delayed response is observed in the corpus callosum in a 
proportion of late TBI survivors where microglia adopt an amoeboid morphology with fat, round cell bodies 
and no processes and densely population in the corpus callosum in a (d) 51-year-old male TBI patient who 
survived 3 years after an assault. In contrast, in the thalamic region, following TBI, demonstrated a similar 
pattern as uninjured controls with an even spread of ramified microglia throughout in a 48-year-old male TBI 
patient who survived 3 years after a fall (e) demonstrates higher magnification of ramified microglia in the 
corpus callosum of a 36-year-old woman with no history of TBI and (f) demonstrates higher magnification of 
amoeboid microglia in the corpus callosum of a 37-year-old male TBI patient who died 4 years following a 
fall. Scale bar = 1mm (low magnification), scale bar = 100μm (high magnification), scale bar = 10µm (higher 
magnification). 
Similar to observations in acute TBI survival, survival of a year or more from a single, 
moderate or severe TBI resulted in no measurable increase in area staining for either CR3/43 
or Iba-1 in any of the multiple white or grey matter regions examined (Table 10, Table 11). 
However, in contrast to localized evidence of early microglial activation in isolated white 
matter regions of a proportion of acute TBI cases, white matter activation in late survival 
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was in evidence in all white and grey matter regions assessed, except the thalamus (
 
Figure 6-6c and d). Regarding white matter involvement, while similar proportions of cases 
showed evidence of microglial activation in subcortical white matter and internal capsule as 
in acute TBI cases, there was notable increased microglial activation in the corpus callosum 
of late TBI survivors, with microglial activation evident up to 4 years survival in this series. 
Specifically, in the corpus callosum staining for CR3/43 revealed 24 of 30 cases with 
activated microglial morphologies (15 mixed, 9 amoeboid) compared to just 3 of 17 controls 
(all mixed) (p = 0.0001; χ2; Cramer’s V = 0.606) and 6 of 24 acute TBI cases (all mixed) (p 
= 0.0001; χ2; Cramer’s V = 0.55) (Figure 6-7). Further, occasional late TBI survival cases 
was identified with evidence of early microglial activation in neocortical grey matter of the 
cingulate gyrus and sulcus and the superior frontal gyrus (Figure 6-7). 
 *** 
+ +++ 
+++ *** 
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Figure 6-7 Regional distribution of the morphology of microglia as defined by CR3/43 
immunoreactivity.  No amoeboid activation was observed in any grey matter regions of the Cingulate Gyrus 
(CG), Cingulate Sulcus (Sulcus), Superior frontal gyrus (SFG) or thalamus. In contrast, in the white matter 
regions, 30% of long-term TBI cases expressed a population of amoeboid activated microglia in the corpus 
callosum (p = 0.0001; χ2; TBI versus uninjured controls CR3/43 immunoreactivity), 3% in the subcortical 
white matter regions and 14% in the internal capsule (NS). A mixed population of microglia was observed in 
the white matter where 50% of chronic TBI cases demonstrated mixed microglia in the corpus callosum 
compared with 18% in the controls (p = 0.0343; χ2; TBI versus uninjured controls CR3/43 
immunoreactivity). Similarly, in the subcortical region, where 70% of chronic TBI cases and 69% of acute 
TBI cases demonstrated mixed microglia compared to 11% in the controls (p = 0.0001; χ2; chronic TBI 
versus uninjured controls CR3/43 immunoreactivity; p = 0.0002; χ2; acute TBI versus uninjured controls 
CR343 immunoreactivity). Localized evidence of early microglial activation in isolated white matter regions 
of a proportion of acute TBI cases (8% of cases in the subcortical white matter region and internal capsule) 
(NS). (+<p = 0.05, +++<p = 0.0005; mixed microglia; χ2 TBI cohort v control; ***<p = 0.0005; amoeboid 
microglia; χ2 TBI cohort v control). 
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6.4 Discussion 
This study has demonstrated histological evidence of a differential glial response following 
a single, moderate to severe TBI with reactive astrogliosis localised to grey matter regions, 
while microgliosis appears localised to white matter regions. In turn, reactive astrogliosis is 
evident in the grey matter immediately after injury and persists into the chronic phase. The 
microglial response, in contrast, evolves after the acute period following injury and persists 
in the white matter in the chronic phase.  
In humans, evidence of astrogliosis following TBI is limited. A post-mortem study using 
blast injury suggests a distinct and previously undescribed pattern of interface astroglial 
scarring at boundaries between brain parenchyma and fluids, and at junctions between grey 
and white matter (Shively et al., 2016). Staining with GFAP, Shively et al. assessed the 
brains of 5 military cases with chronic blast exposure, 3 military cases with acute blast 
exposure, 5 cases with chronic survival from single moderate to severe TBI, 5 with a history 
of opiate use and 3 cases with no neurological disorders. They reported a distinctive pattern 
of reactive astrogliosis in the blast cases with astroglial scarring at the boundaries between 
brain parenchyma and fluids, and at junctions between grey and white matter. In contrast to 
this current study, this pattern of reactive astrogliosis was not reported in the chronic TBI 
cases examined by that group, however, cohort numbers are very small and information 
regarding the cases was minimal. The study also reported reactive microgliosis in both white 
and grey matter, yet the description of assessment used and images of this were not included 
in the paper. This current study shows that this distinct pattern of interface astroglial scarring 
at boundaries between brain parenchyma and fluids, and at junctions between grey and white 
matter is not limited to blast exposure but also noted in a high proportion of cases following 
a single, moderate to severe TBI. 
Much of the evidence surrounding the astrocytic response to TBI has been conducted in 
animal studies and mainly recounts glial scar formation around focal lesions (Susarla et al., 
2014, Villapol et al., 2014, Silver and Miller, 2004, Bardehle et al., 2013). These studies 
document reactive astrocytosis at the site of injury in the acute phase which persist up to 60 
days post injury. Using a mouse CCI, Villapol et al observed a robust astrogliosis up to 60 
days post-injury with the reactive astrocytes occupying an extended region corresponding to 
cortical layers II through to layer VI (Villapol et al., 2014). This astrogliosis, however, was 
only observed around the impact site and around the lesion border. In this current study, 
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however, the astrogliosis is diffuse in nature and is observed at the interface of the grey and 
white matter and at boundaries between brain parenchyma and fluids. 
Following rTBI in transgenic mice, acute astrogliosis has been identified (Petraglia et al., 
2014a, Ojo et al., 2013, Petraglia et al., 2014b, Luo et al., 2014, Ojo et al., 2016). Petraglia 
et al, report a limited acute astrogliosis following a single TBI in mice, with a more 
persistent, widespread astrogliosis following rTBI associated with tau-immunoreactive 
astrocytes. A key focus on astrocytes following rTBI, however, remains tau-immunoreactive 
astrocytes observed in CTE (McKee et al., 2009, Stein et al., 2014). This astrocytic p-tau 
pathology in CTE is proposed to be topographically distinct from wider tauopathies, 
including ARTAG; a four-repeat tauopathy featuring thorn shaped astrocytes (Lopez-
Gonzalez et al., 2013, Lace et al., 2012).  
Where reactive astrogliosis has been reported in a variety of neurodegenerative disease such 
as ALS, Parkinson’s disease and Alzheimer’s disease (Colangelo et al., 2014, Glass et al., 
2010, Maragakis and Rothstein, 2006) there has been emerging evidence of the 
physiopathological potential of astrocytes. Reactive astrogliosis has been attributed to both 
neuroprotective and detrimental effects in the CNS (Laird et al., 2008, Sirko et al., 2015, 
Bardehle et al., 2013, Myer et al., 2006). By using transgenic mice, there is an indication 
that reactive astrogliosis is beneficial and neuroprotective, especially in the early stage of 
AD (Sofroniew and Vinters, 2010), however, this is compromised in chronic 
neuroinflammation. Various therapeutic approaches have been developed to promote this 
astrocytic neuroprotection. Cell based studies such as transplantation of human astrocytes, 
stem cell injections which differentiate into astrocytes at site of lesion and cell grafting 
strategies have all shown to exert neuroprotection (Giralt et al., 2010, Colangelo et al., 2014). 
Targeting signalling pathways has also demonstrated therapeutic potential. Toll-like 
receptors (TLRs) are associated with astrocytic and microglial activation by Aβ; therefore, 
TLR antagonists may provide new targets for neurodegenerative diseases. These strategies 
which exert neuroprotection from reactive astrogliosis could potentially be translated in 
therapeutic targets for TBI, although the therapeutic window may be small, addressing 
reactive astrogliosis early would be key. More work is needed to obtain a comprehensive 
understanding of reactive astrogliosis following TBI, the distinct pattern and distribution 
observed and specific time windows for effective therapeutic interventions. 
The striking pattern of reactive astrogliosis following TBI is intriguing and warrants further 
studies.  Astrocytes cover the CNS in an ordered and well-organised manner with 
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protoplasmic astrocytes lining the grey matter and fibrous astrocytes lining the white matter 
(Sofroniew and Vinters, 2010). Protoplasmic astrocytes envelop neuronal bodies and 
synapses and populate individual domains with the distal tips of the astrocytic processes 
interlocking, forming components of the gap junctions (Sofroniew and Vinters, 2010, 
Halassa et al., 2007, Bushong et al., 2002). These astrocytes, therefore integrate the neuronal 
network with the vascular network (Cabezas et al., 2014). The suggestion is made that the 
pattern and distribution of reactive astrocytes observed here is predominantly a pathology of 
protoplasmic astrocytes which may indicate a disruption of the neurovascular network. 
The pattern of reactive astrogliosis observed in this study occurs in the grey matter, a similar 
outline as seen in BBB disruption after TBI As determined previously (Chapter 3), there is 
a leakage of fibrinogen at the site of BBB disruption (Hay et al., 2015). Where fibrinogen 
has been suggested to induced glial scar formation post injury (Schachtrup et al., 2010), 
activated glial cells have also been suggested to promote further BBB disruption by releasing 
TGF, MMPs, VEGF and glutamate (Carpentier et al., 2005, Price et al., 2016, Kim et al., 
2005). In addition, astrocytic endfeet fully envelope the cerebral vessels (Mathiisen et al., 
2010), which, together with pericytes comprise the BBB (Abbott et al., 2006, Wolburg et 
al., 2009). Swelling and displacement of these endfeet under pathological conditions can 
result in a breach of BBB integrity (Watkins et al., 2014, Ito et al., 2011).  There is a 
suggestion from the observations in this study that reactive astrogliosis in the grey matter is 
associated with BBB disruption.  As such, future studies investigating this continuous 
activation of both astrocytes and BBB disruption may lead to a clearer understanding of the 
chronic pathologies observed following TBI. 
In addition to persistent astrogliosis and interactions with BBB disruption following TBI, 
this study has also demonstrated that microgliosis observed post-TBI is prominently a white 
matter pathology; occurring in the white matter tracts of the corpus callosum and internal 
capsule. This supports the findings by Johnston et al (Johnson et al., 2013a) where, in 
autopsy material from patients surviving a TBI there is evidence of an ongoing 
neuroinflammatory response years after survival following a single injury. Interestingly, 
where these observations demonstrate distinct activated microglia in the corpus callosum, in 
vivo positron emission tomography studies in surviving patients after an sTBI have reported 
no significant differences in binding in this region, although they have reported a difference 
in binding in the thalamic region compared with control patients (Ramlackhansingh et al., 
2011b). 
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Where the studies reporting chronic neuroinflammation in the white matter use 
immunohistochemical techniques (as used here) (Johnson et al., 2013a), imaging studies that 
report chronic inflammation in the grey matter region of the thalamus used PK11195 PET 
as a marker. PK-11195 binds selectively to the peripheral benzodiazepine receptor (PBR) 
(also known as Translocator protein TSPO) which is upregulated in both microglia and 
reactive astrocytes (Chechneva and Deng, 2016a). This tracer, therefore is relatively non-
specific and might mark both reactive microglial and reactive astroglia. This could explain 
why Ramlackasingh et al reported high levels of PK11195 emission in the grey matter; they 
may have inadvertently been reporting the TSPO emission from astrocytes, shown to be 
reactive in this current study, rather than microglial activation as interpreted by the authors. 
Of note, efforts are being made to develop new, more highly specific tracer for PBR binding 
(Doorduin et al., 2008).  In addition, this study used Iba-1 to highlight microglia in the brain, 
however, it often difficult to distinguish microglia from related cell types such as exogenous 
monocytes (Ajami et al., 2018, Ajami et al., 2011, Varvel et al., 2016).  As such, for future 
studies, the use of transmembrane protein 119 (Tmem119) may be useful to more accurately 
demarcate microglia from non-tissue resident monocytes/macrophages (Bennett et al., 
2016). 
6.4.1 Conclusion 
This study has demonstrated histological evidence of a differential glial response following 
a single, moderate to severe TBI with reactive astrogliosis localised to the grey matter and 
microgliosis localised to the white matter compared with uninjured controls.  The 
astrogliosis occurs immediately after injury and persists into the chronic phase.  In contrast, 
microglial activation appears after the acute phase post-TBI and persists in the chronic phase.  
Limitations of the study include challenging numbers to confidently assess the association 
between reactive astrogliosis and BBB breakdown and suitably distinguish microglial 
populations.  
Where previous studies have reported a distinct and ‘unique’ pattern of astroglial distribution 
in blast TBI, this study demonstrates that it is not unique to blast injuries but is observed also 
in survival from a single, moderate to severe TBI. Furthermore, an understanding and 
appreciation is required when assessing the microglial activation. Using markers for 
microglia assessment in human imaging studies may pick up astrocytic activation which may 
lead to conflicting results. Further studies on the differential glial response observed in this 
study may lead to a clearer understanding of the neurodegeneration pathologies observed 
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post-TBI and how they interact with one another which may pave way for potential 
therapeutic targets of TBI. 
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7 Chronically activated perivascular microglia 
express M2-like phenotype in white matter tracts 
following TBI 
7.1 Introduction 
There is increasing evidence of the association between a history of TBI and late 
neurodegenerative disorders, with clinical studies reporting increased risk of Alzheimer’s 
disease (AD) in a proportion of TBI survivors (Molgaard et al., 1990, Mortimer et al., 1985, 
Mortimer et al., 1991, Graves et al., 1990, O'Meara et al., 1997, Salib and Hillier, 1997, Guo 
et al., 2000, Schofield et al., 1997, Plassman et al., 2000, Fleminger et al., 2003). However, 
the pathologies driving these late outcomes remain poorly described. Neuroinflammation is 
increasingly regarded as a key feature of neurodegenerative disorders (Perry et al., 2010, 
Brettschneider et al., 2012b, Brettschneider et al., 2012a), and as an early event in AD 
pathogenesis (Town et al., 2008, Wright et al., 2013, Yamamoto et al., 2007, Yoshiyama et 
al., 2007). More recently, neuroinflammation has been recognised as a key pathology 
following TBI in autopsy studies (see Chapter 6) (Johnson et al., 2013a) and imaging studies 
(Ramlackhansingh et al., 2011b), however, it is unclear what drives this persistent 
inflammation.  
7.1.1 Microglia in neurodegeneration 
A key feature of neurodegenerative diseases such as AD, Parkinson’s disease (PD), Multiple 
sclerosis (MS) and ALS, is a CNS immune response triggered by microglial activation. 
Microglia play a fundamental role in maintaining homeostasis in the CNS; and in response 
to homeostatic changes the microglia become phenotypically active (Perry et al., 2010). 
Activated microglia are both the consequence and contributors of AD pathology, where 
immune responses are raised due to a variety of pathologies, such as Aβ plaques, and this 
continuous activation state becomes neurotoxic. The activation of microglia had both 
beneficial and detrimental properties, depending on the phenotype being expressed. 
Microglia have a diverse spectrum of functionality, which ranges from the neurotoxic and 
pro-inflammatory M1-like phenotype, through to the neuroprotective and 
immunosuppressive roles of the M2-like phenotype (Mantovani et al., 2012, Loane and 
Kumar, 2016, Gordon, 2003). The M2-like phenotype is further categorised into subtypes 
M2a, M2b and M2c. The M1-like phenotype, when activated, produces high levels of pro-
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inflammatory cytokines and chemokines, such as tumour necrosis factor-α (TNF-α), 
interleukin-6 (IL-6) and interferon-ƴ (IFN-ƴ). As such, the M1-like phenotype is suggested 
to be neurotoxic (Gao et al., 2003, Qin et al., 2004, Loane and Kumar, 2016). Conversely, 
the M2-like phenotype has a more neuroprotective role. The phenotypic subtype M2a 
responds to IL-4 and IL-13 stimulation and increases phagocytic activity, the M2b subtype 
is an intermediate phenotype and has both pro-inflammatory and anti-inflammatory effects 
and the M2c subtype is a ‘de-activated’ state which regulates tissue repair and remodelling 
(Sica and Mantovani, 2012, Simon et al., 2017). 
In AD patients, there is an observed shift from the M2-like phenotype to an M1-like 
phenotypic activation in the temporal course of the disease progression. This has been 
detected in both humans and mice models (using APP transgenic mice) where an increase 
of pro-inflammatory cytokines, released by M1-like microglia, has been demonstrated 
(Heneka and O'Banion, 2007, Rojo et al., 2008, Hoozemans et al., 2006, Wyss-Coray, 2006, 
Neuroinflammation Working et al., 2000, Varnum and Ikezu, 2012, Solito and Sastre, 2012). 
In addition, using APP transgenic mice, M1-like activators promote inflammation and 
inhibit clearance of Aβ from the brain, whereas M2a and M2c-like activators promote Aβ 
clearance (Yamamoto et al., 2007, Yamamoto et al., 2008, He et al., 2007, Varnum and 
Ikezu, 2012). This suggests that microglial phenotypes, specifically M1-like, may play a 
fundamental role of the disease progression, however, further studies are required to support 
this hypothesis. 
7.1.2 Microglia in TBI 
Microglia undergo morphological and expressive alterations which contribute to the post-
TBI inflammatory pathways (Aihara et al., 1995, Gentleman et al., 2004, Nagamoto-Combs 
et al., 2007, Wilson et al., 2004, Loane and Byrnes, 2010, Ziebell and Morganti-Kossmann, 
2010). These changes can range from ramified, ‘resting’ state microglia through to activated, 
amoeboid microglia (Walker et al., 2014). Chronic microglial activation has previously been 
described in limited autopsy and imaging studies which indicate increased and prolonged 
microglia activity with long-term survival up to 18 years post-injury (Gentleman et al., 2004, 
Ramlackhansingh et al., 2011b, Johnson et al., 2013a).  
Within the few studies published, there is a consensus of a prolonged and predominant M1-
like phenotype following TBI in the controlled cortical impact (CCI) mouse model (Loane 
et al., 2014, Kumar et al., 2016a). Some studies suggest that both M1 and M2-like 
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phenotypes are present in the early stages following injury, which is then replaced with a 
majority of M1-like microglia, detected by an increase of NOX2 activity (nicotinamide 
adenine dinucleotide phosphate-oxidase), 7 days following injury (Kumar et al., 2016a, 
Kumar et al., 2016b). Further studies using the CCI model report a transient peak of M2-like 
microglia 5 days post-injury, which decreased rapidly thereafter, while M1-like microglia 
continue to remain elevated up to 14 days post-injury in the cortex, striatum and corpus 
callosum (Wang et al., 2013). This work suggests that following TBI, there are dynamic 
microglial changes which vary between grey and white matter. Additionally, Wang et al, 
(2013) report that the M1-like microglial response correlates with the extent of white matter 
injury observed (Wang et al., 2013). In humans, chronically activated microglia have been 
reported in the grey matter (Ramlackhansingh et al., 2011b) and white matter (Johnson et 
al., 2013b) up to 18 years post-TBI, however, the characterisation of the phenotypic profile 
of these activated microglia is yet to be determined. 
7.1.3 Perivascular microglia and BBB 
In the animal model of experimental autoimmune encephalomyelitis (EAE) it has been 
suggested that perivascular clustering of microglia can be induced by fibrinogen leakage, 
due to BBB disruption (Davalos et al., 2012). The study suggests fibrinogen triggers rapid 
perivascular microglial response which contributes to axonal damage in EAE, specifically, 
microglia exhibit cell motility patterns directed specifically toward the vasculature that 
precede the onset of neurological signs and lesion formation (Davalos et al., 2012). In 
addition, the M2-like perivascular microglial marker CD163 has been observed to be 
upregulated in parenchymal microglial in a chronically infected animal with Simian 
Immunodeficiency Virus Encephalitis (Borda et al., 2008). Borda et al, (2008) suggest that 
this upregulation of parenchymal microglia may be due to BBB disruption.  
Following TBI, a study that investigated CD14 (M1-like perivascular microglia marker) 
expression in human brain lesions also reported a similar pattern (Beschorner et al., 2002a). 
Where, under normal conditions CD14 would selectively be expressed in perivascular 
microglia, following TBI, the number of CD14 positive microglia in the parenchyma 
significantly increased (Beschorner et al., 2002a). Selecting 25 TBI cases from autopsy and 
5 control brains, they investigated CD14 expression using immunohistochemical techniques. 
Beschorner et al, (2002) reported that controls expressed CD14 immunoreactive microglia 
in the perivascular space only, however, following TBI the number of CD14 immunoreactive 
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microglial increased in the parenchyma. This increase peaked with 4-8 days post-injury and 
remained elevated weeks post-injury. 
Hypothesis:  The current study will aim to assess the role of perivascular microglia 
following TBI, and, by using the M1-like marker CD14 and the M2-like marker CD163, 
determine the phenotypic profiles associated with post-TBI neuroinflammation.   
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7.2 Materials and Methods  
7.2.1 Case selection and brain tissue Preparation  
From the Glasgow TBI archive cases aged under 60 years at time of death with a history of 
single moderate or severe TBI were selected as acute TBI cases (survival < 14 days from 
TBI; n = 27) or long-term TBI cases (survival >1 year from TBI; n = 32), together with 
uninjured, age-matched controls with no known history of TBI or neurological disease (n = 
21). Autopsy reports and, where necessary, clinical and forensic records were available for 
all cases to confirm a history of moderate or severe TBI on presentation as defined by the 
Glasgow Coma Scale. Demographic and clinical data and detail on neuropathology findings 
at the original autopsy for each cohort are presented in Table 12. 
At the time of the original diagnostic autopsy, whole brains were immersion fixed in 10% 
formal saline for a minimum of 3 weeks, following which the specimens were examined, 
sampled using standardized techniques and processed to paraffin tissue blocks. For this 
study, blocks from a coronal slice of the cerebral hemispheres at mid-thalamic level were 
selected to include the thalamus, with adjacent internal capsule, and corpus callosum, with 
adjacent cingulate gyri and sulcus. From these tissue blocks 8μm sections were prepared for 
immunohistochemistry procedures. 
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Table 12 Demographics and clinical information of all groups 
 TBI: Acute 
survival (n = 27) 
TBI: Long-term 
survival (n = 32) 
Controls 
(n = 21) 
Mean age (range) 44.4 years 
(9-60) 
46.3 years 
(19-60) 
39.9 years  
(14-60) 
Males 17 
(63%) 
31 
(97%) 
13  
(62%) 
Mean PM delay  
(range) 
56.1 hours  
(3-240) 
65.5 hours  
(9-184.5) 
71.6 hours 
(12-144)  
Mean survival interval  
(range) 
69.3 hours 
(6-216)  
7.8 years 
(1-47)  
Not applicable 
Cause of 
TBI 
Fall 15 
(55.5%) 
15 
(46.9%) 
Not applicable  
(No history of 
TBI) RTA 7 
(25.9%) 
5 
(15.60%) 
Assault 4 
(14.8%) 
8 
(25%) 
Unknown 1 
(3.7%) 
4  
(12.5%) 
Cause of 
death 
Head injury 25(92.6%) 0 0 
Bronchopneumonia 2(7.4%) 7(21.9%) 1(4.8%) 
ARDS 0 1(3.125%) 0 
Pulmonary thromboembolism 0 0 0 
Heart disease 0 6 (18.8%) 5(23.8%) 
Alcohol related 0 2(6.25%) 0 
Pyelonephritis 0 1(3.125%) 0 
Multi-organ failure 0 1(3.125%) 0 
GIT haemorrhage 0 1(3.125%) 0 
Polytrauma 0 1(3.125%) 0 
Drug overdose 0 0 3(14.3%) 
SUDEP 0 7(21.9%) 8(38.1%) 
Pulmonary oedema 0 1(3.125%) 0 
Septicaemia 0 0 2(8.3%) 
Inhalation of gastric contents 0 0 2(8.3%) 
Unknown 0 4(12.5%) 0 
Key: TBI = traumatic brain injury; SUDEP = sudden unexpected death in epilepsy; GIT = 
gastrointestinal tract; ARDS= acute respiratory distress syndrome; RTA = road traffic accident 
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7.2.2 Immunohistochemistry 
Sections were deparaffinised and rehydrated, following which, endogenous peroxidase was 
quenched via immersion in 3% aqueous H202 for 15 minutes. Thereafter, heat induced 
antigen retrieval was performed using a microwave pressure cooker for 8 minutes in 
preheated 0.1M Tris EDTA buffer (pH 8), followed by blocking in 50μl of normal horse 
serum (Vector Labs, Burlingame, CA, USA) per 5 mL of Optimax buffer (BioGenex, San 
Ramon, CA, USA) for 30 minutes. Sections were incubated in primary antibody at 4oC for 
20 hours prior to washing and biotinylated secondary antibody was applied for 30 minutes, 
followed by an avidin biotin complex as per manufacturer’s instructions (Vectastain 
Universal Elite Kit, Vector Labs, Burlingame, CA, USA). The target antigen was visualized 
by applying the DAB peroxidase substrate kit (Vector Labs, Burlingame, CA, USA) then 
counterstained with haematoxylin.  
Primary antibodies were selected to reveal CD163 (monoclonal mouse anit-CD163; 1:1000; 
Leica Biosystems, Milton Keynes UK), a perivascular microglial marker and marker for M2-
like phenotype, and CD14 (monoclonal rabbit anti-CD14; 1:500; Abcam, Cambridge, UK), 
a perivascular microglial marker and marker for M1-like phenotype. Known positive and 
negative control sections for each antibody were run in parallel with test sections to confirm 
antibody specificity. 
Sections were viewed using a Leica DMRB light microscope (Leica Microsystems, Wetzlar, 
Germany). Further, sections were scanned and analysed at 20x using a Hamamatsu 
Nanozoomer 2.0-HT slide scanner, with the images viewed via the SlidePath Digital Image 
Hub application (Leica Microsystems, Wetzlar, Germany). The images in this chapter have 
been digitally captured at 4x (2.3µm per pixel) and 20x (0.46µm per pixel). 
7.2.3 Analysis of immunohistochemistry 
7.2.3.1 Percentage area stain 
Assessment of microglial extent for each anatomical region was calculated as percentage 
area of immunostain. Using SlidePath Digital Image Hub software, a 1mm x 1mm square 
was randomly placed over multiple regions of interest (ROI) within grey matter or white 
matter of CD163 and CD14 stained sections. Images of these ROIs were then captured and 
exported to ImageJ (NIH, Bethesda, MD) where the background was subtracted, and the 
Colour Deconvolution plugin applied using the installed Haematoxylin/ DAB vector (H 
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DAB) to produce separate colour channels for the counterstain (Haematoxylin) and specific 
immunostaining (DAB). The DAB-specific image was then manually thresholded and the 
percentage of positive staining in the ROI calculated using standard algorithms in ImageJ. 
7.2.3.2 Microglial Morphology Assessment 
In addition to a quantitative assessment microglial staining, standardized semi-quantitative 
scores of microglial morphologies were recorded for each region to assess microglial 
activation state as described previously (Johnson et al., 2013b). Specifically, regions were 
assessed and reported as either displaying a predominance of perivascular microglia cells 
with amoeboid morphology (A), ramified morphology (R) or mixed amoeboid/ramified 
morphology (M). 
7.2.3.3 Perivascular microglia:  
 In addition to quantitative assessment of microglial staining and of microglial 
morphologies, standardized semi-quantitative scores of perivascular microglia were 
assessed in all grey and white matter regions. Semi quantitative scoring was as follows: 
Score of 0: Microglia were observed contained in the perivascular space only  
Score of 1: In addition to microglia in the perivascular space the is an observed moderate 
microglia population in the surrounding grey and white matter regions 
Score of 2: In addition to microglia in the perivascular space the is an observed extensive, 
widespread and densely packed population of microglia into the surrounding 
grey and white matter (Score of 2).  
Representative examples of immunohistochemical findings and the corresponding semi-
quantitative scores are shown in Figure 7-1. 
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7.2.4 Statistical analysis 
All data were analysed using SPSS (version 22; IBM, Inc.), and applying the χ2 test or 
Student’s t-test to assess data between and within cohorts as appropriate. Cohen’s d and 
Cramer’s V were used to determine the effect size and to indicate the standardised difference 
between two means. A Cramer’s V value of 0.1 suggested a low practical significance, a 
value of 0.3 suggested a moderate practical significance and a value of 0.5 suggested a high 
practical significance. While a Cohen’s d value of 0.2 suggested a low practical significance, 
a value of 0.5 suggested a moderate practical significance and a value of 0.8 suggested a 
high practical significance. All effects were considered statistically significant when p ≤ 
0.05. Quantitative results are expressed as mean ± standard error of the mean. 
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Figure 7-1 Representative images of cortical microglia in cingulate gyrus stained with CD163  
Perivascular microglia are contained within the perivascular space only, limited to the blood vessel wall with 
no microglia in cortex (score of 0) in the cingulate gyrus of (a) a 46-year-old male with no history of traumatic 
brain injury (TBI) and (b) high magnification of perivascular microglia. In addition to the perivascular 
microglia, ramified microglia with long processes and fine cell bodies are highlighted in the surrounding cortex 
(Score of 1) in the cingulate gyrus of (c) a 54-year-old male TBI patient who survived 9 years after a fall and 
high magnification of microglia beyond perivascular space (d) as demoted by arrows. A more extensive 
population of perivascular microglia extending beyond the perivascular space into the surrounding cortex 
(Score of 2) in the cingulate gyrus of (c) a 51-year-old male TBI patient who survived 96 hours following an 
assault and high magnification of microglia beyond perivascular space as denoted by arrows (f). Scale bar = 
100µm, scale bar = 10µm (higher magnification). 
  
a b 
c d 
e f 
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7.3 Results 
7.3.1 Extent, morphology and distribution of CD14 and CD163 
immunoreactive microglia in the white matter 
7.3.1.1 Extent of CD14 and CD163 in the white matter tracts 
In the control group, microglia were observed as small, fine and feathery cells nestled beside 
the vessels; sparsely populated in the white matter tracts of corpus callosum and internal 
capsule (Figure 7-2a). As with the uninjured control group, in material from the acute TBI 
group, all white matter regions expressed a majority of ramified CD14 and CD163 
immunoreactive microglia, localising to similar areas as in the control group; nestle beside 
vessels (Figure 7-2b). In material from the late survival TBI group, ramified CD14 and 
CD163 immunoreactive perivascular microglia were again observed throughout all white 
matter regions, however, in a proportion of late survivors an activated amoeboid microglia 
population was observed, in the white matter tracts of the corpus callosum and the internal 
capsule. A higher proportion of CD163 immunoreactive microglia than CD14 
immunoreactive microglia is observed (Figure 7-2c). There was no evidence of change in 
percentage area stain in either CD14 or CD163 in any white matter region between the 
groups.  However, there was a slight increase of percentage stain in both CD14 and CD163 
in the corpus callosum of the later survivors of TBI (Figure 7-3). 
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Figure 7-2 Representative images of perivascular microglia in the corpus callosum  Where CD163 
immunoreactive microglia were confined to the perivascular space and were absence in the surrounding white 
matter regions, as expected (a) in a 36-year-old female with no history of TBI. A similar pattern is observed in 
material from acute TBI survival where CD163 immunoreactive cells are limited to around blood vessels in 
the corpus callosum of a (b) 20-year-old male TBI patient who survived 48 hours following an assault.  
However, in material from later TBI survivors extensive and densely populated amoeboid CD163 
immunoreactive microglia are observed beyond the perivascular space in a (c) 50-year-old male TBI patient 
who survived 1 year following an assault.  Where densely-packed amoeboid CD163 immunoreactive cells are 
observed to extend beyond the vessels. Scale bar = 1mm (low magnification), scale bar = 100μm (high 
magnification). 
a 
b 
c 
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Figure 7-3 Regional distribution of CD14 and CD163 percentage area stain following TBI versus control  
(a) Percentage area stain of CD14 in all regions assessed. Where no significant increase in area stain in any 
region was observed, a slight increase was observed in the corpus callosum of later survivors compared with 
uninured controls (p = 0.354; Student’s t-test; Cohen’s d = 0.45). (b) Percentage area stain of CD163 in all 
regions assessed. Where no significant increase in area stain of CD163 was observed in any region, a slight 
increase was noted in the corpus callosum of later survivors compared with uninured controls (p = 0.107; 
Student’s t-test; Cohen’s d = 0.67) and in the internal capsule (p = 0.051; Student’s t-test; Cohen’s d = 0.57).  
7.3.1.2 Morphology of CD14 and CD163 in the white matter tracts 
In uninjured, control material a predominately ramified, quiescent morphology of both 
CD14 and CD163 immunoreactive microglia was demonstrated around blood vessels in all 
white matter regions examined, with only 1 control demonstrating a mixed morphology of 
CD163 immunoreactive microglia in the corpus callosum. No controls demonstrated an 
activated amoeboid morphology in either CD14 or CD163 immunoreactivity (Figure 7-4). 
In material from the acute TBI group, there was predominantly ramified, quiescent 
perivascular microglia throughout the white matter regions with 3 cases demonstrating a 
more mixed morphology in CD14 immunoreactive cells and 2 cases demonstrating mixed 
CD163 immunoreactive microglia in the corpus callosum, a similar pattern was observed in 
the internal capsule. In addition, as with the uninjured control group, no cases demonstrated 
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amoeboid morphology (Figure 7-4). Similar to the acute TBI group, the majority of cases in 
the long-term TBI group presented with predominantly ramified, quiescent perivascular 
microglia throughout the white matter regions with limited number of cases demonstrating 
a mixed morphology of CD14 and CD163 immunoreactive microglia. However, in material 
from the late survival TBI group, activated amoeboid microglia in the white matter tracts of 
the corpus callosum and internal capsule in a proportion of cases was observed (Figure 7-2c). 
In the corpus callosum 7% of cases demonstrated CD14 immunoreactive amoeboid 
microglia compared with none in the control group (p = 0.5029; χ2; Cramer’s V = 0.184) 
and 21% of cases demonstrated CD163 immunoreactive amoeboid microglial compared to 
uninjured controls (p = 0.0339; χ2; Cramer’s V = 0.333) (Figure 7-4, Figure 7-5). Fewer TBI 
cases demonstrated activated amoeboid microglia in the internal capsule where only 2 out 
of 31 cases observed CD14 immunoreactive activated microglia and 1 out of 30 cases 
observed CD163 immunoreactive activated microglia.  
 
Figure 7-4 Morphology of CD163 and CD14 immunoreactive microglia in the corpus callosum following 
TBI versus uninjured controls. Where very limited activated perivascular microglia was observed in the 
uninjured controls and localized evidence of early microglial activation in small proportion of acute TBI cases, 
in the late survivors of TBI, 21% of cases demonstrated CD163 amoeboid microglia in the corpus callosum 
and 7% of cases demonstrated CD14 amoeboid microglia (p = 0.0339; χ2; late TBI group vs uninjured controls) 
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Figure 7-5 Representative images of CD14 and CD163 immunoreactive amoeboid microglia 
(a) minimal DAB staining denotes a lack of CD14 immunoreactivity with only sparsely punctuated CD14 
positive perivascular microglia, with no amoeboid microglia present, observed in the corpus callosum in the 
corpus callosum of a 51 year-old male who survived 3 years following a TBI sustained by an assault. However 
in the same case (b), extensive, densely populated CD163 immunoreactive amoeboid microglia displayed by 
fat, round cell bodies and no processes in the corpus callosum of the same patient. Scale bar = 1mm (low 
magnification), scale bar = 100μm (high magnification). 
7.3.1.3 Distribution of CD14 and CD163 in the white matter tracts 
In material from uninjured control group, both CD14 and CD163 immunoreactive cells were 
confined to the perivascular space in all controls. In the acute TBI group 3 cases 
demonstrated CD14 immunoreactive microglia beyond the perivascular space and 5 cases 
demonstrated CD163 immunoreactive microglia beyond the perivascular space in the corpus 
a 
b 
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callosum (p = 0.0693; χ2; acute TBI vs uninjured controls). A similar pattern was observed 
in the subcortical regions and internal capsule. In the material from late survivors of TBI, 5 
cases demonstrated CD14 immunoreactive microglia beyond the perivascular space 
compared with none in the controls (p = 0.1464; χ2; Cramer’s V = 0.261) and 10 cases 
demonstrated CD163 immunoreactive microglia beyond the perivascular space compared 
with uninjured controls (p = 0.0121; χ2; Cramer’s V = 0.391). Of note, of those late survivor 
TBI cases which demonstrated CD163 immunoreactive microglia beyond the perivascular 
space, 90% displayed a mixed or amoeboid morphology (Figure 7-5b). 
7.3.2 Extent, morphology and distribution of CD14 and CD163 
immunoreactive microglia in the grey matter 
 
7.3.2.1 Extent of CD14 and CD163 in the grey matter regions 
In the control group all grey matter regions of the cingulate gyrus, cingulate sulcus and 
thalamus expressed both perivascular CD14 and CD163 immunoreactive microglia. 
Microglia were observed as small, fine and feathery cells nestled beside the vessels (Figure 
7-6a). In material from the acute TBI group, all regions expressed a majority of quiescent 
CD14 and CD163 immunoreactive microglia, localising to similar areas as in the control 
group, however, in a proportion of cases perivascular microglia were observed beside blood 
vessels as expected but also observed in the surrounding cortex (Figure 7-6b). In material 
from the late survival TBI group ramified CD14 and CD163 immunoreactive perivascular 
microglia were observed throughout all grey matter regions with a more mixed morphology 
observed in a proportion of cases throughout all regions assessed. In addition to the expected 
perivascular microglia observed around blood vessels, a higher proportion of cases also 
demonstrated both CD14 and CD163 microglia in the surrounding grey matter regions of 
cingulate gyrus, cingulate sulcus and thalamus (Figure 7-6c). As with the white matter 
regions, there was no evidence of change in percentage area stain in either CD14 or CD163 
in any grey matter region between the groups (Figure 7-3). 
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Figure 7-6 Representative images of perivascular microglia in the cingulate gyrus  Perivascular CD163 
immunoreactive microglia observed sparsely population around blood vessels with an absence of microglia in 
the surrounding cortex in a (a) 46-year-old male with no history of TBI. In addition to the perivascular 
microglia observed around the blood vessels, (b) there is a population of ramified CD163 immunoreactive 
microglia in the surround cortex, in the cingulate gyrus of a 20-year-old male TBI patient who survived 48 
hours following an assault. An extensively populated cortical region of the cingulate gyrus (c) with widespread, 
densely packed CD163 immunoreactive microglia located both around blood vessels and in the surrounding 
parenchyma in a 19-year-old male TBI patient who survived 5 years following an assault. Scale bar = 1mm, 
scale bar = 100µm (high magnification) 
 
a 
b 
c 
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7.3.2.2 Morphology of CD14 and CD163 in the grey matter regions 
In uninjured, control material a predominately ramified, quiescent morphology of both 
CD14 and CD163 immunoreactive microglia was demonstrated around blood vessels in all 
grey regions examined. In the cingulate gyrus 1 control demonstrated a mixed population of 
CD14 immunoreactive microglia. A mixed morphology of CD163 immunoreactive 
microglia were observed in 2 cases in cingulate gyrus region and 1 case in the cingulate 
sulcus. No grey matter regions demonstrated an activated amoeboid morphology. 
Morphologically, the majority of cases in the acute TBI group presented with predominantly 
ramified, quiescent perivascular microglia throughout grey matter regions with limited 
number of cases demonstrating a mixed morphology of CD14 and CD163 immunoreactive 
microglia. In the cingulate gyrus, 21 % of acute TBI cases demonstrated a mixed 
morphology of CD14 immunoreactive microglia with a similar number (20%) demonstrating 
a mixed morphology of CD163 immunoreactive cells. No grey matter regions demonstrated 
an activated amoeboid morphology. In material from the late TBI survivors and similar to 
the acute TBI material the majority of cases presented with predominantly ramified, 
quiescent perivascular microglia throughout grey matter regions with limited number of 
cases demonstrating a mixed morphology of CD14 and CD163 immunoreactive microglia. 
Only 6% of long-term TBI cases demonstrated a mixed morphology of CD14 
immunoreactive cells in the cingulate gyrus and 10% demonstrated with a mixed 
morphology of CD163 immunoreactive cells in the same region (NS compared with 
uninjured controls). No grey matter regions demonstrated an activated amoeboid 
morphology. 
7.3.2.3 Distribution of CD14 and CD163 in the grey matter regions 
In the control group CD14 and CD163 immunoreactive microglia were predominantly 
localised to the perivascular space in the grey matter with only 16% of controls demonstrated 
moderate (score of 1) population of CD14 immunoreactive perivascular microglia in the 
surrounding cortex whereas only 11% of controls demonstrated moderate (score of 1) 
population of CD163 immunoreactive microglia to the cortex. No controls displayed an 
extensive population of microglia in the surrounding cortex (Score of 2). The remaining 
cases expressed perivascular microglia only (Figure 7-6a, Figure 7-7a). A similar pattern 
was observed in the grey matter of the cingulate sulcus and the thalamus on the control group 
(Figure 7-7b and c). 
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From material from the acute TBI survivors, in the cingulate gyrus, 45% of cases 
demonstrated moderate (score of 1) or extensive (score of 2) population of CD14 
immunoreactive microglia in the surrounding cortex (NS). However, 50% of cases 
demonstrated moderate (score of 1) or extensive (score of 2) population of CD163 
immunoreactive microglia in the surrounding cortical region compared with only 11% of 
cases in the control group (p = 0.0086; χ2; Cramer’s V = 0.413) (Figure 7-6b, Figure 7-7a). 
Of those, 7 cases demonstrated an extensive population of CD163 immunoreactive microglia 
in the cortex. In the cingulate sulcus, 26% and 27% of cases demonstrated a moderate or 
extensive population of CD14 and CD163 immunoreactive microglia in the surrounding 
cortex, respectively (Figure 7-7b). A similar pattern was observed in the thalamic region 
where 35% of cases demonstrated a moderate or extensive population of CD14 
immunoreactive microglia beyond the perivascular space and 27% of cases demonstrated a 
moderate or extensive population of CD163 immunoreactive microglia beyond the 
perivascular space (NS) (Figure 7-7c). 
In the cingulate gyrus from the late TBI group, 47% of cases demonstrated a moderate or 
extensive population of CD14 immunoreactive microglia in the surrounding cortex 
compared with 16% in the control group (p = 0.0347; χ2; Cramer’s V = 0.327). Furthermore, 
50% of long-term TBI cases demonstrated a moderate or extensive population of CD163 
immunoreactive microglia in the surrounding cortex compared with 11% in the control 
group (p = 0.05; χ2; Cramer’s V = 0.249) (Figure 7-6c, Figure 7-7a). Of those, 6 cases 
demonstrated an extensive population of CD163 immunoreactive microglia in the cortex. In 
the cingulate sulcus, 31% of cases demonstrated a moderate or extensive population of CD14 
immunoreactive microglia in the surrounding cortex (NS compared with uninjured controls) 
and 38% of cases demonstrated a moderate or extensive population of CD163 
immunoreactive microglia in the cortex compared with only 11% in controls (p = 0.05; χ2; 
Cramer’s V = 0.31) (Figure 7-7b). In the thalamus 37% of long-term TBI cases demonstrated 
a moderate or extensive population of CD14 immunoreactive microglia in the surrounding 
thalamic region (p = 0.05; χ2; Cramer’s V = 0.294). Furthermore, 36% of cases demonstrated 
a moderate or extensive population of CD163 immunoreactive microglia in the surrounding 
thalamic region compared with uninjured controls (p = 0.05; χ2; Cramer’s V = 0.265) (Figure 
7-7c).  
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Figure 7-7 Regional distribution of CD14 and CD163 perivascular microglia populated in perivascular 
space and in surrounding parenchyma.  Where uninjured controls expressed predominantly perivascular 
microglia only, following TBI a proportion of cases in the acute phase and persisting into the late phase (in 
addition to perivascular microglia) expressed a population of CD14 and CD163 microglia in the surrounding 
parenchyma in the (a) cingulate gyrus (b) cingulate sulcus and (c) thalamic regions (* p < 0.01; χ2 TBI 
cohort vs control CD14/CD163 positivity). 
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7.4 Discussion 
This study has demonstrated that activated perivascular microglia in white matter late after 
exposure to TBI predominantly express an M2-like phenotype. In contrast, and further 
supporting observations in Chapter 7, there was no notable microglial activation in grey 
matter in the acute or late phase post-injury in this material. However, following TBI there 
was a noted extension of perivascular microglia into the surrounding grey matter 
parenchyma. In contrast to white matter neuroinflammation, was observed in the acute phase 
and continued into the chronic phase, with both M1-like and M2-like phenotypic profiles 
being expressed. 
In addition to this extensive chronic white matter microglia activation following a single, 
moderate to severe TBI the activated microglia are observed to predominantly have a M2-
like phenotypic profile. Evidence of the microglial phenotypic profiles and temporal course 
following TBI is limited, with all work to date carried out in animal models of TBI.  Where 
several CCI models report a mixed microglia phenotype 5-7 days post-TBI (Morganti et al., 
2016, Turtzo et al., 2014), others report a predominant M1-like phenotype which peaks at 7 
days post-TBI (Kumar et al., 2016a, Kumar et al., 2016b) which remains elevated for up to 
21-28 days following TBI (Wang et al., 2013, Jin et al., 2012).The lifespan of the mice used 
in these studies is short; therefore, the temporal course of the microglial phenotypic profiles 
in humans following TBI is still unknown. This present study has shown that where there is 
no increase in microglial activation in the acute phase, there is extensive amoeboid 
microglial activation, up to 4 years post-TBI and the activated microglia present with a 
predominantly M2-like phenotype. 
The characterisation of microglial phenotypes has evolved rapidly from the previous 
dichotomy (M1 and M2 specific phenotypes) (Ransohoff, 2016) to the current paradigm of 
a microglial spectrum of functionality. The understanding that microglia become polarized 
along an activation spectrum, ranging from the classic M1-like phenotype to an alternative 
M2-like phenotype is now globally accepted (Colton, 2009, Simon et al., 2017). Activated 
microglia display various phenotypes depending on their responses to different stimuli, 
sequence of stimuli, and duration of exposure (Perry et al., 2010). The concept that microglia 
have a range of responses to a number of different stimuli is much more relevant than the 
limited concept of microglial behaviour as previously thought. In this present study, a late 
activation of microglia presents on the activation spectrum with an M2-like profile. 
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In addition to the white matter microglial activation observed in this study, there is also a 
noted increase of CD14 and CD163 microglia in the grey matter, beyond the perivascular 
space. While in health, CD14 and CD163 are exclusively expressed in perivascular microglia 
(Cosenza et al., 2002, Williams et al., 2001a, Ulvestad et al., 1994, Borda et al., 2008, Kim 
et al., 2006), in this study, these markers are also expressed in microglia in the surrounding 
cortical regions following TBI.  This shift of the “status quo” occurs early after injury and 
persists into the late phase. Several animal models studying the effects of simian 
immunodeficiency virus demonstrate this pathology. Borda et al (2008) reported CD163 as 
a selective marker of perivascular macrophages in normal macaques; however, further down 
the disease progression, CD163 positive microglia are also found in parenchyma (Borda et 
al., 2008). Borda et al, (2008) suggest that this expression of CD163 in parenchymal 
microglia is due to vascular compromise. This pattern of CD163 expression in the 
parenchyma is also observed in other animal studies (Kim et al., 2006, Williams et al., 
2001a) and in humans investigating human immunodeficiency virus-associated encephalitis 
(HIVE), AD and Parkinson’s disease (Filipowicz et al., 2016, Roberts et al., 2004, Fabriek 
et al., 2005, Pey et al., 2014). Furthermore, a similar pattern is observed in CD14 expression 
in HIV infected patients (Fischer-Smith et al., 2001, Cosenza et al., 2002). 
Following TBI, these specific perivascular microglial markers have also been observed 
beyond the perivascular space, in the surrounding parenchyma. Using an open skull weight-
drop contusion model, Zhang et al (2012) investigated the accumulation of CD163 microglia 
following TBI. In uninjured control rats CD163 expression was restricted to perivascular 
and meningeal microglia but not to parenchymal microglia, however, following TBI, they 
reported significant CD163 immunoreactive microglia with an amoeboid morphology 
accumulating in the parenchyma (Zhang et al., 2012). This accumulation was observed two 
days post-TBI and increased in the investigated survival time (up to 96 hours post-TBI). 
Parenchymal accumulation of CD14 microglia were also observed following TBI in humans 
(Beschorner et al., 2002a). Similar to CD163 microglia, detection of CD14 in controls was 
solely by perivascular cells and not in parenchymal microglial cells, however, the number 
of CD14 microglia in the parenchyma increased within 1 – 2 days post injury; peaked at 4 – 
8 days and remained elevated weeks after injury (Beschorner et al., 2002a). This pattern of 
parenchymal CD14 microglia was also observed in cases of focal cerebral infarctions 
(Beschorner et al., 2002b). 
The present study supports previous observations as it demonstrates parenchymal 
accumulation of both CD14 and CD163 microglia following TBI. Where the previous human 
158 
 
TBI study investigated brains from 25 patients with an average survival time of 11 days ± 7 
days (Beschorner et al., 2002a), this study presents the first evidence of long-term 
parenchymal accumulation with both CD14 and CD163 observed in the parenchyma of a 
TBI patient who survived 9 years following a fall. Although, where the previous studies 
report a focal pathology of parenchymal accumulation around TBI lesions of both CD14 
(Beschorner et al., 2002a) and CD163 (Zhang et al., 2012) and in ischemic lesions 
(Beschorner et al., 2002b) this study displays diffuse accumulation of CD14 and CD163 in 
cingulate gyrus and thalamic regions.  In addition, Zhang et al reported CD163 amoeboid 
activation of the accumulating microglia at the ipsilateral cortex (lesion site); in this study 
no amoeboid microglia in the grey regions was observed. Whether this accumulation of 
specific perivascular microglia in the parenchyma is due to migration of the microglia 
beyond the perivascular space in response to stimuli or that the specific perivascular markers 
CD14 and CD163 are upregulated in other non-perivascular microglia, it is to be elucidated. 
7.4.1 Conclusion 
In conclusion, this study demonstrated that in relation to perivascular microglia, the M2-like 
phenotype is upregulated in activated microglia in the white matter tracts, specifically the 
corpus callosum, of late survivors following TBI. Furthermore, in the grey matter, there is a 
widespread, diffuse parenchymal accumulation of perivascular microglia following TBI; 
however, unlike the white matter pathology, this observation occurs in the acute phase and 
continues into the chronic phase with both markers being upregulated and no amoeboid 
activation is observed.  These regional differences between the microglial responses 
following TBI are interesting and warrant further investigations, specifically in regard to 
their association with BBB disruption. 
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8 Concluding Remarks 
8.1 Summary 
The data presented here indicate that following a single, moderate to severe TBI several 
vascular and cellular pathologies can be induced that may be associated with 
neurodegenerative diseases. Specifically, BBB disruption is observed in the grey matter 
regions and occurs in the acute phase in a proportion of survivors which persists into the late 
phase following injury. Interestingly, where BBB disruption was reported in a cohort of 
paediatric TBI cases it was preferentially distributed to small vessels unlike adult TBI where 
BBB disruption was predominantly in larger vessels. In addition to this vascular pathology, 
these studies elucidate a previously unreported neuroinflammatory response to TBI with 
specific cellular, anatomical and temporal characteristics. Specifically, in grey matter 
regions a reactive interface astrogliosis is observed subpially, around cortical vessels, at the 
boundary between cortical grey and white matter, and subependymally. This interface 
astrogliosis is evidenced in a proportion of acute and continues into the late phase following 
TBI and is grey matter centric with no observed white matter change. In contrast, while 
astrogliosis after TBI is immediate and long-lasting and localised to grey matter, microglial 
activation is delayed and localised to white matter tracts. In addition, perivascular microglia 
contribution to this delayed microglial response expressed a predominantly M2-like 
phenotype. Furthermore, there was extension of microglia into the parenchyma from the 
perivascular space in grey matter, observed in the acute phase and persisting in a proportion 
of patients surviving years following injury. 
8.2 Vascular Response following TBI  
Blood-brain barrier disruption has been demonstrated in the acute phase following TBI using 
several animal models, however, the evidence of the temporal course is conflicting (Barzo 
et al., 1996, Habgood et al., 2007, Baldwin et al., 1996, Shapira et al., 1993, Rinder and 
Olsson, 1968, Shreiber et al., 1999, Smith et al., 1995, Cortez et al., 1989, Ommaya et al., 
1964, Hekmatpanah and Hekmatpanah, 1985, Hicks et al., 1993, Povlishock et al., 1978, 
Baskaya et al., 1997). In addition to animal models of TBI, several clinical studies report 
elevated levels of serum albumin and S100β in the cerebrospinal fluid (CSF) following a 
severe TBI, suggesting BBB disruption, (Saw et al., 2014, Stahel et al., 2001, Ho et al., 
2014a, Blyth et al., 2009) and one retrospective cohort study observed BBB disruption in 
nearly half of TBI patients (Ho et al., 2014a). This is the first autopsy study to present BBB 
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disruption following TBI which appears in the acute phase and persists into the late phase. 
Furthermore, there is preferential distribution to the crests of the gyri than the depths of the 
sulci and in the deep layers of the cortex. 
A key feature of CTE is abnormal accumulation of hyperphosphorylated tau (Smith et al., 
2013) which has also been reported in late survivors of sTBI (Johnson et al., 2012). 
Interestingly, tau pathology is characterised by the accumulation of abnormal, 
hyperphosphorylated tau in both neurons and glia, around vessels and with preferential 
involvement of the depths of the sulci in the neocortical grey matter (Omalu et al., 2011a, 
McKee et al., 2009). Furthermore, the extravasation of serum proteins such as FBG have 
been demonstrated to correlate with the presence of AD-type pathology (Viggars et al., 
2011). Where similarities in pattern of distribution between tau and BBB disruption are 
observed (around blood vessels, in neurons and glia) the conflicting distribution in the depths 
of the sulci and crests of the gyri would be interesting to further investigate. One hypothesis 
could be that the crests of the gyri are more susceptible to vascular damage than protective 
location of the depths of the sulci, however, further work would be required to prove this. 
Furthermore, it has been well documented that possession of the ε4 allele of the APOE gene 
is also associated with an increased risk of AD (Corder et al., 1993, Saunders et al., 1993) 
and, to a limited extent, in CTE(Jordan et al., 1997, Kutner et al., 2000, Stein et al., 2015). 
The APOE protein transports cholesterol to neurons via lipoprotein (LDLR) receptors (Bu, 
2009) and supports maintenance and integrity of the BBB (Obermeier et al., 2013). 
Furthermore, APOE knockout mice demonstrated increased vascular permeability, and more 
specifically, APOE ε4 is observed to promote BBB disruption (Hafezi-Moghadam et al., 
2007, Nishitsuji et al., 2011, Bell et al., 2012). Unfortunately, cohort numbers were 
challenging in this work but investigating the relationship between post-TBI BBB disruption 
and the APOE ε4 in association with an increased risk of dementia-like pathologies would 
be beneficial and may indicate areas of therapeutic intervention. 
In addition to a suggested genetic link with post-TBI BBB disruption, investigating the 
structural deficiencies that occur during the loss of BBB integrity both in the acute phase 
and late phase would be valuable. Primary damage of the BBB has been described as a result 
of mechanical forces on the brain that results in acute changes such as shearing injuries, 
contusions, and haematomas; whereas a secondary BBB damage is due to such events as 
oedema, inflammation and neurotoxic periphery substances (such as Fibrinogen) entering 
the CNS (Shlosberg 2010, Price 2016, (Petersen et al., 2018)). Whether the acute phase post-
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TBI BBB breakdown observed in this work was due to primary damage and the late phase 
post-TBI BBB breakdown was due to secondary damage is unknown but further experiments 
could confirm this.  
Other structural anomalies, such as pericyte loss may also be responsible for the post-TBI 
breakdown. Pericytes contribute to the stability to microvessels and tight localization of the 
pericytes with the endothelial cell is crucial for BBB integrity (Armulik et al., 2010, 
Daneman et al., 2010, Bell et al., 2010, Winkler et al., 2011). Several animal studies have 
been able to demonstrate that degradation of pericytes can lead to vascular damage by BBB 
breakdown and subsequence toxic influx and by diminished capillary perfusion (Armulik 
and Betsholtz, 2010, Bell et al., 2010, Winkler et al., 2011). Furthermore, a reduction of 
pericytes has been observed in AD patients (Sagare et al., 2013) and in limited animal studies 
following TBI (Zehendner et al., 2015). This would be an interesting study to undertake and 
may provide valuable insight to underlying structural deficiencies in post-TBI vessels. 
Furthermore, in sharp contrast to adult TBI cases, BBB disruption in paediatric cases appears 
preferentially distributed to vessels of 10μm or less in diameter, in keeping with capillary 
sized vessels. This vulnerability of the small vessels was rarely observed in adult material. 
A notable pathology observed in paediatric TBI is diffuse brain swelling (DBS) where 
incidence of DBS in clinical series of paediatric severe TBI approximately twice that 
recorded in adults and is also associated with high mortality (Kazan et al., 1997). DBS can 
be observed even after mild injury when it is often referred to as second impact syndrome 
(SIS). Interestingly, where the majority of paediatric TBI cases with reported DBS also 
presented with BBB disruption, those disrupted vessels showed a propensity to smaller 
vessels. This suggests there could be a correlation between the capillary pathology and DBS 
however more work would be required to confirm this. Imaging studies on paediatric TBI 
patients to record the CBF and CBV and, if any, associated BBB disruption, shortly after 
injury would be fundamental in understanding the mechanisms behind DBS and may 
identify key therapeutic targets. 
8.3 Cellular response following TBI 
In addition to the BBB disruption observed, evidence of a differential glial response 
following a single, moderate to severe TBI was demonstrated, with reactive astrogliosis 
localised to the grey matter and activated microglia localised to the white matter. Further, 
while reactive astrogliosis is evident immediately after injury and persists into the chronic 
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phase, in contrast, the microglial response evolves after the acute period following injury 
and persists in white matter in the chronic phase. 
This pattern of astrogliosis has been reported in ALS (Nagy et al., 1994), however, only one 
other post-mortem study has documented this distinct pattern of astrogliosis following TBI, 
and there following exposure to blast injury (Shively et al., 2016). The study had concluded 
that the pattern was unique to blast injuries as they did not find the same distribution in their 
limited series of sTBI cases. Although the sTBI number in that study were small this is an 
interesting conflict of evidence. Perhaps, this astroglial phenomenon is purely a consequence 
of TBI, regardless of mechanism of injury or, perhaps, blast injuries sustain a similar closed 
rotational injury as observed in sTBI (McKee and Robinson, 2014) and therefore may 
present with the same pathologies. Future studies would be fundamental in supporting these 
interesting possibilities. 
Furthermore, this distinct astroglial pattern is noted to be a grey matter pathology which 
creates interesting hypotheses around associations with other grey matter pathologies 
following TBI. This work has demonstrated BBB disruption in the grey matter with 
preferential distribution in the crests of the gyri than the depths of the sulci and in the deep 
layers of the neocortical ribbon; the distribution of reactive astrocytes follows a similar 
pattern. Astrocytes have a key role in maintaining and supporting the BBB (Cabezas et al., 
2014) and have previously been reported to be involved in BBB disruption in animal models 
(Wang et al., 2014) and in AD patients (Zenaro et al., 2017). In addition, studying the 
relationships to other grey matter pathologies observed following TBI such as abnormal 
accumulation of tau would be interesting. Tau deposits have been reported following sTBI 
and CTE around blood vessels, in neurons and glia with preferential involvement of the 
depths of the sulci in the neocortical grey matter (Smith et al., 2013, Omalu et al., 2011a, 
McKee et al., 2009, McKee et al., 2010, McKee et al., 2013, Goldstein et al., 2012, Johnson 
et al., 2012, Stewart et al., 2016), furthermore, tau-immunoreactive thorn-shaped astrocytes 
are demonstrated in subpial and perivascular locations in the neocortex and subependymally 
(McKee et al., 2013). This juxtaposition between reactive astrocytes and tau at the subpial 
plate, around vessels and in the subependymal zone is interesting, however, conflicting 
patterns in the neocortical layers and in the sulci and gyri could be further investigated. 
Furthermore, although numbers were challenging in this study, investigating the association 
between reactive astrocytes and other grey matter pathologies such as BBB disruption and 
tau may provide a clearer understanding of the chronic pathologies observed following TBI 
and the mechanisms driving them. 
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In addition to the grey matter astroglial pathology observed, there is a delayed microglial 
response arising in the white matter tracts which appears after the acute phase and persists 
late after TBI. Supporting this study is a previous autopsy study where amoeboid microglia 
were reported in the corpus callosum of a proportion of chronic TBI cases (Johnson et al., 
2013a). In contrast, an in vivo positron emission tomography study have reported have 
reported no significant differences in binding in these regions yet have reported a difference 
in binding in the grey matter of the thalamic region (Ramlackhansingh et al., 2011b). This 
imaging study used the marker PK-11195 which binds selectively to the peripheral 
benzodiazepine receptor (PBR; also known as Translator Protein, TSPO), which is 
upregulated in both microglia and reactive astrocytes (Chechneva and Deng, 2016a). As 
such, given the observations reported in this thesis, the possibility that imaging studies in 
vivo following TBI using such TSPO ligands might be reporting ligand binding to a reactive 
astrogliosis in grey matter, rather than microgliosis as reported, should be considered. 
Interestingly, axonal damage following TBI has been reported in white matter tracts 
(Johnson et al., 2013c, Browne et al., 2011). Specifically, sites of microglial activation have 
previously been reported to coincide with neuronal degeneration and axonal abnormality 
(Maxwell et al., 2010, Giunta et al., 2012). In addition, oligodendrocytes may contribute to 
post-TBI white matter pathology (Flygt et al., 2016). Oligodendrocytes provide support and 
insulation for axons therefore, much like the supporting pericytes in the BBB, loss of such 
fundamental cellular components may render the axons vulnerable to further damage. 
Further studies to investigate co-localisation of axonal damage and microglial activation, in 
addition to the impact of oligodendrocytes following TBI would be beneficial and may 
contribute to sourcing therapeutic targets. 
Regarding specific subpopulations of perivascular microglia, these studies show a 
polarization towards the M2-like phenotype in activated microglia in the white matter tracts. 
Microglia have diverse spectrums of functionality, which range from the neurotoxic and pro-
inflammatory M1-like phenotype, through to the neuroprotective and immunosuppressive 
roles of the M2-like phenotype (Mantovani et al., 2012, Loane and Kumar, 2016, Gordon, 
2003). In animal models of TBI, some studies suggest a predominantly elevated M1-like 
phenotypic expression (Kumar et al., 2016a, Wang et al., 2013, Jin et al., 2012). However, 
to-date, this current body of work is the first to explored microglia phenotypes in human 
TBI, where this study demonstrates that the M2-like phenotype is predominantly expressed 
in the late phase. Within the polarization spectrum, the M2 phenotype lies towards the anti-
inflammatory functionality where M2-like expression is believed to be beneficial and 
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neuroprotective. Therefore, exploiting favourable properties the microglial states by 
modulating their phenotypic expression would provide key therapeutic targets. 
Interestingly, in addition to the white matter activation of microglia there is a change in the 
grey matter in a subpopulation of perivascular microglia following TBI. Immediately after 
injury and persisting into the late phase, perivascular microglia are observed to populate, and 
increase in density, in the surrounding parenchyma. Similar responses have been reported in 
animal models of TBI and autopsy studies where the number of perivascular microglia 
increase in the parenchyma (Beschorner et al., 2002a, Zhang et al., 2012). In addition, in one 
study of spinal cord injury reports where microglia become enlarged with retracted processes 
(amoeboid morphology) in the white matter, in contrast, in the grey matter ramified 
microglia become activated without morphologic transformation (McKay et al., 2007), 
similar to observations in this study. Whether this accumulation of perivascular microglia in 
the parenchyma is due to migration of the microglia beyond the perivascular space in 
response to stimuli, perivascular markers being upregulated in non-perivascular microglia 
or an infiltration of periphery monocytes is unknown. Further work utilising novel markers 
such as TMEM could be performed to address if the microglia observed are infiltration 
monocytes, additionally, further experiments using perivascular markers such as CD45 and 
CD11b could be performed to confirm the findings in this study. 
Future studies investigating the association between the grey matter microglial changes and 
BBB disruption post-TBI would be valuable in understanding the underlying mechanisms 
driving post-TBI pathology. Numbers were limited, and any associations could not be 
determined. Several studies support a relationship between a change in perivascular 
microglia and BBB disruption (Borda et al., 2008, Davalos et al., 2012). As with astrocytes, 
microglia form close relationships with the BBB where microglia can influence barrier 
function (Obermeier et al., 2013). Activation of microglia induces the release of several 
cytokines such as IL-1β and VEGF which promotes BBB breakdown as seen in AD 
(Obermeier et al., 2013, da Fonseca et al., 2014, Zenaro et al., 2017). Using markers for 
VEGF and IL-1β experiments could determine the impact of circulating cytokines on the 
BBB following TBI. In addition, fibrinogen which is observed in the grey matter regions 
post-TBI in response to BBB disruption, is reported to activate microglia in AD and induce 
perivascular clustering (Davalos et al., 2012, Petersen et al., 2018) therefore further 
understanding on the impact of this neurotoxic substance on the CNS would be beneficial. 
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This inflammation response post-TBI appears region specific with reactive astrocytes 
accumulating in the grey matter interfaces, perivascular microglia expressing post-TBI 
change in the grey matter and activated microglia dominating the white matter tracts. In 
multiple Sclerosis (MS), white matter lesions are pathologically characterized by the 
presences of infiltrating immune cells while grey matter lesions have an absence of immune 
cells (Bo et al., 2006). Furthermore, predominant white matter microglia activation has been 
observed in the ageing brain and in AD(Raj et al., 2017). Whereas, reactive astrocytes have 
been reported in the cortical grey matter of ALS (Nagy et al., 1994), however, evidence of 
this regionally specific inflammation response is limited. Understanding these regional 
differences in astrocytes and microglia would benefit the wider knowledge of post-TBI 
pathologies. Whether following TBI, reactive astrocytes are ‘switched on’ in response to 
BBB disruption and infiltrating substances in the grey matter while activated microglia target 
the white matter in response to axonal disruption and subsequence cellular debris is unknown 
but a possible hypothesis. Exploiting these regional specific responses could create potential 
therapeutic pathways in post-TBI neurodegeneration. 
In summary, this work has demonstrated a distinct vascular response following a single, 
moderate to severe TBI in humans; furthermore, a persistent cellular response appears in the 
early phase in distinct regions of the white matter and grey matter. All tissue collected for 
this work was retrospective, limited clinical data was available and some numbers were 
challenging. Therefore, associations between pathological findings and clinical outcomes 
observed are difficult. Prospective studies would be highly advantageous in order to 
investigate the distinct vascular and cellular responses observed together with the nature of 
injury, clinical outcomes and possible therapeutic interventions. Another limiting factor was 
the small study numbers, larger number of cases would allow investigation of associations 
between the vascular response and cellular pathology observed. Nonetheless, these findings 
may indicate potential therapeutic interventions by targeting the loss of vascular integrity 
and may be interesting to examine these findings in context along with associations with 
known TBI pathologies. 
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Table 13 Summary of aims, findings and possible future investigations 
Hypotheses Aims Findings Future investigations 
sTBI results in 
disruption of BBB 
function acutely and 
in long-term 
survivors. 
To characterise 
the pattern, 
distribution and 
temporal 
evolution of 
BBB disruption 
at varying 
survivals from 
sTBI. 
BBB disruption is 
observed in the grey 
matter regions and 
occurs in the acute 
phase in a proportion of 
survivors which 
persists into the late 
phase following injury. 
In addition, in 
paediatric TBI BBB 
disruption is 
preferentially 
distributed to small 
vessels 
1. Investigate the structural 
components of the BBB disruption 
following TBI 
2. Investigate the association with 
Tau, Amyloid and inflammation 
3. Investigate the association with 
APOE 
4. Investigate the impact on CBF 
and CBV 
5. Investigate the pattern and 
distribution of BBB disruption  
sTBI results in a 
mixed astroglial and 
microglial 
neuroinflammatory 
response that is 
geographically and 
temporally distinct. 
To characterise 
the extent, 
distribution and 
temporal 
evolution of the 
astroglial and 
microglial 
response to 
sTBI. 
In grey matter regions a 
reactive interface 
astrogliosis is observed 
subpially, around 
cortical vessels, at the 
boundary between 
cortical grey and white 
matter, and 
subependymally. 
However, microglial 
activation is an 
observed delayed 
response and localised 
to the white matter 
tracts 
1. Investigate the associations with 
astrocytes and BBB 
2.  Investigate the associations with 
astrocytes and tau. 
3. Investigate microglia activation 
and axonal damage and 
oligodendrocytes 
4.Investigate relationship between 
microglia and infiltrating 
monocytes 
The microglial 
response to sTBI is 
defined by 
phenotypically 
distinct microglial 
population. 
To determine 
the microglial 
phenotypes 
associated with 
survival from 
sTBI. 
 
M2-like phenotype is 
apparent in the delayed 
activated response in 
the white matter tracts. 
 
1. Further understanding of 
Microglial phenotypes post-TBI. 
2. Investigate the perivascular 
microglia with association with 
BBB 
3. Further understanding of the 
perivascular microglia in the grey 
matter 
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Appendix 2 Full Cohort and demographics 
 
  
 TBI: Acute 
Survival  
(n = 74) 
TBI: 
Intermediate 
Survival (n = 11) 
TBI: Long-Term 
Survival (n = 32) 
Controls  
(n = 30) 
Mean age (Range) 24 years 
(4-60) 
32 years 
(17-56) 
46.3 years 
(19-60) 
28.3 
(7-60) 
 
Males 53 
(72%) 
11 
(100%) 
31 
(96.9%) 
18 
(60%) 
Mean PM Delay (Range) 46.7 hours  
(3-240) 
 
74.7 hours  
(26-192) 
 
65.5 hours  
(9-184.5) 
 
76.3 hours 
(12-264 hours)  
Mean Survival Interval (Range) 69.1 hours 
(1-216)  
72.8 days 
(14-279)  
7.8 years 
(1-47)  
Not applicable 
Cause of 
TBI 
Fall 21 
(28.4%) 
2 
(18%) 
15 
(46.9%) 
Not 
applicable 
(No history 
of TBI) RTA 48 
(64.9%) 
5 
(41.6%) 
5 
(15.60%) 
Assault 9 
(12.2%) 
3 
(25%) 
8 
(25%) 
Unknown 1 
(3.7%) 
1 
(8.3%) 
4  
(12.5%) 
Cause of 
Death 
Head injury 70(94.6%) 4 (33.3%) 0 0 
Bronchopneumonia 2(2.7%) 4(33.3%) 7(21.9%) 1(3.33%) 
ARDS 2(2.7%) 2(16.7%) 1(3.125%) 0 
Pulmonary 
thromboembolism 
0 1(8.3%) 0 2 (6.67%) 
Heart disease 0 0 6 (18.8%) 6(20%) 
Alcohol related 0 0 2(6.25%) 1 (3.33%) 
Pyelonephritis 0 0 1(3.125%) 1 (3.33%) 
Multi-organ failure 0 0 1(3.125%) 1 (3.33%) 
GIT haemorrhage 0 0 1(3.125%) 1 (3.33%) 
Polytrauma 0 0 1(3.125%) 1 (3.33%) 
Drug overdose 0 0 0 4(13.33%) 
SUDEP   7(21.9%) 8(26.67%) 
Pulmonary oedema 0 0 1(3.125%) 0 
Septicaemia 0 0 0 2(6.67%) 
Inhalation of gastric 
contents 
0 0 0 2(6.67%) 
Unknown 0 0 4(12.5%) 0 
Key: TBI = traumatic brain injury; SUDEP = sudden unexpected death in epilepsy; GIT = gastrointestinal 
tract; ARDS 
= acute respiratory distress syndrome; RTA = road traffic accident 
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Appendix 3 List of Antibodies 
Antigen Clone/description Antibody 
Source 
Method of Antigen 
Retrieval 
concentration 
Fibrinogen Polyclonal rabbit  Dako, USA Microwave 
pressure cooker 
and Tris Buffer 
(pH8) 
1:17,500 
IgG Polyclonal rabbit Dako, USA Microwave 
pressure cooker 
and Tris Buffer 
(pH8) 
1:10,000 
CD34 QBEnd/10 Leica 
Biosystems, 
UK 
Microwave 
pressure cooker 
and Tris Buffer 
(pH8) 
1:100 
Collagen IV CIV 22 Dako ,USA Microwave 
pressure cooker 
and Tris Buffer 
(pH8) 
1:25 
GFAP GA 5 Leica 
Biosystems, 
UK 
Microwave 
pressure cooker 
and Tris Buffer 
(pH8) 
1:250 
CR343 Anti-Human HLA-
DP,DQ,DR 
Dako, USA Microwave 
pressure cooker 
and Tris Buffer 
(pH8) 
1:800 
IBA-1 C-terminus of Iba1 
Polyclonal rabbit 
Wako  1:5000 
CD14 goat polyclonal Abcam, UK Microwave 
pressure cooker 
and Tris Buffer 
(pH8) 
1:500 
CD163 10D6 Leica 
Biosystems, 
UK 
Microwave 
pressure cooker 
and Tris Buffer 
(pH8) 
1:1000 
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